Protocol (3): I4T-MC-JVDA
A Phase [ADDRESS_690466] the Vascular 
Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Recurrent or Refractory 
Solid Tumors, including CNS Tumors
[STUDY_ID_REMOVED]
Approval Date: 31-Jan-2019

$'9/



9HUVLRQ'DWH

$FWLYDWHG 1RYHPEHU 9HUVLRQ'DWH 
&ORVHG  $PHQGPHQW 
 
 

&+,/'5(1Â¶621&2/2*<*5283 

$'9/ 

$3+$6(678'<2)5$0 8&,580$%$+80$10212& /21$/$17,%2'<$*$ ,167
7+(9$6&8/$5(1'27+(/,$/*52:7+)$&7259(*)55(&(3725,1
&+,/'5(1:,7+5()5$&725<62/,'780256,1&/8',1*&16780256

/HDG2UJDQL]DWLRQ&2*3HGLDWULF (DUO\3KDVH&OLQLFDO7ULDOV1H WZRUN3(3&71



7
+,6[ZIP_CODE]&2/,6)255(6($5&+385326(621/< $1'6+28/'127%(&23,(' 5(',675,%87('
2586(')25$1< 27+(5385326( 0(',&$/$1'6&,(17,),&,1)25 0$7,21&217$,1(':,7+,1
7+,6[ZIP_CODE]&2/,6127,1&/8'('72 $87+25,=(25)$&,/,7$7(7+(35 $&7,&(2)0(',&,1(%<
$1<3(562125(17,7< 5(6($5&+ 0($16$6<67(0$7,&,19(67,*$7,21 ,1&/8',1*5(6($5&+
'(9(/230(17 7(67,1*$1'(9$/8$7,21 '(6,*1('72'(9(/23 25&2175,%87(72
*(1(5$/,=$%/(.12:/('*( 7+,6[ZIP_CODE]&2/,67+(5(6($5&+3/$1'(9(/23('%<7+(
&+,/'5(1 Â¶621&2/2*<*528372,19(67,*$ 7($3$57,&8/$5678'<48(67,2125 6(72)678'<
48(67,216$1'6+28/' 127%(86('72',5(&77+(35$&7,&( 2)0(',&,1(%<$1<3(562125
723529,'(,1',9,'8$/,=('0(',&$/&$5( 75($70(17 25$'9,&(72$1<3$7,(1725678'<
68%-(&77+(352&('85(6,17+,6[ZIP_CODE]&2/ $5(,17(1'('21/<)2586(%< &/,1,&$/
21&2/2*,676,1&$5()8//<6758&785('6(77,1*6 $1'0$<1273529(72%(025(())(&7,9(
7+$167$1'$5'75($70(17 $1<3(5621:+25(48,5(60(', &$/&$5(,685*('72&2168/7
:,7++,625+(53(5621$/3+<6,& ,$12575($7,1*3+<6,&,$1259,6 ,77+(1($5(67/2&$/
+263,7$/25+($/7+&$5(,167,787,21 


678'<&+$,5 


)RU3(3&712SHUDWLRQVDQG'DW D6WDWLVWLFV&RQWDFWVVHHKWWS PHPEHUVFKLOGUHQVRQFRORJ\JURXSRUJ
[COMPANY_003]
                                            
ADVL1 416                                                                                                                                                              
 
2 
Version Date: 01/31/[ADDRESS_690467]  7 
EXPERIMENTAL DESIGN SCHEMA  7 
1.0 GOALS AND OBJECTIVES  (SCIENTIFIC AIMS)  8 
1.1 Primary Aims  8 
1.2 Secondar y Aims  8 
1.3 Exploratory Aims 8 
2.0 BACKGROUND  8 
2.1 Introduction/Rationale for Development  [ADDRESS_690468] Requirements  21 
3.5 Informed Consent/Assent [ADDRESS_690469]  21 
3.8 Institutional Pathology Report 21 
3.9 Study Enrollment 22 
3.10  Dose Assignment  22 
4.0 PATIENT ELIGIBILITY  22 
4.1 Inclusion Criteria 22 
4.2 Exclusion Criteria 25 
5.0 TREATMENT PROGRAM  27 
5.1 Overview of Treatment Plan  27 
5.2 Criteria for Starting Subsequent Cycles 28 
5.3 Dose Escalation Schema (Completed)  28 
5.4 Grading of Adverse Events 29 
5.5 Definition of Dose- Limiting Toxicity (DLT)  29 
6.0 DOSE MODIFICATIONS F OR ADVERSE EVENTS  32 
6.1 Dose Modifications for Hematological Toxicity  32 
6.2 Dose Modifications for Non -Hematological Toxicity  32 
6.3 Dose Modifications for Infusion- Related Reactions  33 
6.4 Dose Modifications for Hypertension 34 
6.5 Dose Modifications for Proteinuria 36 
7.0 SUPPORTIVE CARE AND OTHER CONCOMITANT THERAPY  37 
                                            
ADVL1 416                                                                                                                                                              
 
3 
Version Date: 01/31/19 
 
7.1 Concurrent Anticancer Therapy  37 
7.2 Investigational Agents  37 
7.3 Supportive Care 37 
7.4 Growth Factors  37 
7.5 Surgery  37 
7.6 Concomitant Medications  37 
7.7 Concurrent Anti- Hypertensive Therapy  37 
8.0 EVALUATIONS/MATERIAL  AND DATA TO BE ACCESSIONED  38 
8.1 Required Clinical, Laboratory and Disease Evaluation 38 
8.2 Monitoring for Specific Toxicities  39 
8.3 Radiology Studies 40 
8.4 Pharmacokinetics (Required)  40 
8.5 Immunogenicity Studies (Required)  41 
8.6 Circulating Plasma Molecular Marker Studies  42 
8.7 Pharmacogenomic Studies 43 
8.8 Peripheral Blood Flow- Cytometry (PBFC) Studies (Part A Only)  44 
8.9 Tissue Studies  46 
9.0 AGENT INFORMATION  46 
9.1 Ramucirumab  46 
9.2 Agent Accountability 49 
9.3 Obtaining the Agent 49 
10.0  CRITERIA FOR REMOVAL  FROM PROTOCOL THERAPY AND OFF STUDY CRIT ERIA 50 
10.1  Criteria for Removal from Protocol Therapy 50 
10.2  Off Study Criteria  50 
11.0  STATISTICAL AND ETHICAL CONSIDERATIONS  50 
11.1  Sample Size and Study Duration 50 
11.2  Definitions  51 
11.3  Dose Escalation and Determination of MTD 52 
11.4  Inclusion of Children, Women and Minorities 53 
11.5  Pharmacokinetic and Correlative Studies and Response Analysis  53 
11.6  Statistical methods  54 
12.0  EVALUATION CRITERIA 56 
12.1  Common Terminology Criteria for Adverse Events (CTCAE) [ADDRESS_690470] Response 65 
13.0  ADVERSE EVENT REPORT ING REQUIREMENTS  68 
13.1  Steps to Determine If an Adverse Event Is To Be Repor
ted In an Expedited Manner  68 
13.2  When to Report an Event in an Expedited Manner 70 
13.3  Expedited Reporting Methods  71 
13.4  Definition of Onset and Resolution of Adverse Events 71 
13.5  Other Recipi[INVESTIGATOR_6681]  71 
13.6  Reporting Secondary AML/MDS  72 
13.7  Reporting Pregnancy, Pregnancy Loss, and Death Neonatal 72 
                                            
ADVL1 416                                                                                                                                                              
 
4 
Version Date: 01/31/[ADDRESS_690471] for Data Submission/ Data Reporting  74 
14.3  CDUS  74 
14.4  Data and Safety Monitoring Plan  75 
REFERENCES  76 
APPENDIX I: PERFORMANCE STATUS SCALES/SC ORES  81 
APPENDIX II: CORRELA TIVE STUDIES GUIDE  82 
APPENDIX III: PHARMA COKINETIC STUDY FORM  83 
APPENDIX IV: IMMUNOGENICITY FORM:  ANTI - RAMUCIRUMAB ANTIBODY STUDIES  85 
APPENDIX V -A: CIRCULATING PLASMA MOLECULAR MARKER STUDIES FORM  86 
APPENDIX V -B: PHARMACOGENOMICS STUDY FORM  87 
APPENDIX VI: PERIPHE RAL BLOOD FLOW CYTOM ETRY SETUDIES FORM ( PART A ONLY) 88 
APPENDIX VII: TISSUE STUDIES FORM  89 
APPENDIX VIII: BLOOD PRESSURE LEVELS FOR CHILDREN BY [CONTACT_6740]  90 
APPENDIX IX:  URINE PROTEIN TO CREATININE (UPC) RATIO 92 
APPENDIX X: TOXICITY- SPECIFIC GRADING  93 
APPENDIX XI: CTEP AN D CTSU REGISTRATION PROCEDURES  94 
 
 $'9/ 

7+,6[ZIP_CODE]&2/,6)255(6($5&+385326(621/< 6((3$*( )2586$*(32/,&< 

9HUVLRQ'DWH

[COMPANY_003]
 $'9/ 

7+,6[ZIP_CODE]&2/,6)255(6($5&+385326(621/< 6((3$*( )2586$*(32/,&< 

9HUVLRQ'DWH

678'<&200,77((FRQW









 




 


 $*(1716&$1',1'Â¶V 
 5DPXFLUXPDE ,0&%16&,1'


 ,1'6SRQVRU (OL/LOO\


)RU3(3&712SHUDWLRQVDQG'DWD 6WDWLVWLFV&RQWDFWVVHHKWWSP HPEHUVFKLOGUHQVRQFRORJ\JURXSRUJ 

6((6(&7,21 DQG$SSHQGL[;,,,)2563(&,0(16+,33,1*$''5(66(6 [COMPANY_003]
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
7 
Version Date: 01/31/[ADDRESS_690472] or 
his/her guardian requests the release of information in writing, the Certificate does not protect against that 
voluntary disclosure.  Furthermore, federal agencies may review our records under limited circumstances, 
such as a D HHS request for information for an audit or program evaluation or an FDA request under the 
Food, Drug and Cosmetics Act. 
 
The Certificate of Confidentiality will not protect against mandatory disclosure by [CONTACT_6741], reportable communicable diseases, and/or possible threat of harm 
to self or others. 
 
ABSTRACT  
This is a Phase 1 study of ramucirumab (IMC -1121B; LY3009806), a recombinant, human monoclonal 
antibody of the immunoglobulin G subclass 1 developed agains t the vascular endothelial growth factor- 2 
receptor (VEGFR -2), to be conducted in children with recurrent or refractory solid tumors including CNS 
tumors. Ramucirumab specifically binds to the extracellular domain of human VEGFR -2 with high 
affinity and le ads to a comprehensive inhibition of the signaling pathways activated by [CONTACT_12270] -A (VEGF) 
binding. In addition to VEGF, Ramucirumab also inhibits the binding of VEGF -C and VEGF -D to 
VEGFR -2. By [CONTACT_531896] -2, ramucirumab has less potential to induce â€œoff -
targetâ€ toxicities seen with VEGFR -[ADDRESS_690473] shown that 
ramucirumab is efficacious as either  a single agent or in combination with doxorubicin across a series of 
pediatric patient -derived xenograft sarcoma models including synovial, osteosarcoma, Ewing s, and 
undifferentiated histologies  and in a cell -derived neuroblastoma xenograft. It has undergone Phase  1, 2, 
and 3 testing in adults and ha s been  FDA approved for advanced gastro- esophageal carcinoma and 
metastatic non -small cell lung cancer . The adult recommended FDA approved doses are 8 mg/kg I.V. 
administered every other week  in gastric indications and 10 mg/kg I.V. administered every 3 weeks in 
non-small cell lung cancer . In Part  A, we will evaluate the maximum tolerated dose (MTD) and/or RP2D 
of ramucirumab given intravenously every other week in children with solid tumors, excluding  CNS 
tumors. In Part  B of the study we wil l evaluate the toler ability and /or RP2D of ramucirumab in children 
with recurrent or refractory CNS tumors. In addition to pharmacokinetic and immunogenicity studies, 
correlative biologic endpoints will include evaluation of angiogenic proteins and circulating 
hematopoietic and endothelial progenitor cells.  
 
EXPERIMENTAL DESIGN SCHEMA 
 
Ramucirumab         Ramucirumab  Ramucirumab  Tumor Disease Evaluation *  
 
Cycle :    
                         Day 1   Day 15  Day 29    Day 42 
* Tumor Disease Evaluations will occur at the end  of cycl es 1 and 2, and then  every other cycle. 
 
Therapy will be discontinued  if there is evidence of progressive disease or drug related dose- limiting 
toxicity that requires removal from therapy. Therapy may otherwise continue  up to 8 cycles  or until one 
of the off protocol therapy criteria in Section 10.1  is met . 
 
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
8 
Version Date: 01/31/19 
 
1.0 GOALS AND OBJECTIVES  (SCIENTIFIC AIMS)  
 
1.1 Primary Aims 
 
1.1.1 To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 
dose (RP2D) of ramucirumab administered as a n intravenous infusion over 60 
minutes , every 2 weeks, to children with recurrent or refractory solid tumors . 
 
1.1.2 To determine the tolerability of the MTD and/or RP2D of ramucirumab in 
children with recurrent or refractory CNS tumors.  
 1.1.3 To def ine and describe the toxicities of ramucirumab administered on this 
schedule.  
 
1.1.4 To characterize the pharmacokinetics and immunogenicity of ramucirumab in 
children with recurrent or refractory solid tumors including CNS tumors. 
 
1.2 Secondary Aims  
 
1.2.1 To preliminarily define the antitumor activity of ramucirumab within the 
confines of a Phase 1 study.  
 
1.3 Exploratory Aims 
 
1.3.1 To explore the pharmacodynamics (PD) effects of ramucirumab in this pediatric 
population.                   
1.3.2 To explore potential predi ctive biomarkers relevant to pediatric cancers, cancer -
related conditions, ramucirumab and angiogenesis.  
 
2.0 BACKGROUND  
 
2.1 Introduction/Rationale for Development  
Angiogenesis, the generation of new blood vessels from existing ones, is an essential 
physiological process that is deregulated in various pathological conditions including 
cancer.
[ADDRESS_690474] decade.3  
 The vascular endothelial growth factor (VEGF)/vascular endothelial growth factor 
receptor (VEGFR -2) pathway (VEGF pathway hereafter) is considered the most 
important mediator of tumor angiogenesis.
[ADDRESS_690475] majority of human tumors including 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
9 
Version Date: 01/31/[ADDRESS_690476]. While clinical benefit has not been universally demonstrated acros s several tumor types, the positive findings of prolonged overall 
survival (OS) and progression free survival (PFS) in the prospective, randomized, 
double- blind phase III VELOUR study (aflibercept versus placebo in combination with 
irinotecan and 5 -FU [FOL FIRI] in the treatment of patients with metastatic colorectal 
cancer [mCRC] after failure of an oxaliplatin based regimen) led to the recent US approval of the aflibercept -FOLFIRI combination  for use  in this patient population.
14 
However, the toxicity profile demonstrated that more patients on the aflibercept arm had 
grade 3 or 4 adverse events (83.5% vs. 62.5%). These events included not just those 
expected with anti -VEGF agents, such as hypertension, hemorrhage, and arterial and 
venous thromboembolic events, but also the potentiation of adverse effects associated 
with FOLFIRI.  
 Anot her therapeutic modality to inhibit angiogenesis involves targeting the VEGF 
pathway by [CONTACT_531897] (TKIs) to block the intracellular tyrosine kinase activity triggered by [CONTACT_12270]/VEGFR -2 binding . TKIs impede the downstream 
signals necessary for endothelial proliferation, survival, and migration that are required 
for tumor growth and metastasis; however, lack of absolute specificity of TKIs for 
VEGFR -2 results in significant â€œoff -targetâ€ inhibition. For example, although the specific 
patte rn of kinase inhibition varies, the TKIs sorafenib,  sunitnib, cediranib, pazopanib, 
and motesanib all additionally inhibit VEGFR s [ADDRESS_690477] mechanism of action.   To this end, selective inhibition of the extracellular domain of VEGFR -2 has been explored.  Ramucirumab, (IMC -
1121B; LY3009806), is a recombinant human monoclonal, receptor -targeted antibody of 
the immunoglobulin G subclass 1 that specifically binds to the extracellular domain of human VEGFR -2 with high affi nity (approximately 50 pM).
17,[ADDRESS_690478], but also 
all other VEGFR -2 activating ligands inclu ding VEGF -C and VEGF -D (Preclinical, Eli 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
10 
Version Date: 01/31/19 
 
Lilly and Company, data on file) . Ramucirumab thus provides a highly specific and 
comprehensive inhibition of the VEGF pathway , effectively  blocking the downstream 
intracellular signaling, which results in prolifera tion, survival, and migration of 
endothelial cells.20-23 Ramucirumab may further reduce signaling by [CONTACT_531898] -2 
internalization  (Preclinical, Eli Lilly and Company, data on file) . Finally, by [CONTACT_531899] -2, ramucirumab has less potential to induce â€œoff -targetâ€ toxicities 
seen with VEGFR -2 TKIs.   
 
Rationale for Use in Pediatrics : Although sur vival for pediatric patients with solid 
tumors has improved with more than 75% cured, prognosis is still poor for patients with metastatic or recurrent disease. These patients need innovative therapi[INVESTIGATOR_531873]. Similar to adult tumors, angiogenesis is upregulated in pediatric embryonal 
tumors making it an important pathway to target with novel anti- angiogenic agents. 
VEGF and its downstream signaling play a vital role in tumor growth and metastasis in children.  Studies have shown high le vels of circulating VEGF levels in children with 
tumors at baseline.
24,25 Neuroblastoma and Wilmâ€™s tumor  tissues express VEGF, and high 
expression is correlated with invasion, metastasis, and risk of recurrence. 26-28 VEGF 
expression drives tumor angiogenesis and in some instances tumor growth and metastasis 
among patients with Ewingâ€™s sarcoma, osteosarcoma, and rhabdomyosarcoma.29-31 
Among osteosarcoma patients, VEGF upregulation is associated with adverse clinical outcomes.
32,33 
 The pre -clinical testing of various anti-angiogenic agents in pediatric cancers has been 
investigated with VEGF ligand or intracellular VEGF receptor inhibition. VEGF ligand 
inhibition with bevacizumab and aflibercept suppresses tumor angiogenesis and growth 
in murine models of rhabdomyosarcoma, neuroblastoma, and hepatoblastoma. In 
addition, aflibercept decreased the tumor vasculature resulting in regression of 
established tumors and lung metastases in an orthotopic xenograft model of Wilmâ€™s tumor.
[ADDRESS_690479] a panel of pediatric solid tumor cell lines by [CONTACT_458354] (PPTP). Although complete responses were rare when tested in vivo, all [ADDRESS_690480] completed Phase- 1 clinical testing in children: 
bevacizumab ,
[ADDRESS_690481] are growth plate abnormalities and cardiotoxicity, given the prevalent use of 
anthracyclines in pediatric regimens. Physeal widening was observed in a single anti -
angiogenic phase 1 trial with pazopanib; no other pediatric studies of VEGF pathway inhibitors have reported growth plate defects. Cardiotoxicities have been observed in 
some patients with prior anthracycline exposure w ho were treated with anti -angiogenic 
agents, though the pathogenesis of this cardiotoxicity and its association with VEGF 
pathway inhibition is not yet known.  Regarding efficacy, while there is minimal data on 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
11 
Version Date: 01/31/[ADDRESS_690482] been reported in patients 
with soft- tissue sarcoma, Ewingâ€™s sarcoma, osteosarcoma, Wilmâ€™s tumor, 
hepatoblastoma, ependymoma, and gliomas.[ADDRESS_690483] â€œoff -targetâ€ toxicities.46,[ADDRESS_690484] udies. Therefore , 
DC101, a rat antibody targeting mouse VEGFR -2 has been used to validate the 
therapeutic utility of targeting VEGFR -2 in vivo . DC101 has pharmacological 
characteristics very similar to ramucirumab meeting the scientific criteria of a surrogate antibody. DC101 was evaluated in a pancreatic cancer BxPC -3 
xenograft model to establish an effective dose regimen and determine the associated plasma concentration to guide subsequent studies. 
48 In this model, 
significant tumor growth inhibition was observed at doses which were on average 
associated with a mi nimum serum drug concentration of 18 Âµg/mL . DC101 has 
demonstrated anti -tumor effect in numerous mouse xenograft solid tumor models 
that include gastric, hepatic, breast, colorect al, and non- small cell lung 
cancers.49,50 Monotherapy with DC101 produced tumor growth inhibition ( TGI) 
up to 59% (range: 27% -78%) and also produced additive effects when combined 
with chemotherapy in multiple tumor types.  Importantly, single agent DC101 
was active across a series of pediatric patient -derived xenograft (PDX) sarcoma 
models including synovial, osteo, Ewingâ€™s, and undifferentiated histologies (TGI 
ranging from 52 % to 88%). Significant activity of DC101 was also observed in combination with doxorubicin in PDX models of Ewings sarcoma and in a mouse 
cell-derived xenograft model of human neuroblastoma (TGI >100% in both 
cases) (Preclinical, Eli Lilly and Company, data on file). Tumor growth 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
12 
Version Date: 01/31/19 
 
inhibition in excess of 100% was also observed in a synovial sar coma PDX 
model when treated with DC101 monotherapy following initial doxorubicin 
therapy and in combination with doxorubicin.  Since the affinity of ramucirumab 
to human VEGFR -[ADDRESS_690485] shown that targeting 
VEGFR -2 with antibody produces tumor growth inhibition in xenografts that 
were resistant to the anti-VEGF TKIs.52 
 
2.2.2 Animal Toxicology:  
The animal toxicology studies of ramucirumab were conducted in cynomolgus 
monkeys. A tissue cross- reactivity study was conducted with a full panel of 
cynomolgus monkey and human tissues that showed that the tissue reactivity  of 
ramucirumab observed in both tissues was similar, indicating that the 
cynomolgus monkey is an appropriate animal model for toxicity testing of 
ramucirumab. In a 5 -week, 4 -dose study, cynomolgus monkeys were given 
ramucirumab I.V. weekly at dose levels 0, 4, 12, or 40 mg/kg on Days 1, 15, 22, and 29, with a subset of monkeys sacrificed after the last dose and a second 
subset of monkeys entering a [ADDRESS_690486] level was 40 mg/kg, the highest dose administered. A second toxicology 
study assessed the long -term (chronic) administration of ramucirumab  in 
cynomolgus monkeys who received doses of 0, 5, 16, or 50 mg/kg administered 
intravenously every week for 12 or 39 weeks . The results revealed nephrotoxicity 
consisten t with multi- focal and marked glomerulonephritis in both kidneys in 
monkeys receiving doses of 16 and 50 mg/kg for [ADDRESS_690487] umab was also conducted at doses 5, 15, and 50 mg/kg  since there is a 
strong role for VEGF  pathway in wound healing. This study did not reveal a 
clinical or histological impairment of wound- healing in this cynomolgus monkey 
linear incision model after a si ngle dose.48 
 
2.2.3 Preclinical Pharmacokinetic Studies : Non-compartmental analysis of the 
concentration -vs-time data from the cynomolgus monkey studies mentioned 
above indicated that the PK behavior of ramucirumab was non- linear over the 4 -
50 mg/kg dose range. Area under the concentration- vs-time curve extrapolated to 
infinity (AUC 0-inf) and maximum concentration (C max) increased in a greater than 
dose- proportional manner. Ramucirumab half -life increased and clearance 
decreased with increasing dose. Mean ramucirumab AUC 0-inf in the 50mg/kg 
group increased between the 1st and the 39th dose, indicating drug accumulation 
consistent with a saturation of receptor mediated clearance.  48  
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
13 
Version Date: 01/31/19 
 
2.3 Adult Studies  
 
2.3.1 Phase 1 Studies : Several adult Phase [ADDRESS_690488] been escalating, single- arm studies in which 
ramucirumab was administered as a single agent (Table 1). In addition, [ADDRESS_690489] also been completed where a fixed dose of ramucirumab has been used in combination with other cytotoxic agents to assess 
safety, tolerability and eff icacy (Table 2).  
 
Table  1: Single -arm, Phase  1 Studies using escalating doses of Ramucirumab17,26-28,48,53 
Study name  [CONTACT_531929]  
I4T-IE-
JVBM  Open -label, 
single -arm Advanced 
solid tumors  2-16 mg/kg qw X  4  Hypertension; 
DVT  13 
mg/kg  
I4T-IE-
JVBN  Open -label, 
single -arm Advanced 
solid tumors  Cohort 1 -3: 6-10 mg/kg  q2w X 4  
Cohort 4 -5: 15 -20 mg/kg   q3w X 4  None  None  
I4T-IE-JVBI  
Japanese  Open -label,  
single -arm Advanced 
solid tumors Cohort 1: 6 mg/kg  q2w  
Cohort 2: 8 mg/kg  q3w 
Cohort 3: 10 mg/kg  q3w None  None  
DLT: dose -limiting toxicity; DVT: deep vein thrombosis . MTD: maximum tolerated dose ; qw: once a week; q2w: 
every 2 weeks; q3w: every 3 weeks .  
The I4T -IE-JVBM study was an open- label, single -arm, dose -escalation study 
involving adults with advanced solid tumors. Pharmacokinetic data revealed 
dose- dependent elimination and nonlinear exposure consistent with saturable 
clearance. At all dose levels,  mean trough concentrations exceeded 20 Âµg/mL.  
This was greater than the biologically significant level for target inhibition of VEGFR -2.
 17,26-[ADDRESS_690490] -treatment levels were 1.5 -3.5 times higher 
than the baseline levels at all dose levels thr oughout the treatment.   
Table 2: Combination studies of fixed- dose ramucirumab and chemotherapy agents in 3 different 
Japanese studies . 48 
Study name  [CONTACT_531930]  
I4T-IE-JVBW  
Japanese  Open -label, 
single -arm Gastric ACA 
(n=6)  RAM: 10  mg/kg  Days 1 and 15 and 
PAC : 80 mg/m2 - Days 1, 8, and 15  SD:5; PR:[ADDRESS_690491] CA  
(n=7)  RAM: 10  mg/kg  q3w + DOC : 75 
mg/m2 q3w SD:3; PR:4  
I4T-IE-JVBY  
[CONTACT_531900] -label, 
single -arm Colorectal CA  
(n=6)  RAM: 10  mg/kg  q2w + FOLFIRI  SD:4;  PR:1, PD:1  
ACA: adenocarcinoma; CA: carcinoma;  DOC: docetaxel; FOLFIRI: folinic acid, 5 -FU, irinotecan; n: sample size; 
PAC: paclitaxel; PR: partial response; PD: progressive disease RAM: ramucirumab;  SD: stable dis ease;  q2w: every 
2 weeks; q3w: every 3 weeks . 
 
2.3.2 Phase 2 Studies : 8 mg/kg I.V. q2 weeks as a monotherapy was selected as the 
adult RP2D in certain selected indications based on PK data from the Phase 1 
I4T-IE-JVBM study.17 The results of the Phase 2 studies are summarized in the 
Table 3.  
Table 3: Response data from single- arm and double -arm Phase  2 studies48,54-56 
Study name  [CONTACT_531931]/PFS/OS (95% CI)  
I4T-IE-
JVBQ  Open -label, 
single -arm Liver CA   (n=43)  RAM: 8  mg/kg  q2w ORR: 9.5% (2.7 -22.6%)  
OS: 12 (6.1 -19.7) 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
14 
Version Date: 01/31/19 
 
I4-IE-JVBP  Open -label, 
single -arm mRCC. (n=39)  RAM: 8  mg/kg  q2w ORR: 5.1% (0.6 -17.3%)  
OS: 24.8 (18.9 -32.6)  
I4T-IE-JVBJ  Open -label, 
single -arm NSCLC. (n=40)  RAM (10 mg/kg  q3w) + PAC 
+ CARBO  ORR: 55%  
PFS: 7.85 (5.49-9.86) 
OS: 16.85 (14.82 -28.58)  
I4T-IE-
JVBH  Open -label, 
single -arm mCRC. (n=48)  RAM (8  mg/kg  q2w) + OXA 
+ FA + 5 -FU ORR: 58.3%  
PFS: 11.5 (8.6-13.1) 
OS: 20.4 (18.5 -25.1)  
I4T-IE-JVBR  Open -label, 
single -arm Ovarian/fallopi[CONTACT_1629] / 
primary peritoneal  
 CA  (n=60)  RAM: 8 mg/kg  q2w ORR: 5%  
PFS: 3.5 (2.3-5.3) 
OS: 11.1 (8.3 -17) 
I4T-IE-
JVBO  Open -label, 
double- arm Melanoma. 
(n=105) Arm A : RAM (10 mg/kg 
q3w) + DAC (1000mg/m2) 
q3w 
Arm B :  RAM (10 mg/kg 
q3w) Arm A : ORR: 17.3% 
              PFS-2.6 (1.4- 5.4)    
              OS -8.7 (7.1-12.9) 
Arm B : ORR: 4%  
              PFS-1.7 (1.4-2.9) 
              OS-11.1 (7.7-14.6) 
I4T-IE-JVBS  Open -label, 
double- arm Prostate CA. 
(n=66) Arm A : CIXUT  (6 mg/kg  
q3w)+ MITO+ PRED  
Arm B : RAM (6  mg/kg  q3w) 
+ MITO + PRED  Arm A : PFS -4.1 (2.2 -5.6)    
               OS -10.8 (6.5-13) 
Arm B : PFS-6.7 (4.5-8.3) 
               OS-13 (9.5 -16) 
5-FU: 5 -fluorouracil ; CA: carcinoma; CARBO: carboplatin; CI: confidence interval;  CIXUT : cixutumumab ; DAC: 
dacarbazine;  FA: folinic acid; mCRC: metastatic colo -rectal carcinoma; mRCC: metastatic renal cell carcinoma; 
MITO: mitoxantrone; n: sample size;  NSCLC: non -small cell lung cancer; ORR: objective response rate; OS: 
median overall survival in months ; OXA; oxaliplatin ; PAC: paclitaxel; PRED: prednisone ; PFS: median 
progression- free survival in months; RAM: ramucirumab ; q2w: every 2 weeks ; q3w: every 3 weeks . 
 
2.3.3 Phase 3 Studies : Results from six Phase [ADDRESS_690492] been completed and 
summarized  in Table 4  below.  
 
Table 4: Median PFS and OS from Phase  3 trials of ramucirumab57-62 
Study name  [CONTACT_531932]  
(months)  Median OS                
(months)  
REGARD  randomized , 
placebo -
controlled, 
blinded  Advanced 
gastric/GE J 
CA RAM: 8 mg/kg   q2w + BSC  2.1 vs.  1.3 
p<0.0001 5.2 vs.3.8  
p=0.047 
RAINBOW  randomized , 
placebo -
controlled, 
blinded  Gastric/GE J 
CA RAM (8 mg/kg  q2w) + 
PAC   4.40 vs.  2.86  
p<0.0001 9.63 vs.7.36  
p=0.0169 
REVEL  randomized , 
placebo -
controlled, 
blinded  NSCLC  RAM ( 10 mg/kg  q3w) + 
DOC  4.5 vs. 3  
p<0.0001  10.5 vs.9.1  
p=0.[ADDRESS_690493] CA  RAM ( 10 mg/kg  q3w) + 
DOC  9.5 vs. 8.2  
p>0.05 27.3 vs. 27.2  
p=0.915 
REACH  randomized , 
placebo -Liver CA  RAM: 8 mg/kg  q2w + BSC  NS NS 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
15 
Version Date: 01/31/19 
 
controlled, 
blinded  
RAISE  randomized , 
placebo -
controlled, 
blinded  Metastatic 
Colorectal 
CA RAM (8  mg/kg  q2w) +  
FOLFIRI  5.7 vs. 4.5  
p=0.0005 13.3 vs. 11.7  
p=0.0219 
BSC: Best Supportive Care;  DOC: docetaxel;  FOLFIRI: 5 -FU, folinic acid  and irinotecan ; GEJ CA: gastro -
esophageal junction adeno carcinoma; NS: not significant; NSCLC: non-s mall cell lung cancer; RAM: ramucirumab; 
PAC: paclitaxel; q2w: every 2 weeks ; q3w: every 3 weeks.   
 
2.3.4 Safety : Adverse events (AEs) for [ADDRESS_690494] received ramucirumab 
on 7 Phase 1/1b studies, 16 open- label Phase 2 studies, and 1 Phase 3 study are 
available. Adverse drug reactions (AEs for which a causal relationship to ramuciru mab was considered at least possible ) of special interest include AEs 
which  have been associated with other anti -angiogenic agents and monoclonal 
antibodies and include the following  categories : infusion -related reaction s, 
hypertension, proteinuria, arterial thromboembolic events, bleeding/hemorrhagic 
events, and gastro -intestinal perforation.  
 
In the Phase 3, REGARD study (n=236 ramucirumab arm), the AE profile of ramucirumab was similar to the placebo. Majority of patients received full dose 
of ramucirumab (dose intensity= 99.6%) with few dose delays or modifications. 
The most common treatment emergent AE that occurred in the ramucirumab 
group versus the placebo group at a higher rate (any grade) was hypertension 
(16.1% vs 7.8%), diarrhea (14.4% vs.8.7%), and headache (9.3% vs.3.5%). The 
overall incidence of Grade 3 -5 treatment emergent AEs were similar between the 
2 groups (56.8% vs.58.3%). The most common Grade â‰¥ 3 treatment emergent 
AE occurring in the ramucirumab group at a higher rate was hypertension (7.2% vs. 2.6% for Grade -3 hypertension). No individual Grade â‰¥ 3 treatment emergent 
AE was observed i n > than 10% of patients. Serious AEs, hospi[INVESTIGATOR_531874] 2 groups indicating a good 
therapeu tic-index profile for ramucirumab. Discontinuations due to AE were low 
in both groups but higher in the ramucirumab group than the placebo (10.5% 
vs.6%) with no specific AEs resulting in discontinuation. Deaths due to AEs  
were less common in ramucirumab vs. placebo group (9.3% vs.13%).  
2.3.5 Pharmacology/Pharmacokinetics/Correlative and Biological Studies  
 
Pharmacokinetic Studies : The PK of ramucirumab was first studied in patients 
with solid tumors administered across a range of doses from 2 to 16 mg/kg adminis tered weekly via 1 -hour I.V. infusions in I4T-IE-JVBM (IMCL CP12 -
0401). Apparent nonlinear PK profiles were observed between 2 and 8 mg/kg; 
PK profiles appeared to be linear at doses of 8 mg/kg and above, suggesting 
saturation of the target- mediated (VEGF  Receptor 2) clearance pathway.
17  
 
Trough concentrations (or minimum concentrations [C min]) were collected in two 
Phase 3 studies (REGARD and RAINBOW) in patients with gastric cancer.  Following the recommended clinical dose regimen of 8 mg/kg every [ADDRESS_690495] and RAINBOW ( Table 1 ). 
The geometric mean (percentage coefficient of variation [CV%])  observed 
trough values approached 50 Âµ g/mL before the fourth dose, and ranged between 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
16 
Version Date: 01/31/19 
 
60 and 75 Âµ g/mL before the seventh dose.48  
Table 1. Summary of Observed Ramucirumab Trough Concentrations for Patients with 
Advanced Gastric Cancer Following Administration of 8  mg/kg of Ramucirumab 
Every 2 Weeks as an IV Infusion over Approximately 1  Hour Alone (REGARD) or 
in Combination with Paclitaxel (RAINBOW)  
 Trougha Serum Concentrations ( Âµg/mL)  
Dose Number  [ADDRESS_690496]  RAINBOW  
nPK 53 203 34 142 
Geo Mean  49.5 45.0 74.4 62.8 
Geo CV%  81 50 58 47 
Abbreviations:  CV% = percentage coefficient of variation; Geo = geometric; IV = intravenous; n PK = number of 
pharmacokinetic observations included in calculation.  
a Trough concentrations were obtained prior to Doses 4 and 7.  They also represent C min following Doses 3 and 6.  
 
Pharmacokinetic data from the 8  studies involving 497 patients were also pooled 
together for a population pharmacokinetic (PopPK) analysis. In these studies, 
ramucirumab  was administered as a 1 -hour I.V. infusion, at either 8 mg/kg once 
every 2  weeks on a 14- or 28- day cycle, or 10 mg/kg every 3  weeks on a 21 -day 
cycle. The studies included patients with varying cancer indications:  gastric 
cancer (80.5% of patients), non- small cell lung cancer (NSCLC; 8.2%), breast 
cancer (2.2%), colorectal cancer (CRC; 1. 6%), and other tumor types (7.4%).  
The geometric mean of PopPK model -derived estimates of ramucirumab 
clearance (CL), volume of distribution at steady state  (Vss) and terminal half -life 
(t1/2) were 0.0140 L/h (29.8%), 5.5 L (14.4%), and 15 days (24.1%), re spectively. 
These parameter estimates were consistent with those observed with other human 
monoclonal IgG1 antibodies.63 Results from the PopPK analyses indicate that the 
PK of ramucirumab following 8- and 10- mg/kg dose administrations were dose 
linear (absolute dose range:  169 to 1234 mg) and time  independent. In addition, 
covariate analysis indicated that ramucirumab PK was not affected by [CONTACT_149262] (range, 31.9 to 133.0 kg), sex, age (range, 19 to 86 years), serum albumin 
(range, 15.5 to 64.8 g/L), race (Whi te and Asian), hepatic status (as assessed by 
[CONTACT_14427]  [range, 1 to 251 IU/L], aspartate transaminase [range, 1 to 276 IU/L], alkaline phosphatase [range, 31 to 2300 IU/L], and total bilirubin 
[range, 1.2 to 78.5 Âµ mol/L]), and renal functi on (as assessed by [CONTACT_3158] -Gault 
creatinine clearance [range, 20.2 to 231 mL/min]).  
 
Immunogenicity :  Ramucirumab is a human monoclonal antibody with a 
potential to induce formation of anti -drug antibody (ADA) when administered to 
human. The development of ADA has been studied across 16 studies involving 
1462 evaluable patients (1033 receiving ramucirumab and 429 receiving placebo) 
and the frequency of ADA and neutralizing ADA is low.[ADDRESS_690497] baseli ne ADA sample was greater than 4 -fold higher than baseline value or 
with a titer > than 1:20. Overall the number of patients with treatment emergent 
ADA was low at 1.1% in ramucirumab- treated patients who had at least [ADDRESS_690498] 
treatment sample tested (n=884) .  In the 321 patients who received either placebo 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
17 
Version Date: 01/31/[ADDRESS_690499] supportive care (BSC) or placebo plus paclitaxel and who had at least [ADDRESS_690500]- treatment sample tested, 16 patients (5.0%) had ADA detected post -
treatment and 2 patients (0.6%) had treatment emergent ADA.  None of these [ADDRESS_690501] Phase 3 studies.  
48 
 
Correlative and Biological Studies : 
Pharmacodynamic circulating plasma molecular markers: Ramucirumab, 
(IMC -1121B, LY3009806) is a human receptor -targeted antibody that 
specifically blocks VEGF Receptor 2.  The binding of ramucirumab to VEGF 
Receptor [ADDRESS_690502] shown that VEGF -A levels were increased from 
baseline (range: 0 to 10 -fold) following ramucirumab administration. Since it 
prevents receptor binding of circulating VEGF , this is consistent with its 
mechanism of action. Other VEGF ligands such as VEGF -D which also bind to 
VEGFR -2 were also elevated. Placental growth factor (PlGF)  levels were also 
elevat ed from baseline (range: 0 to 20 fold), even though PlGF  has not been 
shown to bind to VEGFR -2.64,65 The mechanism of the elevation of placental 
growth factor levels is not known. Additionally, using newly- developed assays, 
correlation s between pharmacodynamics changes with tumor response and 
survival are currently ongoing for multiple ramucirumab adult Phase 3 trials.  
These analyses may provide i nsight into ramucirumab activity that could be 
important to investigate in the pediatric population as well.    
 
Circulating pharmacodynamic cellular biomarkers: To date, a c onsistent 
predictive biomarker for clinical efficacy of anti -VEGF therapy has not been 
identified. This produces challenges for clinicians in the upfront select ion of  
which patients might  benefit or not from  anti- VEGF therapi[INVESTIGATOR_014]. In adult patients 
with gastrointestinal stromal tumors treated with sunitinib, a rise in mature circulating endothelial cells was associated with clinical benefit
66 while results 
from a Phase- I pediatric study of bevacizumab showed circulating endothelial 
cells correlated with prolonged stable disease.36 Circulating endothelial 
progenitor cells (EPCs) have been identified as predictive biomarkers of clinical 
efficacy for anti -angiogenic agents.67 However, there has been a  lack of 
consensus  in defining EPCs  leading to groupi[INVESTIGATOR_531875] â€œEPCâ€  and thus an inability  to compare  study results. Utili zing a 
novel multi- parametric flow  cytometry  (MPFC)  protocol, our group has 
identified  and defined the bona fide EPC,  nam ely  the  endothelial  c olony  
forming  ce lls  (ECFCs)  that  are  identified  CD31+CD34bright CD45- AC13 3- 
CD14-LIVE/DEA D- cells,  have  high proliferative  potential, and give rise to 
perfused  vessels in vivo. 68-[ADDRESS_690503]  also enumerated circulating  
endothelial cells (CECs)  that are identified  as CD31 bright CD4 5- CD3 4dimAC1 33- 
cells which  are mature,  apoptotic  endothelial c ells sloughed off from the vessel  
wall during vascular  remodeling and do not form  perfused  blood vessels in 
vivo. Fin ally, using MPFC  we have  identified  a unique circulating  
hematopoietic stem and progenitor cell (CHSPC)  population in both 
peripheral  blood ( PB) and umbilic al cord blood, which  is phenotypi [INVESTIGATOR_897] a nd 
functiona lly distinct from  EPCs but is still activ ely invol ved in angiogenesis .68,73 
These  CHSPCs  are vital for blood vessel format i on in physiologic al and 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
18 
Version Date: 01/31/[ADDRESS_690504] cellular subsets based on both 
cell surface antigen expression and function.74 The pro-angiogenic CHSPCs  
(pCHSPCs) express  AC133, while  the non-angiogenic CHSPCs (nCHSPCs)  do 
not, otherwise  they are   identical   in    their    phenotypic    definition    
showing  the  exp ression  of CD31+ CD34bright CD4 5dim CD1 4- LIVE/DEAD-. 
The ratio of the pCHSPCs  to nCHSPCs  is a  way  to  normalize  variability  in  
the  total  number  of  CHSPC s,  with  normal  ratios between  1.2-1.8. An 
increased  pCH SPC: nCHS PC ra tio (>2.0) is associated with tumor -induced 
angiogenesis.74-[ADDRESS_690505] cancer, results 
show ed a decrease i n the pCHSPC: nCHSPC ratio among women who 
responded to treatment .76 Therefore, the pCHSPC: nCHSPC ratio, CECs  and the 
ECFCs are the circulating, cellular markers are of particular interest  for further  
investigat ion in additional Phase  [ADDRESS_690506] been completed in adults and 3 additional Phase 3 trial s are ongoing.  The 
recommended dose in adults is 8 mg/kg IV administered over 1 hour every 2 weeks for 
patients with gastric cancer. For patients with NSCLC, the recommended dose in adults is 
10 mg/kg IV administered over [ADDRESS_690507], including dose -limiting hypertension at 10 mg/kg IV weekly, and deep 
venous thrombosis at 16 mg/kg IV weekly. Similar to other monoclonal antibodies, ramucirumab has a long half -life and is expected to accumulate.  Based on adult PK 
studies, steady state is anticipated to be achieved after the third dose administered q 2 weeks.  Initial PK studies in adults demonstrated non -dose proportional exposure at dose 
levels 2 - 8 mg/kg weekly.  At 8 mg/kg q week and above, systemic clearance decreased 
indicating a saturable receptor mediated clearance mechanism such as binding to VEGFR -2. The target trough concentration established in vitro was 18 Âµg/mL.   
However, in the pi[INVESTIGATOR_9205] [ADDRESS_690508] (8 mg/kg I .V. q 2 week s, as 
monotherapy ) and RAINBOW (8 mg/kg IV q 2 weeks  in combination with paclitaxel ) 
exposure- efficacy analyses indicated that improvements in OS and PFS were associated 
with increasing ramucirumab exposure. In RAINBOW  (N=321) , patients with 
ramucirumab ex posure greater than  the median (in the 3
rd and 4th quartile s) were 
associated with longer OS and PFS and significantly better treatment effects (smaller HR) as compared to patients with ramucirumab exposure lower than the median ( in the 1
st and 
2nd quartiles) . The median OS times for 1st, 2nd, 3rd, and 4th exposure quartiles were 6.5, 
8.6, 11.0, and 12.[ADDRESS_690509] ratios were 1.04, 0.84, 0.69, and 0.53, respectively, in ramucirumab plus paclitaxel arm. Similar exposure- efficacy trend 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
19 
Version Date: 01/31/[ADDRESS_690510] despi[INVESTIGATOR_531876] (N=72). Further PKPD 
modelling and simulation analysis indicated EC 50 value (in terms of minimum 
concentration at steady state, C min,ss) was ~ 50 ug/mL, which was also the approximate 
media nCmin,ss value in RAINBOW. It is therefore of interest to identify a dose which will 
produce C min,ss  of 50 ug/mL or higher in a majority of patients, and identify a safety 
profile so as to assist in the selection of a potentially efficacious dose for pediatric 
populations entering Phase 2 studies and beyond. 
 
Based on the safety profile in adults and the lack of DLTs at 8 mg/kg IV q 2 week dose 
level, we propose a dose finding study that, in the absence of DLTs, the recommended 
dose of ramucirumab in c hildren and adolescents will be based on achieving a C min,ss â‰¥ 
50 Âµg/mL after 3 doses of ramucirumab administered every 2 weeks (C min will be 
obtained course 1 day 42 Â±[ADDRESS_690511] before dose 4).  A 
rolling 6 design will be used.  Starting dose will be 8 mg/kg IV every 2 weeks x 3 doses 
per 42 day course. In this pediatric trial in the absence of dose limiting toxicity that 
defines a maximum tolerated dose, we propose a dose escalation to achieve a Cmin,ss of 
50 Âµg/mL  in children and adolescents with relapsed or refractory solid tumors. One 
observation from the RAINBOW and REGARD trials was a tendency for concentrations 
to be decreased  in the lower  body weight quartiles in population PK analysis . The 
planned dose escalation in children and adolescents will permit evaluation of a  higher 
dose to achieve comparable serum exposures seen in adults [personal communication 
with Eli Lilly]. If the  MTD is not exceeded (0 or 1 DLT/6 fully evaluable patients) at 8 
mg/kg dose level , a second dose level will be explored at the escalated dose of 12 mg/kg 
IV q 2 weeks x 3 doses per course. After accrual to Dose Level 2 is completed, PK comparisons from dose levels 1 and 2 will be performed. If PK analysis indicates that 
more than one patient treated at 12 mg/kg dose level has a day 4 2 C
min significantly less 
than 50 Âµg/mL, and the MTD has not been exceeded, additional dose levels will be 
considered.  The next dose level will be established based on C min from children who 
received 8 mg/kg/dose and 12 mg/kg/dose on this trial, and will not exceed 16 mg/kg per 
dose q 2 weeks x 3 doses (adult MTD: 13 mg/kg weekly).  If the MTD in children and 
adolescents is exceeded at 8 mg/kg IV q 2 weeks x 3 doses within the 4 2 day evaluation 
period for  toxicity during course 1, de -escalation to 6 mg/kg will be considered, and the 
recommended dose will be based on the MTD. An expansion cohort will accrue at the 
lowest tolerable dose at which C min of â‰¥ 50 ug/mL has been achieved in at least 5 out of 
6 eva luable patients, to acquire PK data in a representative number of young patients 
(i.e. patients < 12 years old). If at least [ADDRESS_690512] a 
steady state concentration of ramucirumab greater than 50 Âµg/mL, then the RP2D has  
been defined.  
 
3.0 SCREENING AND STUDY  ENROLLMENT PROCEDURE S 
 
Patient enrollment for this study will be facilitated using the Slot- Reservation System in 
conjunction with the Oncology Patient Enrollment Network ( OPEN ), a web -based registration 
system available on a 24/7 basis. It is integrated with the NCI Cancer Trials Support Unit (CTSU) 
Enterprise System for regulatory and roster data and, upon enrollment, initializes the patient 
position in the RAVE  database.    
Access requirements for OPEN :  
Investigators and site staff will need to be registered with CTEP and have a valid and active 
Cancer Therapy Evaluation Program -Identity and Access Management (CTEP- IAM ) account  
(check at <  https://ctepcore.nci.nih.gov/iam/index.jsp >). This is the same account (user id and 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
20 
Version Date: 01/31/[ADDRESS_690513]) used for credentialing in the CTSU members' web site. To perform registrations in 
OPEN, the site user must have been assigned the 'Registr ar' role on the relevant Group or CTSU 
roster. OPEN can be accessed at https://open.ctsu.org or from the OPEN tab on the CTSU 
membersâ€™ side of the website at https://www.ctsu.org.  Registrars must hold a minimum of an AP 
registration type.   
All site staff will use OPEN to enroll patients to this study. It is integrated with the CTSU 
Enterprise System for regulatory and roster data and, upon enrollment, initializes the patient 
position in the Rave database . OPEN can be accessed at  https://open.ctsu.org  or from the OPEN 
tab on the CTSU membersâ€™ side of the website at  https://www.ctsu.org . To assign an IVR or 
NPI[INVESTIGATOR_6688], crediting, consenting, drug shipment (IVR only), or investigator receiving 
a transfer in OPEN, the IVR or NPI[INVESTIGATOR_6689] 1572 in RCR the IRB number used on the siteâ€™s IRB approval.   
 
3.1 Current Study Status  
Investigators should refer to the COG website to determine if the study is currently open 
for accrual.  If the study is listed as active, investigators should  then access the Studies 
Requiring Reservations page to ensure that a reservation for the study is available. To access the Studies Requiring Reservations page:  
1. Log in to https://open.ctsu.org/open/ 2.  Click the Slot Reservation Tab.  The Site Patient page opens.  
3.  Click the Report Tab. The Slot Reservation Report opens. Available Slots are 
detailed per study strata.  
3.[ADDRESS_690514] submit IRB/REB approvals to the NCIâ€™s Cancer Trials Support Unit 
(CTSU) Regulatory Office and allow [ADDRESS_690515] include a coversheet (or optional CTSU IRB Transmittal Sheet) and the IRB 
approval document(s). The CTSU IRB Certification Form may be submitted in lieu of the 
signed IRB approval letter.  All CTSU forms can be located on the CTSU web page 
(www.ctsu.org ). Any other regulatory documents needed for access to the study 
enrollment screens will be listed for the study on the CTSU Memberâ€™s Website under the RSS Tab.    
Sites participating on the NCI CIRB initiative and accepting CIRB approval for the study 
are not required to submit separate IRB approval documentation to the CTSU Regulatory 
Office for initial, continuing or amendment review. This information will be provided to 
the CTSU Regulatory Office from  the CIRB at the time the siteâ€™s Signatory Institution 
accepts the CIRB approval. The Signatory site may be contact[CONTACT_531901]. 
 
Submitting Regulatory Documents: 
 
Submit required forms and documents to the CTSU Regulatory Office via the Regulatory 
Submission Portal, where they will be entered and tracked in the CTSU RSS. 
 
Regulatory Submission Portal: www.ctsu.org (membersâ€™ area) ï€¢ Regulatory Tab 
ï€¢ Regulatory Submission 
When applicable, original documents should be mailed to: 
CTSU Regulatory Office  
[ADDRESS_690516] 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
21 
Version Date: 01/31/19 
 
Philadelphia, PA [ZIP_CODE] 
 
Institutions with patients waiting that are unable to use the Portal should alert the CTSU 
Regulatory Office immediately at 1 -866-651- 2878 in order to receive further instruction 
and support. For general (non -regulatory) questions , call the CTSU General Helpdesk at 
[PHONE_031] or contact [CONTACT_531902]  [EMAIL_013] . 
 
Study centers can check the status of their registration packets by [CONTACT_99221]â€™s Website under the Regulatory Tab. 
(Note: Sites will not receive formal notification of reg ulatory approval from the CTSU 
Regulatory Office.) 
 
3.[ADDRESS_690517] be assigned a COG patient ID number. This 
number is obtained via the COG Registry  system  once authorization for the release of 
protected health information (PHI) has been obtained. 
 
3.[ADDRESS_690518] be made through the OPEN 
website and the Study Chair or Vice Chair should be notified. (The patient will need a 
COG patient ID number in order to obtain a reservation). Patients must be enrolled within 
7 calendar days of making a reservation.   
Reservations may be obtained 24 -hours a day through the OPEN website.   
3.5 Informed Consent/Assent  
The investigational nature and objectives of the trial, the procedures and treatments 
involved and their attendant risks and discomforts, and potential alternative therapi[INVESTIGATOR_6691]â€™s parents or guardian if the patient is a 
child, and a signed informed consent and assent will be obtained according to 
institutional guidelines.  
3.[ADDRESS_690519] only be done after obtaining written informed consent.  This can be 
accomplished through one of the following mechanisms: a) an IRB -approved institutional 
screening protocol or b) the study -specific protocol.  Docu mentation  of the informed 
consent for screening will be maintained in the patientâ€™s research chart . Studies or 
procedures that were performed for clinical indications (not exclusively to determine 
eligibility) may be used for baseline values even if the st udies were done before informed 
consent was obtained.  
 
3.[ADDRESS_690520] 
include the associated study number and COG patient registration and accession 
numbers. Personal identifiers, including the patientâ€™s name [CONTACT_531933]1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
22 
Version Date: 01/31/[ADDRESS_690521] 
been met. Patients who give informed consent for the protocol in order to undergo 
screening for eligibility are not considered enrolled and should not be enrolled until the screening is completed and they are determined to meet all eligibility criteria. Study 
enrollment is accomplished by [CONTACT_99222] (Oncology Patient Enrollment 
Network) https://open.ctsu.org/open/ . For questions, please contact [CONTACT_531903], or the  CTSU OPEN helpdesk at 
https://www.ctsu.org/CTSUC ontact.aspx.  Patients must be enrolled before treatment 
begins.  The date protocol therapy is projected to start must be no later than five ( 5) 
calendar days after the date of study enrollment. Patients must not receive any protocol 
therapy prior to enrollment.  
 
3.[ADDRESS_690522] be no 
older than seven (7) days at the start of therapy.  Laboratory tests need not be repeated if therapy 
starts within  seven (7) days of obtaining labs to assess eligibility .  If a post -enrollment lab value 
is outside the limits of eligibility, or laboratory values are older  than [ADDRESS_690523] be re- checked within 48 hours pr ior to initiating therapy: CBC with 
differential, bilirubin, ALT (SGPT) and serum  creatinine.  If the recheck is outside the limits of 
eligibility, the patient may not receive protocol therapy and will be considered off protocol 
therapy. Imaging studies , bone marrow biopsy  and/ or aspi[INVESTIGATOR_521399] 14 days  
prior to start of protocol therapy (repeat the tumor imaging if necessary).   
 
 
Clarification in timing when counting days : As an example, please note that if the patientâ€™s last 
day of prior  therapy is September 1st, and the protocol requires waiting at least  7 days for that 
type of prior therapy, then that patient cannot be enrolled until September 8th.   
 
Important note : The eligibility criteria listed below are interpreted literally and cannot be 
waived (per COG policy posted 5/11/01).  All clinical and laboratory data required for 
determining eligibility of a patient enrolled on this trial must be available in the patien tâ€™s 
medical or research record which will serve as the source document for verification at the 
time of audit.  
 
4.1 Inclusion Criteria  
 
4.1.1 Age:  Patients must be â‰¥ 12 months and â‰¤ 21 years of age at the time of study 
enrollment.  
 
4.1.2 Diagnosis:  
Part A : Patients with recurrent or refractory non-CNS solid tumors are eligible. 
Patients must have had histologic verification of malignancy at original diagnosis or relapse
 except patients with extra -cranial germ-cell tumors who have 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
23 
Version Date: 01/31/[ADDRESS_690524] CNS metastases.  
 
Part B: Patients with recurrent or refractory CNS tumors will be eligible and 
must have a histological verification of malignancy at original diagnosis or 
relapse except in patients with intrinsic brain stem tumors, optic pathway 
gliomas, or patients with CNS -germ cell tumors and elevations of CSF or serum 
tumor markers including alpha-fetoprotein or beta -HCG. 
 
4.1.3 Disease Status: Patients must have either measurable or evaluable disease (see 
Sections 12.2 and 12.3  for definitions).  
 
4.1.4 Therapeutic Options : Patientâ€™s current disease state must be one for which there 
is no known curative therapy or therapy proven to prolong survival with an 
acceptable quality of life.  
  
4.1.5 Performance Level :  Karnofsky â‰¥ 50% for patients > 16 years of age and Lansky 
â‰¥ 50 for patients â‰¤ 16 years of age (See Appendix I ).  Note :  Ne urologic deficits 
in patients with CNS tumors must have been relatively stable for at least  7 days 
prior to study enrollment.  Patients who are unable to walk because of paralysis, 
but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.  
 
4.1.6 Prior Therapy  
 [IP_ADDRESS]  Patients must have fully recovered from the  acute toxic effects of all 
prior anti -cancer therapy .  
a. Myelosuppressive chemotherapy:  At least [ADDRESS_690525] dose 
of myelosuppressive chemotherapy (42 days if prior nitrosourea).  
b. Hematopoietic growth factors : At least [ADDRESS_690526] dos e of 
a long -acting growth factor (e.g. Neulasta) or [ADDRESS_690527] be discussed with the study chair.  
c. Biologic (anti- neoplastic agent) :  At least [ADDRESS_690528] be discussed with the study 
chair.  
d. Immunotherapy : At least 42 days after the completion of any type of 
immunotherapy, e.g. tumor vaccines. 
e. Monoclonal antibodies : At least [ADDRESS_690529] dose of a monoclonal antibody. (See table on DVL homepage 
listing monoclonal antibody half- lives.)  
f. XRT :  At least 14 days after local palliative XRT (small  port); At 
least [ADDRESS_690530] elapsed if prior TBI, craniospi[INVESTIGATOR_99187] 
â‰¥ 50% radiation of pelvis; At least [ADDRESS_690531] elapsed if 
other substantial BM radiation. 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
24 
Version Date: 01/31/19 
 
g. Stem Cell Infusion without TBI :  No evidence of active graft vs. host 
disease and at least [ADDRESS_690532] received prior exposure to ramucirumab . 
 
4.1.7 Organ Function Requirements 
 
[IP_ADDRESS]  Adequate Bone Marrow Function Defined as: 
 
a. For patients with solid tumors without known bone marrow 
involvement: 
- Peripheral absolute neutrophil count (ANC) â‰¥ 1000/mm3 
- Platelet count â‰¥ 100,000/ mm3 (transfusion independent, defined 
as not receiving platelet transfusions for at least 7 days prior to 
enrollment) 
- Hemoglobin â‰¥   8.0 g/dL at baseline (may receive RBC 
transfusions)  
 
b. Patients with known bone marrow metastatic disease will be 
eligible for study provided they meet the blood counts in 
[IP_ADDRESS].a (may receive transfusions provided they are not known to be refractory to r ed cell or platelet transfusions). These 
patients will not be evaluable for hematologic toxicity . At least [ADDRESS_690533] be evaluable for hematologic toxicity.  
 
[IP_ADDRESS]  Adequate Renal Function Defined as: 
- Urine protein: â‰¤ 30 mg/dl in urinalysis or â‰¤ 1+ on dipstick, unless quantitative protein is < 1000 mg in a 24 h urine samp le. 
- Creatinine clearance or radioisotope GFR â‰¥ 70ml/min/1.73 m2 or 
- A serum creatinine based on age/gender as follows:   
Age 
 Maximum Serum  
Creatinine (mg/dL)  
 Male  Female  
1 to < 2 years  0.6 0.6 
2 to < 6 years  0.8 0.8 
6 to < 10 years  1 1 
10 to < 13 years  1.2 1.2 
13 to < 16 years  1.5 1.4 
â‰¥ 16 years  1.7 1.4 
The threshold creatinine values in this Table were derived from the Schwartz 
formula for estimating GFR  (Schwartz et al. J. Peds, 106:522, 1985)  utilizing 
child length and stature data published by [CONTACT_6750].  
 
[IP_ADDRESS]  Adequate Liver Function Defined as: 
- Bilirubin (sum of conjugated + unconjugated) â‰¤ 1.5 x upper limit of 
normal (ULN) for age  
- SGPT ( ALT) â‰¤ 110 U/L.  For the purpose of this study, the ULN for 
SGPT is 45 U/L.  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
25 
Version Date: 01/31/19 
 
- Serum albumin â‰¥  2 g/dL. 
  
[IP_ADDRESS]  Adequate Cardiac Function Defined As : 
- Shortening fraction of  â‰¥  27% by [CONTACT_6751], or 
- Ejection fraction of â‰¥ 50% by [CONTACT_6752]. 
 
[IP_ADDRESS]  Adequate Blood Pr essure Control Defined as: 
A blood pressure (BP) â‰¤ the 95th percentile for age, height, and gender 
(Appendix VIII) measured as described in  Section 6.4 , and not receiving 
medication for treatment of hypertension.  Please note that 3 serial blood 
pressures should be obtained and averaged to determine baseline BP. 
 
[IP_ADDRESS]  Adequate  Coagulation Defined as: 
- INR â‰¤ 1.5  
 
4.1.8 Informed Consent : All patients and/or their parents or legally authorized 
representatives must sign a written informed consent. Assent, when appropriate, 
will be obtained according to institutional guidelines.   
 
4.1.[ADDRESS_690534] dose of ramucirumab . A highly effective method of 
contraception is defined as one that results in a low failure rate (that is, <1% per year) when used consistently and correctly. Barrier methods used alone are not 
highly e ffective methods of contraception. For female patients, if a barrier 
method is used, a hormonal method must be used with it to ensure that pregnancy does not occur. Abstinence is an acceptable method of birth control . Those who 
become pregnant while on tre atment with ramucirumab  must discontinue 
immediately and consult their treating physician.  
 
4.2.2 Concomitant Medications  
 
[IP_ADDRESS]  Corticosteroids :  Patients receiving corticosteroids who have not been on 
a stable or decreasing dose of corticosteroid for at least  7 days prior to 
enrollment are not eligible.  
 
[IP_ADDRESS]  Investigational Drugs :  Patients who are currently receiving another 
investigational drug are not eligible.  
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
26 
Version Date: 01/31/19 
 
[IP_ADDRESS]  Anti-cancer Agents:  Patients who are currently receiving other anti-
cancer agents are not  eligible.  
 
[IP_ADDRESS]  Anti-GVHD agents post -transplant :  
Patients who are receiving cyclosporine, tacrolimus or other agents to 
prevent graft -versus- host disease post bone marrow transplant are not 
eligible for this trial.  
 
[IP_ADDRESS]  Anti-inflammatory agents: Patients who are chronical ly receiving aspi[INVESTIGATOR_248], 
ibuprofen or other non- steroidal anti- inflammatory drugs are not eligible.  
 
[IP_ADDRESS]  Anti-platelet agents : Patients who are currently receiving anti -platelet 
agents are not eligible.  
 
[IP_ADDRESS]  Anti-hypertensives:  
Patients who are receiving anti-hypertensive medications for control of 
blood pressure at the time of enrollment are not eligible for this trial. 
 
[IP_ADDRESS]  Anti-coagulation: Patients who are currently receiving therapeutic anti -
coagulation with heparin, low -molecular weight heparin or coumadin are 
not eligible for this trial.  
 
[IP_ADDRESS]  Belimumab : Patients who are currently receiving belimumab (a 
monoclonal anti body for systemic lupus erythematosus)  are not eligible.  
 
[IP_ADDRESS]   Bisphosphonate derivatives: Patients who are currently receiving 
bisphosphonate deri vatives  are not eligible.  
 
4.2.3 Surgery : Patients who have had or are planning to have the following invasive 
procedures are not eligible: 
â€¢ Major surgical procedure, laparoscopic procedure, open biopsy or 
significant traumatic injury within 28 days prior to enrollment.  
â€¢ Central line placement or subcutaneous port placement is not considered major surgery . External central lines must be placed at least [ADDRESS_690535] 7 days prior 
to enrollment 
â€¢ Core biopsy within 7 days prior to enrollment. 
â€¢ Fine needle aspi[INVESTIGATOR_354533] 7 days prior to enrollment.  
â€¢ Surgical or other wounds must be adequately healed prior to enrollment 
NOTE: For purposes of this study, bone marrow aspi[INVESTIGATOR_531877] 14 days 
prior to start of protocol therapy. 
 
4.2.4 Bleeding and Thrombosis: 
â€¢ Patients with evidence of active bleeding: intratumoral hemorrhage by [CONTACT_531904], or bleeding diathesis are not eligible.  
â€¢ Patients with  known or prior history in prior 3 months of esophageal 
varices are not eligible.  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
27 
Version Date: 01/31/19 
 
â€¢ Patients with a history  of CNS arterial/ venous thr omboembolic events 
including transient ischemic attack (TIA) or cerebrovascular accident 
(CVA) within 6 months prior to study enrollment are not eligible.  
â€¢ Patients with a history  of deep vein thrombosis (including pulmonary 
embolism)  within 3 months prior to study enrollment are not eligible.  
â€¢ Patients with a history of hemoptysis  or other signs of pulmonary 
hemorrhage within 3 months prior to study enrollment are not eligible.  
â€¢ Patient s with a history of â‰¥ Grade  3 bleeding disorders, vasculitis, or had a 
significant (â‰¥ Grade 3) epi[INVESTIGATOR_531878], within  6 
months prior to enrollment are not eligible.  
â€¢ For Part B : Patients with CNS tumors and evidence of new CNS 
hemorrhage of more than punctate size and/or more than three foci of 
punctate hemorrhage on baseline MRI obtained within 14 days prior to 
study enrollment are not eligible. Note: ECHO Gradient MRI sequence s 
per institutional guidelines are required for patients with CNS tumors  
 
4.2.[ADDRESS_690536] non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment are not eligible.  
 
4.2.9 Immunocompromised patients (other than that related to the primary oncologic 
diagnosis or to the use of corticosteroids) including patients known to be HIV 
positive are not eligible.  
 
4.2.10  Infection:  Patients who have an uncontrolled infection are not eligible.  
 
4.2.[ADDRESS_690537] received a prior solid organ transplantation are not eligible.  
 
4.2.12  Patients who in the opi[INVESTIGATOR_6696].  
 
 
5.0 TREATMENT PROGRAM  
 
5.1 Overview  of Treatment Plan  
 
Treatment Schedule Table  
Day Ramucirumab (i.v. over 60 minutes)  Disease Evaluation  
1 X  
15 X  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
28 
Version Date: 01/31/19 
 
29 X  
42  X 
 
A cycle of therapy is considered to be 42 days.  A cycle may be repeated for a total of 8 
cycles, up to a total duration of therapy of approximately 12 months. This is an open-
label study. 
 Effort should be made to begin protocol therapy on Monday through Thursday if possible 
to accommodate correlative sample shipments.  
 Drug doses should be adjusted based on actual  weight measured  within 7 days  prior to  
the beginning of each cycle.   
 
Update:  With the release of Amendment #2A, the dose escalation portion of the 
study is complete. Given this, Part B will open to patients with relapsed or refractory CNS tumors.  
 
5.[ADDRESS_690538] stable disease and has 
again met laboratory parameters as defined in the eligibility section,  Section 4.0 .  
 
5.3 Dose  Escalation Schema  (Completed)  
 
5.3.1 Inter -Patient Escalation  for Part A: 
Part A of the study is an open- label, Phase  1, dose -escalation study. 
Ramucirumab will be administered as an intravenous infusion over 60 minutes 
every other week for 3 infusions over a 6 -week period constituting a cycle.  The 
anticipated maximum number of evaluable subjects required to complete Part A 
is 24 patients (See Section 11.1).  
 
Patients should receive diphenhydramine  (1 mg/kg, maximum dose 50 mg)  (or 
alternative antihistamine) within 30 to 60 minutes prior to each infusion with 
ramucirumab . Anaphylactic precauti ons should be observed during ramucirumab  
administration. If â‰¥ Grade 2 infusional reaction occurs, the infusion should be 
stopped and supportive care given as per institutional guidelines.   
See Section 6.3  for management and dose modification guidelines for infusional 
reactions (IRR) . For the first infusion, vital signs should be monitored prior to 
infusion, every 30 (Â± 5) minutes during the infusion, and every 30 (Â± 5) minutes for a one -hour observation period after the completion of the infusion. If there is 
no evidence of an IRR during  the initial 2 infusions of ramucirumab, then no 
observation period is required for subsequent  treatment cycles. In the event an 
IRR occurs thereafter, then the one-hour observation period should be  
reinstituted.  
 
The starting dose of ramucirumab will be 8 mg/kg (dose level 1) with dose levels 
for subsequent groups of patients as follows.  
 
Dose Level  Dose (mg /kg) 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
29 
Version Date: 01/31/19 
 
-1 6 
1* 8 
2 12 
3^ â‰¤ 16 
* Starting Dose Level  
^ Escalation to Dose level 3 will only be considered after evaluation of PK  and toxicity at 
dose Level 2. If C min,ss of â‰¥ 50 Âµg/mL has not been achieved in at least 5 out of 6 
evaluable patients from dose level 2, and if the MTD has not yet been reached, then dose 
level 3 will be cons idered. 
 
Ramucirumab will be provided by [CONTACT_105410]. Do not use 
commercial supply.  
 
There will be no escalations beyond dose level 3 (16 mg/kg). If the MTD has 
been exceeded at the first dose level, then the subsequent cohort of patients will be treated at a dose of 6 mg/kg (dose level -1). If dose level -1 is not well 
tolerated, further de -escalation will not occur. The study will be closed to 
accrual.  
 
Defining RP2D : After accrual to dose l evel [ADDRESS_690539] tolerable dose at which C
min of â‰¥ 50 ug/mL has been achieved in at least 5 
out of 6 evaluable patients to acquire PK data in a representative number of 
young patients (i.e. patients < 12 years old). If at least [ADDRESS_690540] a steady state concentration of ramucirumab greater than 
50 Âµg/mL, then the RP2D has been defined. If C
min,ss of â‰¥ 50 Âµg/mL has not been 
achieved in at least 5 out of 6 evaluable pati ents from dose level 2, and if the 
MTD has not yet been reached, then dose level 3 will be considered . 
 
Update:  The RP2D was determined to be 12 mg/kg. 
 
5.3.2 Part B : Once the RP2D has been determined in Part A, Part  B will open to enroll 
children with relapsed or refractory CNS tumors who will receive  ramucirumab 
at the MTD or RP2D. Part B of the study will require up to 6 evaluable patients 
enrolled at the MTD or RP2D as determined in Part A (See Section 11.1 ). 
 
5.3.3 Intra -Patient Escalation  
Intra -patient dose escalation is not allowed.  
 
5.4 Grading of Adverse Events  
Adverse events (toxicities) will be graded according to the NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.0.  All appropriate treatment areas should  
have access to a copy of the CTCAE version 5.0. A copy of the CTCAE version 5.0 can be downloaded from the CTEP web site http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.  Any 
suspected or confirmed dose -limiting toxicity should b e reported immediately (within 24 
hours) to the Study Chair. 
 
5.5 Definition of Dose -Limiting Toxicity ( DLT)  
DLT will be defined as any of the following events that are possibly, probably or definitely attributable to protocol therapy . The DLT  observation period for the purposes 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
30 
Version Date: 01/31/[ADDRESS_690541] cycle of therapy.  
 
Dose limiting hematological and non- hematological toxicities are defined differently.   
 
5.5.1 Non-hematological dose -limiting toxicity  
[IP_ADDRESS]  Any Grade 3 or Grade 4 non- hemato logical toxicity a ttributable 
to the investigational  drug with the specific exclusion of:  
â€¢ Grade 3 nausea , vomiting , diarrhea, or constipation < 3 days 
duration 
â€¢ Grade 3 liver enzyme  elevation , including ALT/AST/GGT,  that 
returns to Grade â‰¤ 1 or baseline prior to the time for the next 
treatment cycle. Note:  For the purposes of this study the ULN for 
ALT is defined as 45 U/L.  Adverse event grades will be based on 
increases above the upper limit of normal, regardless of the 
subjectâ€™s baseline. See Appendix X  for toxicity grading table.  
â€¢ Grade 3 fever < 5 days duration 
â€¢ Grade 3 infection   
â€¢ Grade 3 hypophosphatemia, hypokalemia, hypocalcemia or hypomagnesemia responsive to oral supplementation  
 
[IP_ADDRESS]  Dose -limiting hypertension  
â€¢ Any Grade 4 hypertension 
â€¢ A blood pressure >  25 mmHg above the 95th percentile for age, 
height, and gender (Appendix VIII ) confirmed by [CONTACT_531905].  
â€¢ In patients who begin antihypertensive therapy a blood pressure > 10 mmHg but â‰¤ 25 mmHg above the 95th percentile for age, height, and gender (Appendix VIII
) for > 14 days is dose limiting. 
 
[IP_ADDRESS]  Non-hematological toxicity  that causes a delay of â‰¥ 14 days 
between treatment cycles will be considered dose- limiting.  
 
[IP_ADDRESS]  Proteinuria: Urine protein/creatinine (P/C) ratio > 1 and <  1.9 
confirmed with a second measurement within 72 hours  will be 
considered a DLT  (See Section 6.5 ) 
 
[IP_ADDRESS]  Any gastrointestinal perforation even t will be considered a DLT 
and require removal from protocol therapy. 
 
[IP_ADDRESS]  Grade â‰¥ 2 wound complication or wound dehiscence will be 
considered a DLT and require removal from protocol therapy. 
 
[IP_ADDRESS]  Grade â‰¥ 3 hepatic failure will be considered a DLT and require 
removal from protocol therapy. 
 
[IP_ADDRESS]  Grade â‰¥ 2 reversible posterior leukoencephalopathy syndrome 
(RPLS)  will be considered a DLT and require removal from 
protocol therapy. 
 
[IP_ADDRESS]  Grade â‰¥ 3 congestive heart failure will be considered a DLT and 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
31 
Version Date: 01/31/19 
 
require removal from pro tocol therapy. 
 
[IP_ADDRESS]  Any toxicity that is possibly related to the study medication that 
requires removal from protocol therapy. Note: Allergic reactions 
that necessitate discontinuation of study drug will not be 
considered a dose -limiting toxicity.  
 
5.5.2 Hematologic al dose limiting toxicity  
[IP_ADDRESS]  In patients evaluable for hematological toxicity (see Section [IP_ADDRESS] ), 
hematological dose limiting toxicity is defined as: 
â€¢ Grade 4 neutropenia for > 7 days 
â€¢ Platelet count < 20,000/mm3 on 2 separate days, or requiring a platelet 
transfusion on 2 separate days, within a 7 day period   
â€¢ Myelosuppression that causes a delay of > 14 days between treatment 
cycles.  
 
[IP_ADDRESS]  Other hematological dose -limiting toxicities:  
â€¢ Any arterial thromboembolic eve nt (including cerebrovascular 
ischemia, peripheral or visceral arterial ischemia)  
â€¢ Any â‰¥ Grade 3 venous thromboembolic event  
â€¢ Any thrombotic event requiring systemic anti-coagulation 
â€¢ Any â‰¥ Grade 3 hemorrhage  
[IP_ADDRESS]  Note:  Grade 3 or 4 febrile neutropenia will not  be considered a dose-
limiting toxicity.  
 
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
32 
Version Date: 01/31/[ADDRESS_690542] be removed from protocol therapy:  
â€¢ Any arterial thromboembolic event (including cerebrovascular 
ischemia, peripheral or visceral arterial ischemia)  
â€¢ Any â‰¥ Grade 3 venous thromboembolic event  
â€¢ Any thrombotic event requiring systemic anti-coagulation 
â€¢ Any â‰¥ Grade [ADDRESS_690543] any dose- limiting non -hematological toxicity (as defined in 
Section 5.5.1
) may continue  on protocol therapy upon meeting eligibility lab 
requirements or baseline but should receive subsequent infusions  at the  next 
lower dose level , except as outlined in Sections  6.4 and 6.5.  Doses reduced for 
toxicity will not be re -escalated, even if there is minimal or no toxicity with the 
reduced dose. 
 
 
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
33 
Version Date: 01/31/[ADDRESS_690544] allergic or acute infusion reactions to ramucirumab, therapy 
modifications based on grade should be as follows. 
Grad e  
Infusion Related 
Reaction  Action  
Grade 1  
Transient flushing or rash, drug fever 
< 38Â° C 
 â€¢ Monitor patient until recovery from symptoms; infusion 
rate may be slowed.  
â€¢ If the infusion is interrupted, then restart the infusion at 
50% of the original infusion rate when symptoms resolve. Monitor patient closely.  
 
The following prophylactic premedications are recommended: 
diphenhydramine 1 mg/kg with max 50 mg (or equivalent) 
and/or acetaminophen 10- 15 mg/kg (max 1000 mg) at least 30 
minutes before additional ramucirumab administrations, 
slowing infusion rate as above.  
Grade 2  
Rash, flushing, 
urticaria, dyspnea, 
drug fever â‰¥ 38Â°C  â€¢ Stop infusion , begin an IV infusion of normal saline, and 
treat the subject with diphenhydramine 1 mg/kg with max 
50 mg IV (or equivalent) and/or acetaminophen  10-15 
mg/kg ( max 1000 mg); remain at bedside and monitor 
patient until resolution of symptoms. Corticosteroid or 
bronchodilator therapy may also be administered as approp riate. 
â€¢ If the infusion is interrupted, then restart the infusion at 
50% of the original infusion rate when symptoms resolve. 
Monitor patient closely.  
â€¢  If symptoms recur, then no further ramucirumab  will be 
administered at that visit. Administer diphenhydramine 1 mg/kg with max 50 mg IV (or equivalent), and remain at bedside and monitor the patient until resolution of 
symptoms.  
 
The following prophylactic premedications are recommended: diphenhydramine 1 mg/kg with max 50 mg IV (or equivalent) 
and acetaminophen (10 -15 mg/kg, max 1000 mg) should be 
administered at least 30 minutes before additional 
ramucirumab  administrations. If clinically indicated , 
corticosteroids (recommended dose: 1-2 mg/kg/day 
methylprednisolone IV  or equivalent) may be used . 
Grade 3 or 4  
Symptomatic 
bronchospasm with â€¢ Immediately discontinue infusion of ramucirumab .  
â€¢ Begin an IV infusion of normal saline, and treat the subject 
as follows. Recommend bronchodilators, epi[INVESTIGATOR_238] 0.2 to 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
34 
Version Date: 01/31/19 
 
or without urticaria, 
allergy  related 
edema/angioedema, 
hypotension; 
Anaphylaxis 1 mg of a 1:1,000 solution for subcutaneous administration , 
0.1 to 0.25 mg of a 1:10,000 solution injected slowly for IV 
administration , 0.01 mg/kg of 1:1000 dilution (0.01 
ml/kg/dose) for intramuscular administration , and/or 
diphenhydramine 1 mg/kg with max 50 mg IV with 1-2 
mg/kg/day methylprednisolone IV (or equivalent), as 
needed.  
â€¢ Patient should be monitored until the investigator is 
comfortable that the symptoms will not recur.  
â€¢ Ramucirumab  will be permanently discontinued. 
 
Investigators should follow their institutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor 
patient until recovery from symptoms. In t he case of late-
occurring hypersensitivity symptoms ( e.g., appearance of a 
localized or generalized pruritis within 1 week after treatment), 
symptomatic treatment may be given (e.g., oral antihistamine, 
or corticosteroids).  
 
6.4 Dose Modifications for Hypert ension  
â€¢ Baseline blood pressure (BP) is defined as the blood pressure obtained at the 
examination used for study enrollment. This baseline BP should be obtained 
as follows:  1) Obtain [ADDRESS_690545] 5 minutes apart . Avoid using the lower 
extremity if possible. 2) Average the systolic blood pressure from the 2nd and 
3rd measurements. 3) Average the diastolic blood  pressure from the 2nd and 3rd 
measurements.  4) The baseline BP is the average of the systolic over the 
average of the diastolic measurements.  
â€¢ Elevation  in either the systolic or diastolic blood pressure should be  
considered when following the algorithm below. 
â€¢ The upper limit of normal (ULN)  is defined as a BP equal to the 95th 
percentile for age, height, and gender. See  Appendix VIII . 
â€¢ The NCI CTCAE  will be utilized to determine the grade of  hypertension for 
reporting purposes.  
â€¢ Elevated BP measurements should be repeated on the same day to confirm  the 
elevation. If confirmed, patients with elevated BP should have BP 
measurements performed at least twice weekly until BP is â‰¤ ULN. 
â€¢ The algorithm below will be used to manage ramucirumab - related 
hypertension. 
â€¢ Hypertension should be managed with appropriate anti -hypertensive agent(s) 
as clinically indicated. It is strongly recommended that nephrology or  
cardiology be consulted in the evaluation and management of hypertension. 
 
ADVL1 416
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY,SEE PAGE 1FOR [LOCATION_003]GE POLICY
35
Version Date: 01/31/19 
Arm 1 of algorithm:
â€¢If blood pressure (BP) â‰¤ 95% for age, height, and gender, continue ramucirumab at
the same dose.
Arm 2 of algorithm:
â€¢If BP â‰¤ [ADDRESS_690546] for age, height, and gender, continue
ramucirumab at the same dose and recheck the BP within 72 hours. 
oIf the BP is â‰¤ ULN on recheck, continue ramucirumab at the same dose.
oIf the BP remains above the ULN on recheck, then start antihypertensive therapy 
(Section 7.7 )and follow Arm 3 of the algorithm from the point that anti -
hypertensive therapy is started.
Arm 3 of algorithm:
â€¢If BP is 11 to 25 mm Hg above the 95% for age, height, and gender on â‰¥ 2 of 3 
measurements or > 35 mmHg above baseline on â‰¥ 2 of 3 measurements, start anti-
hypertensive therapy (see Section 7.7 ), continue ramucirumab at the same dose, and 
monitor BP at least twice weekly.
oIf the BP returns to â‰¤ ULN within 14 days, conti nue ramucirumab at the same
dose and continue anti-hypertensive therapy. 
oIf the BP remains elevated â‰¤ 25 mm Hg above the 95% or > 35 mm Hg  above 
baseline for more than 14 days after the institution of anti -hypertensive therapy, 

                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
36 
Version Date: 01/31/[ADDRESS_690547].  
ï‚§ If the BP returns to â‰¤ ULN within 14 days, restart ramucirumab  at a reduc ed 
dose (Section 6.2 ). 
ï‚§ If the BP remains > ULN for more than 14 days, patient is Off Protocol 
Therapy. 
o  If the BP increases to > [ADDRESS_690548] despi[INVESTIGATOR_6698] -hypertensive 
therapy, hold ramucirumab , but continue the anti -hypertensive agent(s). Monitor 
the BP as clinically indicated and follow Arm 4 of the algorithm from the point that ramucirumab  is held. 
ï‚§ I f  t h e  B P  i s  â‰¤  U L N  w i t h i n  1 4  d a y s ,  ramucirumab  may be restarted at a 
reduced dose ( Section 6.2
). 
ï‚§ If the BP is > ULN for > 14 days, the patient is Off Protocol Therapy 
(Section 10.1 ). 
 
Arm 4 of algorithm:  
â€¢ If BP is > 25 mm Hg above the 95% for age, height, and gender hold ramucirumab , 
monitor BP and administer anti -hypertensive therapy as clinically  indicated.  
o If the BP returns to â‰¤ ULN within 14 days, ramucirumab  may be restarted at a  
reduced dose ( Section 6.2 ). 
o If the BP is > ULN for >14 days, the patient  is Off Protocol Therapy (Section 
10.1). 
 
Arm 5 of algorithm:  
â€¢ If the participant develops Grade 4 hypertension, discontinue  ramucirumab , monitor 
BP and administer anti -hypertensive therapy as clinically  indicated. The patient  is 
Off Protocol Therapy (Section 10.1 ). 
 
6.5 Dose Modifications for Proteinuria  
If urinalysis shows â‰¥ trace protein then obtain Urine Protein to Creatinine (UPC) 
concentrations (See Appendix IX ).  
  
Proteinuria: UPC Ratio  Action  
If < 1  Continue protocol therapy  
If 1-1.9 
 Hold next infusion. A second measurement should be 
obtained within 72 hours. A second confirmation of urine protein/creatinine (P/C) ratio  1-1.9 will be 
considered a DLT. If resolves to <1 within 14 days, resume protocol therapy. Subsequent infusions will be 
given at a lower dose as outlined in  
Section 6.2 . Monitor 
the UPC weekly for 2 consecutive weeks once protocol 
therapy resumes.  UPC â‰¥ 1 t hat persists â‰¥ 14 days will 
require removal  from protocol therapy.   
If > 1.9 Off protocol therapy  
 
 
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
37 
Version Date: 01/31/[ADDRESS_690549] elective surgical procedures while on  therapy. For patients who 
require emergent or urgent procedures, therapy should be held and may not be restarted 
until 28 days after major procedures and 7 days after minor procedures such as line replacement (3 days for external lines [e.g. Hickman or Broviac]) , as detailed in  
Section 
4.2.3 . 
 
7.6 Concomitant Medications 
Anticoagulation : Use of therapeutic anticoagulation with heparin, low -molecular weight 
heparin, or warfarin should be avoided.  
 
Anti-platelet agents : Use of aspi[INVESTIGATOR_248], ibuprofen or other non- steroidal anti -inflammatory 
drugs or anti- platelet agents  for chronic use is not allowed while on study therapy. 
 
Anti-hypertensives : Patients who develop hypertension while on study therapy may be 
treated with anti-hypertensive agents and may remain on therapy as long as hypertension is well controlled on medication (See 
Section 7.7 ). 
 
The use of b elimumab (a monoclonal antibody  for systemic lupus erythematosus) and 
bisphosphonate derivatives are prohibited while the patient is on study therapy. 
 
7.7 Concurrent Anti -Hypertensive Therapy  
The algorithm in Section 6.4  will be used to grade and manage ramucirumab - related 
hypertension. Should initiation of anti -hypertensive therapy be required, single agent 
therapy (commonly including the calcium channel blockers amlodipi[INVESTIGATOR_6705], which are permissible without discussion with the study chair) should be started and the 
blood pressure should be monitored at least twice weekly until BP is within the 95
th 
percentile for age, hei ght, and gender per  Section 6.4 . 
   
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
38 
Version Date: 01/31/19 
 
8.0 EVALUATIONS/MATERIAL  AND DATA TO BE ACCESSIONED 
 
8.[ADDRESS_690550] be performed within 7 
days prior to enrollment unless otherwise indicated. Laboratory values used to assess 
eligibility (see  Section 4.0 ) must be no older than seven (7) days at the start of therapy.  
Laboratory tests need not be repeated if therapy starts within  seven (7) days of obtaining 
labs to assess eligibility.  If a post -enrollment lab value is outside the limits of eligibility, 
or laboratory  values are older  than [ADDRESS_690551] 
be re -checked within 48 hours prior to initiating therapy: CBC with differential, bilirubin, 
ALT (SGPT) and serum  creatinine.  If the recheck is outside the limits of eligibility, the 
patient may not receive protocol therapy and will be considered off protocol therapy. 
Imaging studies, bone marrow aspi[INVESTIGATOR_6706]/or biopsy, must be obtained within 14 days  
prior to start of protocol therapy (repeat the tumor imaging if necessary). 
 
STUDIES TO BE OBTAINED  Pre-Study  During Cycle 1  Subsequent 
Cycles^  Off 
Protocol 
Therapy  
([ADDRESS_690552] 
dose)  
History  X Weekly   X 
Physical Exam with vital signs  X Weekly  X X 
Pregnancy Test1 X  X  
Height, weight  X  X  
Performance Status  X   X 
Blood Pressure2 X Weekly  Every other week  X 
CBC, differential, platelets  X Twice Weekly  
(every 3 to 4 days)3 Weekly4 X 
Urinalysis5 X  Every 2 weeks  X X 
Electrolytes including Ca++, PO 4, Mg++ X Weekly  X X 
Creatinine, ALT, bilirubin  X Weekly  X X 
Albumin  X  X X 
INR X  X X 
Tumor Disease Evaluation6 X End of Cycle 1  End of Cycle 2, 
then every other 
cycle   
Plain radiograph tibial growth plate7 
X  Prior to cycles 2, 5 
and every 6 
months  X 
ECHO or gated radionuclide study  X   X 
Pharmacokinetic (PK) Studies8 X X  X 
Immunogenicity Studies9 X X  X 
Circulating Plasma Molecular Marker  
Studies10 X X  X 
Pharmacogenomic Studies11  X   
Peripheral Blood Flow -Cytometry  (PBFC) 
Studies  (Part A Only)12 X    
Tumor Tissue Studies13 X    
     
^  Studies may be obtained within 72 hours prior to the start of the subsequent cycle.  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
39 
Version Date: 01/31/[ADDRESS_690553] prior to starting treatment and 
before starting each subsequent cycle; sexually active patients must  agree to use a highly effective  
method of contraception during protocol therapy and for at least [ADDRESS_690554]. Blood pressure measurement 
will be repeated  within the same day if the blood pressure (BP) is elevated (> the 95th percentile for 
age, height, and gender). Please note that 3 serial blood pressures should be obtained and averaged to 
determine baseline BP (See Section 6.4 ). If both BP measurements are >95th percentile for age, 
height, and gender, follow the guidelines in Section 6.[ADDRESS_690555] twice weekly until BP is  within the 95th percentile for age, 
height, and gender (See  Appendix VIII ). 
[ADDRESS_690556] every other day until 
recovery to Grade 3 or until meeting the criteria for dose limiting toxicity.  
4 If patients develop Grade 4 neutropenia then CBCs should be checked every 3 to 4 days until recovery to Grade 3 . 
5 See Appendix IX  for UPC rationale and calculation and  Section 6. 5 for dose modifications if UPC > 1. 
If patient is being followed for prior proteinuria and UPC is obtained  at the scheduled time points , 
urinalysis is not also require d. If patient has proteinuria (urine protein/creat inine (P/C) ratio > 1), a 
second measurement should be obtained within 72 hours.  
6 Tumor Disease Evaluation should be obtained on the next consecutive cycle after initial documentation 
of either a PR or CR. Subsequent scans may restart 2 cycles after the co nfirmatory scan. Please note 
that for solid tumor patients, if the institutional investigator determines that the patient has progressed based on clinical or laboratory evidence, he/she may opt not to confirm this finding radiographically . 
For patients with CNS disease  (Part B), ECHO gradient MRI sequences per institutional standards are 
required to evaluate for hemorrhage (See Appendix X
).  
[ADDRESS_690557] dose 
of protocol therapy. In patients with open growth plates, follow -up plain radiographs of the same 
growth plate(s) should be obtained according to Section 8.2.1. 
8 See Section 8. 4 and Appendix III  for timing and details of PK studies.  
9 See Section 8. 5 and Appendix IV  for timing and details of Immunogenicity studies.  
10 See Section 8. 6 and Appendix V -A for timing and details of the pharmacodynamic Circulating Plasma 
Molecular Marker studies.  
11 See Section 8.7  and Appendix V -B for details of Pharmacogenomic studies.  
12 See Section 8. 8 and Appendix VI  for details of Peripheral Blood Flow -Cytometry (PBFC) cellular 
marker studies.  
[ADDRESS_690558] an open tibial growth plate, then repeat plain AP 
radiographs of the same tibial growth plate will be obtained prior to cycles 2, 
5 and every 6 months. â€¢ Patients with evidence of growth plate thickening or other changes 
should have a knee MRI performed to further assess the degree of 
physeal pathology and undergo more frequent x- ray follow up at least 
every [ADDRESS_690559].  
â€¢ Patients with knee MRI changes should be managed in  an individualized 
manner. Decisions regarding continuation of ramucirumab should be 
 $'9/ 

7+,6[ZIP_CODE]&2/,6)255(6($5&+385326(621/< 6((3$*( )2586$*(32/,&< 

9HUVLRQ'DWH

PDGHDIWHUGLVFXVVLRQZLWKWKH6WXG\&KDLURU6WXG\9LFH&KDLU DQG
'9//HDGHUVKLSWDNLQJLQWRDFFRXQWWKHSUHVHQFHRIDQ\V\PSWRP V
UHIHUDEOHWRWKHNQHHDVZHOODVWKHSDWLHQWÂ¶VUHVSRQVHWRUDPX FLUXPDE
&RQVXOWDWLRQZLWKDQRUWKRSHGLFVXUJHRQPD\DOVREHLQGLFDWHG 3ODQVIRU
IROORZXSLPDJLQJZLOODOVREHPDGHRQDQLQGLYLGXDOL]HGEDVLV WDNLQJ
LQWRDFFRXQWWKHSUHVHQFHRIV\PSWRPVDWWKHNQHHRURWKHUMRLQ WVDVZHOO
DVWKHGHFLVLRQWRFRQWLQXH UDPXFLUXPDERUQRW

5DGLRORJ\6WXGLHV

%RQH$JH.QHH05,
$OOWLELDO UDGLRJUDSKV DQG NQHH 05,V LI REWDLQHG VKRXOG EHVX EPLWWHG IRU
UHYLHZ

&HQWUDO5DGLRORJ\5HYLHZIRU5 HVSRQVH3DWLHQWVZKRUHVSRQG& 535WR
WKHUDS\RUKDYHORQJWHUPVWDEOHGLVHDVH6'Â•F\FOHVRQS URWRFROWKHUDS\
ZLOO EH FHQWUDOO\ UHYLHZHG &2* 2SHUDWLRQV &HQWHU ZLOO QRWLI\ W KH ,PDJLQJ
&HQWHURIDQ\SDWLHQWUHTXLULQJFHQWUDOUHYLHZ7KH,PDJLQJ&HQ WHUZLOOWKHQ
UHTXHVW WKDW WKHWUHDWLQJ LQVWLWXWLRQIRUZDUGWKH UHTXHVWHGLPD JHV IRU FHQWUDO
UHYLHZ7KHFHQWUDOLPDJHHYDOXDWLRQUHVXOWVZLOOEHHQWHUHGLQ WR5$9(IRU
UHYLHZE\WKH&2*2SHUDWLRQV&HQ WHUDQGIRUGDWDDQDO\VLV

7KHLPDJHVDUHWREHIRUZDUGHGHOHFWURQLFDOO\WRWKH,PDJLQJ5H VHDUFK&HQWHUDW
&KLOGUHQÂ¶V+RVSLWDO/RV$ QJHOHVYLDWKH,PDJH,Q%R[

&2*LQVWLWXWLRQVWKDWDUHQRWFRQQHFWHGYLDWKH,PDJH,Q%R[FDQ VHQGWKHLPDJHV
RQKDUGFRS\ILOP&'52086%IODVKGULYHRUE\)736XEPLWWH GLPDJLQJ
VWXGLHV VKRXOG EH FOHDUO\ PDUNHG ZLWK WKH &2* SDWLHQW ,' VWXG\ Q X P E H U 
$'9/DQGGDWHDQGVKLSSHGWR6\HG$DPHUDWWKHDGGUHVVEH ORZ



3KDUPDFRNLQHWLFV5HTXLUHG

'HVFULSWLRQRI6WXGLHVDQG$VVD\
3KDUPDFRNLQHWLFDQDO\VLVWRGHWHUPLQHUDPXFLUXPDEFRQFHQWUDWLRQ LQVHUXPZLOO
EHFRQGXFWHGE\(OL/LOO\DQG&RPSDQ\XVLQJYDOLGDWHG(/,6$DVV D\

6DPSOLQJ6FKHGXOH
%ORRG VDPSOHV  PO RI ZKROH EORRG ZLOO EH REWDLQHG SULRU WR G UXJ
DGPLQLVWUDWLRQDQGDWWKHWLPHSRLQWVRXWOLQHGLQ $SSHQGL[,,, ,QWKHHYHQWDQ
LQIXVLRQUHODWHGUHDFWLRQLVH[SHULHQFHGDQDGGLWLRQDOEORRGV DPSOHIRU3.DQG
,PPXQRJHQLFLW\ZLOOEHFROOHFWHGDVFORVHWRWKHRQVHWRIWKHL QIXVLRQUHODWHG[COMPANY_003]
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
41 
Version Date: 01/31/19 
 
reaction, at the time of its resolution, and approximately 30 days after resolution 
of the event.  
 8.4.3 Sample Collection and Handling Instructions ( Appendix III
) 
Blood samples (2 ml) will be collected in  [ADDRESS_690560] time that the drug is administe red. 
 
8.4.4 Sample Processing  
1. Immediately after collection, gently invert each blood sample > 5 times and 
allow blood to clot for 30- 45 minutes at room temperature (20- 25Â°C, 60 min. 
max).  
2. Centrifuge samples at room temperature for 15 -20 minutes at ~1500- 2000 x 
g. 
3. Transfer serum into appropriately labeled transfer tube.  
4. Store the serum samples immediately at -20Â°C until shipment  on dry ice to 
Covance. 
 
8.4.[ADDRESS_690561] be labeled with the patientâ€™s I.D. and accession number and the 
study I.D. (ADVL1 416). 
 
8.4.6 Sample Shippi[INVESTIGATOR_531879].  
 
8.4.7 Sample Storage   
Bioanalytical samples collected to measure ramucirumab concentration will be retained for a maximum of 1 year following study publication. 
 
 
8.5 Immunogenicity  Studies (Required)  
 
8.5.1 Description of Studies and Assay:  
Immunogenicity analysis to determine antibody production against ramucirumab 
will be conducted by [CONTACT_531906] . 
  
8.5.2 Sampling Schedule  
Blood samples  (2.5 ml of whole blood)  will be obtained prior to drug 
administration and at the time points outlined in Appendix IV . In the event an 
infusion -related reaction is experienced, an additional blood sample for PK and 
Immunogenicity will be collected as close to the onset of the infusion -related 
reaction, at the time of its resolution, and approximately 30 days after resolution of the event.  
 8.5.3 Sample Collection and Handling Instructions ( Appendix IV
) 
Blood samples will be collected in 2.5 mL gold top serum tube at a site distant 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
42 
Version Date: 01/31/[ADDRESS_690562] 
time that the drug is administered.  
 
8.5.4 Sample Proce ssing  
1. Immediately after collection, thoroughly mix the blood with the clotting 
activation agent by [CONTACT_531907].  
2. Allow blood to clot for 30 minutes (tube standing upright). 
3. Centrifuge samples for 15 -20 minutes at ~1500- 2000 x g until clot and serum 
are well separated by a well formed polymer barrier.  
4. Use pi[INVESTIGATOR_531880]  
5. Freeze serum samples at -20Â°C or colder until shipment on dry ice to 
Covance.  
 
8.5.[ADDRESS_690563] be labeled with the patientâ€™s I.D. and accession number and the 
study I.D. (ADVL1416).    
8.5.6 Sample Shippi[INVESTIGATOR_531879].   
8.5.7 Sample Storage   
Samples may be stored for a maximum of 15 years after study completion to  
enable further analysis of immune responses to ramucirumab  and allow the 
sponsor to respond to regulatory requests related to ramucirumab. 
 
8.6 Circulating Plasma Molecular Marker Studie s  
 
8.6.1 Description of Studies : Plasma samples will be collected as part of the ongoing 
efforts to understand the relationship between cancer, genetics/biology, and response to therapy, this study may analyze biomarkers relevant to pathways 
associated with cancer -related conditions, the mechanism of action of 
ramucirumab, and/or angiogenesis, and may also be used for related research methods or validation of diagnostic tools or assay(s). Potential 
pharmacodynamics and/or circulating markers may include, but are not limited to, placental growth factor, vascular endothelial growth factor A (VEGF- A), 
VEGF -C, VEGF -D, soluble vascular endothelial growth factor receptors 1, 2 and 
3 (sVEGFR -1,VEGFR -2, and sVEGFR-3). 
  
8.6.2 Sampling Schedule 
Blood samples  will be obtained  prior to drug administration and at the time 
points outlined in Appendix V-A . 
 8.6.3 Sample Collection and Handling Instructions ( Appendix V-A
) 
Blood samples (4 ml) will be collected in [ADDRESS_690564] time that the drug is administered.  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
43 
Version Date: 01/31/[ADDRESS_690565] 8 to 10 times.  
2. Centrifuge samples at ~1500 -2000 x g until clot for 15 minutes until cel ls 
and plasma are well separated.  
3. Use pi[INVESTIGATOR_531881]  
4. Freeze serum samples at -20Â°C until shipment  on dry ice to Covance. 
 
8.6.[ADDRESS_690566] be labeled with the patientâ€™s I.D. and accession number and the 
study I.D. (ADVL1416).   
 
8.6.6 Sample Shippi[INVESTIGATOR_531879].  
 
8.6.7 Sample Storage   
The samples will be coded with the patient number and stored for up to a maximum 15  years after the study completion at a f acility selected by [CONTACT_103]. 
 
8.7 Pharmacogenomic Studies  
 
8.7.1 Description of Studies: A blood sample will be collected for pharmacogenetic 
analysis.  These samples are not being collected to create a biobank for 
unspecified disease or population genetic research either now or in the future.  Samples may be periodically assessed and  used to investigate variable response 
to ramucirumab and to investigate genetic variants thought to play a role in cancer.  Assessment of variable response may include evaluation of adverse 
events or differences in efficacy.  
 
8.7.2 Sampling Schedule 
A single b lood sample (0.5 mL) will be collected in 0.[ADDRESS_690567]. 
  
8.7.3 Sample Collection and Handling Instructions: (Appendix V -B)  
Record the exact time that the sample is drawn along with the exact time that the 
drug is administered.   
Blood will be spotted onto a DBS or FTA card:  
â€¢ Always use sterile technique when handling the FTA card.   
â€¢ Collect 0.5 ml whole blood in a tuberculin syringe and immediately transfer  
to the K2EDTA lavender top tube. Gently mix blood by [CONTACT_24518] 10-15 
times.  
â€¢ Using enclosed pi[INVESTIGATOR_531882], transfer [ADDRESS_690568]. 
â€¢ Attach the bar code label containing patient identifier information in the 
designated area of the FTA card.  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
44 
Version Date: 01/31/19 
 
â€¢ Allow the blood spots to air dry for at least one hour at room temperature. 
â€¢ After the sample has dried, carefully fold the flap over the specimen.  
â€¢ Place the FTA card into the pre- labeled, foil -lined pouch provided in the kit, 
and seal the pouch.  
â€¢ Store ambient and ship to Covance with next ambient shipment. 
 
8.7.[ADDRESS_690569] be labeled with the patientâ€™s I.D. and accession number and the 
study I.D. (ADV L1416).   
 
8.7.[ADDRESS_690570] ug is commercially available.  
Genotypi[INVESTIGATOR_531883], will not be used for any other purpose and will be otherwise 
destroyed .  
 
8.8 Peripheral Blood Flow -Cytometry  (PBFC)  Studies  (Part A Only) 
 
8.8.1 Description of Studies :  
The Peripheral Blood Flow â€“Cytometry (PBFC) cellular marker assay must be 
performed within 24 hours after PB collection. The Angio BioCore located at Indiana University will perform the PBFC studies.  
 
8.8.2 Sampling Schedule (See  Appendix VI
) 
Samples will be collected at baseline on Day [ADDRESS_690571] infusion ( Cycle 2, Day 1). 
 
8.8.3 Sample Collection and Handling Instructions 
Blood samples ( 8 ml) will be collected in  [ADDRESS_690572] the K 2EDTA tube. 
4. Centrifu ge the CP T at 1500-1800 x g for 30 m inutes at room tempe rature. 
Centrifu gation shou ld occ ur within 2 hou rs of dra wing blo od in to the 
lavende r top K 2EDT A tube. A CPT tube filled with water will be used as a 
balance tube. The same centrifuge should be used for all specimens if possible. 
 
$'9/
7+,6[ZIP_CODE]&2/,6)255(6($5&+385326(621/< 6((3$*( )2586$*(32/,&<

9HUVLRQ'DWH
1RWH 7KH VSHHG IRU FHQWULIXJDW LRQ LV YHU\ LPSRUWDQW ,I \RXU
FHQWULIXJHRQO\KDVVHWWLQJIRU530\RXZLOOQHHGWRFDOFXODWH WKH
FRUUHFW530VHWWLQJ
 7UDQVIHU WKHSODVPDDQGEXII\FRDW DVVKRZQLQWKHILJXUHIURP WKH&37WXEH
E\ILUVWJHQWO\URWDWLQJWKH&37WXEHDIHZWLPHVDQGWKHQJHQW O\SRXULQJWKH
VXSHUQDWDQWLQWRDQHZ. ('7$WXEHUHDG\IRUVKLSPHQW7KHUHGFHOOVDQG
WKHSOXJVKRXOGUHPDLQLQWKH&37WXEHWKDWLVGLVFDUGHG
 6DPSOH/DEHOLQJ
(DFKWXEHPXVWEHODEHOHGZLWKWKHSDWLHQWÂ¶VVWXG\UHJLVWUDWLRQ QXPEHUWKHVWXG\
,'DQGWKHGDWHDQGWLPHWKHVDPSOHZDVGUDZQ'DWDVKRXOG EHUHFRUGHGRQ
WKH3HULSKHUDO%ORRG)ORZ&\WRPHWU\ 6WXG\)RUP $SSHQGL[9, ZKLFKPXVW
DFFRPSDQ\WKHVDPSOHV
5HSODFHWKHFDSRQWKH. ('7$WXEHDQGEHVXUHWKHFDSLVVHFXUHG 7,*+78VH
SDUDILOPRUWDSHDURXQGWKHFDS
3ODFHWKHODEHOOHG. ('7$WXEHDORQJZLWKWKHFRUUHODWLYHVWXG\IRUPLQDVHDOHG
ELRKD]DUGODEHOHGSODVWLFEDJ3ODFHSODVWLFEDJLQWKH6W\URIRD PER[WRVKLSDV
JLYHQEHORZ
 6DPSOH6KLSSLQJ,QVWUXFWLRQV
(IIRUWVKRXOGEHPDGHWREHJLQSURWRFROWKHUDS\RQ0RQGD\WKURX JK7KXUVGD\LI
SRVVLEOHWRDFFRPPRGDWHFRUUHODWLYHVDPSOHVKLSPHQWV 2Q0RQGD\ WKURXJK
7KXUVGD\VKLSER[DWURRPWHPSHUDWXUHRYHUQLJKWYLD)HGHUDO([ SUHVV3ULRULW\
2YHUQLJKW WRWKHIROORZLQJDGGUHVV 1R)ULGD\VKLSPHQWVKRXOGEHPDGH 
[COMPANY_003]
[COMPANY_003]
 $'9/ 

7+,6[ZIP_CODE]&2/,6)255(6($5&+385326(621/< 6((3$*( )2586$*(32/,&< 

9HUVLRQ'DWH



7LVVXH6WXGLHV

'HVFULSWLRQRI6WXGLHV
$UFKLYDOWXPRUWLVVXHVKRXOGEHVXEPLWWHGIRUDOOSDWLHQWV XQVWDLQHGVOLGHVRU
DSDUDIILQEORFN>ZKROHRUSDUWLDO@XVLQJWKH$UFKLYH7XPRU7L VVXHNLWIURP
&RYDQFH6OLGHVVKRXOGEHSUHSDUHGZLWKPLFURQWLVVXHWKLFNQH VVSHUVOLGH,ID
SDWLHQWGRHVQRWKDYHWLVVXHDYDLODEOHWKHVWXG\FKDLUPXVWEH QRWLILHGSULRUWR
HQUROOPHQW

7XPRUVDPSOHVIURPSDWLHQWVPD\EHXVHGIRUUHVHDUFKRQWKHGUX JWDUJHWGLVHDVH
SURFHVVSDWKZD\VDVVRFLDWHGZLWKFDQFHUPHFKDQLVPRIDFWLRQR IUDPXFLUXPDE
DQGRUUHVHDUFKPHWKRGRULQYDOLGDWLQJGLDJQRVWLFWRROVRUDVV D\VUHODWHGWR
FDQFHUDQGZLOOQRWEHXVHGIRUDQ\WKLQJHOVH

6DPSOH/DEHOLQJ $SSHQGL[9,, 
(DFKWXEHPXVWEHODEHOHGZLWKWKHSDWLHQWÂ¶V,'DQGDFFHVVLRQ QXPEHUDQGWKH
VWXG\,'$'9/7KHGDWHDQGWLPHWKHVOLGHVZHUHSUHSD UHGVKRXOGEH
UHFRUGHG

6DPSOH6KLSPHQW
7KHEORFNVRUVOLGHVRIWXPRUPDWHULDOVKRXOGEHVHQWDWURRPW HPSHUDWXUHYLD
FRXULHU'XULQJWKHZDUPHUPRQWKV-XQHÂ±$XJXVWLWLVDGYLVD EOHWRVKLSWKH
EORFNVZLWKDQLFHSDFNLQRUGHUWRSUHYHQWWKHPHOWLQJRISD UDIILQHPEHGGHG
WLVVXHEORFNVGXULQJWUDQVLW(QVXUHFROGSDFNLVQRWLQGLUHFW FRQWDFWZLWK
VSHFLPHQ6OLGHVVKRXOGEHVKLSSHGDPELHQWWR&RYDQFHLPPHGLDWH O\DIWHUWKH\
DUHSUHSDUHG

6DPSOH6WRUDJH
7KHVDPSOHVZLOOEHFRGHGZLWKWKHSDWLHQWQXPEHUDQGVWRUHGIR UXSWRD
PD[LPXP\HDUVDIWHUWKHVWXG\FRPSOHWLRQDWDIDFLOLW\VHOHF WHGE\WKH
VSRQVRU7KLVUHWHQWLRQSHULRGHQDEOHVXVHRIQHZWHFKQRORJLHV UHVSRQVHWR
UHJXODWRU\TXHVWLRQVDQGLQYHVWLJDWLRQRIYDULDEOHUHVSRQVHWK DWPD\QRWEH
REVHUYHGXQWLOODWHULQGUXJGHYHORSPHQWRUZKHQWKHGUXJLVFR PPHUFLDOO\
DYDLODEOH


$*(17,1)250$7,21

5DPXFLUXPDE
&\UDP]D Â“,0&%/<16&,1'
[COMPANY_003]
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
47 
Version Date: 01/31/19 
 
9.1.1 Description  
Ramucirumab is an anti -VEGF Receptor 2 recombinant human monoclonal 
antibody of the IgG1 subclass. It is composed of 4 polypeptide chains, 2 identical 
heavy (Î³) chains consisting of 446 amino acids each, and 2 identical light (Îº) 
chains consisting of 214 amino acids each. The antibody contains 1 conserved N-
linked glycosylation site at each heavy chain, in the Fc region.  All excipi[INVESTIGATOR_531884]. No 
animal -derived components are used in the manufacture of ramucirumab 
excipi[INVESTIGATOR_840].  
 
9.1.2 Supplied by : [CONTACT_531908] . Do not use commercial supply.  
 
9.1.3 Formulation 
Ramuciruma b is supplied in single -use, 50- mL nominal volume, [LOCATION_002] 
Pharmacopeia (USP) Type I glass vials. Each vial contains 500 mg of 
ramucirumab at a concentration of 10 mg/mL in a sterile, preservative- free 
solution.  Each vial is stoppered with a chlorobu tyl elastomer stopper laminated 
with FluroTecÂ® (West Pharmaceutical Services, Inc., Exton, PA), and secured with an aluminum 2 -pi[INVESTIGATOR_531885] -top seal. The buffer contains 10mM histidine, 
75mM sodium chloride, 133mM glycine, and 0.01% polysorbate 80. Ramucirum ab is a clear to slightly opalescent and colorless to slightly yellow 
liquid without visible particles. The pH is 6.0. The osmolality is 285 mmol/kg.  
9.1.[ADDRESS_690573] vials of ramucirumab refrigerated at 2 -8 Â°C (36- 46Â°F). Protect from 
light. DO NOT FR EEZE OR SHAKE. The formulation contains no 
preservatives.  
 Prepared dosing solution should be used immediately in order to minimize the 
risk of microbial contamination. If not used immediately, the prepared 
ramucirumab dosing solution should be stored under refrigeration at 2Â°C to 8Â°C 
(36Â°F to 46Â°F), for a duration not to exceed 24 hours. If the prepared solution is 
stored at room temperature (below 25Â°C [77Â°F]), it must be used within [ADDRESS_690574]. DO NOT FREEZE AND/OR SHAKE PREPARED RAMUCIRUMAB FOR INFUSION.  
 
9.1.5 Solution Preparation  
Ramucirumab is compatible with common infusion containers. The use of a low 
protein binding 0.22 micron inâ€“line filter is required . Aseptic technique is to be 
used when preparing and handling ramucirumab for infusion. Drug doses should be adjusted based on actual weight measured within 7 days prior to the beginning 
of each cycle. Based on the calculated volume of ramucirumab, add (or remove 
from pre -filled [with 0.9% normal saline] I.V infusion container) a sufficient 
quantity of sterile normal saline (0.9% weight/volume) to the container to a 
concentration > 0.4 mg/mL by [CONTACT_531909] 100 mL for pa tients 
weighing 8-25 kg, and total volume 250 mL for patients weighing > 25 kg . For 
patients < [ADDRESS_690575] 50 mL and concentration should 
be > 0.4 mg/mL. Do not use dextrose containing solutions. The container should 
be gently inve rted to ensure adequate mixing.   
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
48 
Version Date: 01/31/19 
 
9.1.6 Stability  
Prepared solutions of ramucirumab are stable for up to 24 hours refrigerated (2 â€“ 
8Â° C).  If the prepared solution is stored at room temperature (below 25Â°C 
[77Â°F]), it must be used within 4 hours. 
 
9.1.7 Administration  
See Treatment and Dose Modification sections of the protocol. 
Patients should receive premedication with diphenhydramine or alternative 
antihistamine within 30 to 60 minutes prior to each infusion with ramucirumab 
(see Section 5.3.1 ). The infusion should be delivered via infusion pump over 60 
minutes. The infusion rate should not exceed 25 mg/minute. Infusions of duration 
longer than 60 minutes are permitted in specific circumstances (that is, for larger 
patien ts in order to maintain an infusion rate that does not exceed 25 mg/minute, 
or in the setting of prior ramucirumab infusion- related reaction); the infusion 
duration must always be accurately recorded. The infusion set must be flushed 
post infusion with sterile sodium chloride 0.9% equal to or greater than infusion 
set holdup volume to ensure delivery of the calculated dose. 
 
9.1.8 Ramucirumab Toxicities  
The toxicities in the table below are based on version 15.0 of the Investigatorâ€™s 
Brochure and US prescribing information data from single agent trials. The following events have been observed in patients receiving single agent 
ramucirumab  in clinical trials  or are potential toxicities for anti -angiogenic 
agents. 
 
Incidence  Toxicities  
Common  
(>20% of patients)  Gastrointestinal : Abdominal pain 
Occasional  
(4-20% of patients)  Cardiovascular : Hypertension  
Blood and Lymphatic System Disorders:  Neutropenia  
Gastrointestinal:  Diarrhea  
Metabolism & Nutrition Disorders:  Hypokalemia , Hyponatremia 
Nervous System Disorders:  Headache  
Respi[INVESTIGATOR_696], Thoracic, & Mediastinal Disorders: Epi[INVESTIGATOR_531886]:  Rash  
Rare  
(â‰¤ 3% of patients)  Blood and Lymphatic System Disorders:  Severe b leeding  
Cardiovascular : Arterial  thromboembolic events 
Gastrointestinal : Intestinal obstruction, Gastrointestinal perforation,  
General Disorders and Administration Site Conditions: Infusion-
related reactions , Impaired wound healing * 
Hepatic disorders:  Worsening Liver failure ** 
Renal and urinary disorders:  Proteinuria  
Pregnancy & 
Lactation Pregnancy  
Discontinue use in pregnant women. Animal studies have not been 
specifically conducted to evaluate the effect of ramucirumab on female 
reproduction and fetal development, and there are no studies in 
pregnant women. Based on ramucirumabâ€™s mechanism of action, it is 
likely to inhibit angiogen esis and may potentially result in adverse 
effects during pregnancy and postnatal development. Patients (male 
and female) of childbearing potential must agree to use highly effective 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
49 
Version Date: 01/31/[ADDRESS_690576] milk antibodies do  not enter the neonatal and infant 
circulation in substantial amounts. Because of the potential risk for 
serious adverse reactions in nursing infants from ramucirumab, advise 
women that breastfeeding is not recommended during treatment with 
ramucirumab. 
 
* Potential toxicity for anti -angiogenic class of agents  
**Clinical deterioration, manifested by [CONTACT_531910], ascites, or 
hepatorenal syndrome was reported in patients with Child -Pugh B or C cirrhosis who received 
single -agent ram ucirumab . 
  
9.[ADDRESS_690577] or other appropriate individual. Drug accountability records indicating the drugâ€™s delivery date to the site, inventory at the site, 
use by [CONTACT_6904], and amount returned to Eli Lilly  or disposed, if approved , will be 
maintained by [CONTACT_977]. Before destroying any unused inventory, site should 
contact [CONTACT_531911] . These records will adequately document that the patients were provided the doses 
as specified in the protocol and should reconcile all ramucirumab received from Eli Lilly . 
Accountability records will include dates, quantities, batch/serial numbers, expi[INVESTIGATOR_6939] (if applicable), and patient numbers.   
All unused or expi[INVESTIGATOR_531887], disposed 
of at the study site and documented. All material containing ramucirumab  will be treated 
and disposed of as hazardous waste in accordance with governing regulations. 
 
9.[ADDRESS_690578] form provided on the ADVL1416 protocol page of 
the COG website ( https://members.childrensoncologygroup.org/ ).  
The drug supply must be stored in a locked limited access area.  Ramucirumab is for 
investigational use only, and is to be used only within the context of this study. Under no 
circumstances should the investigator or other site personnel supply study drug to other 
investigators, subjects, or clinics, or allow supplies to be used other than directed by [CONTACT_47375]. 
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
50 
Version Date: 01/31/19 
 
10.0 CRITERIA FOR REMOVAL  FROM PROTOCOL THERAP Y AND OFF STUDY 
CRITERIA  
 
10.1 Criteria for Removal from Protocol Therapy  
a) Clinical (including physical examination or serum tumor markers) or radiographic 
evidence of progressive disease (See  Section  12.0 ). 
b) Adverse Events requiring removal from protocol therapy (See Section 6.0). 
c) Refusal of protocol therapy by [CONTACT_4676]/parent/guardian 
d) Non-compliance that in the opi[INVESTIGATOR_6712]. 
e) Completion of 8 cycles of therapy.  
f) Physician determines it is not in the patientâ€™s best interest.  
g) Repeated eligibil ity laboratory studies ( CBC with differential, bilirubin, ALT (SGPT) 
or serum creatinine)  are outside the parameters required for eligibility prior to the start 
of ramucirumab (See Section 8.1 ). 
h) Study is terminated by [CONTACT_2728]. 
i) Pregnancy  
 
Patients who are removed from  protocol therapy during cycle [ADDRESS_690579] resolved  per Section 13.4.4 , whichever happens 
LATER. The only exception is with documentation of the patientâ€™s withdrawal of 
consent . Patients who are removed from protocol therapy in subsequent cycles 
should have the necessary observations to ensure adequate clinical care .  
 
Patients who are off protocol therapy are to be followed until they meet the criteria for 
Off Study (see below) . Ongoing adverse events, or adverse events that emerge after the 
patient is removed from protocol therapy, but within [ADDRESS_690580] and CTEP -AERS  (if 
applicable).  Follow-up data will be required unless consent is withdrawn.  
 
10.2 Off Study Criteria  
 
a) Thirty days after the last dose of the investigational agent.  
b) Death  
c) Lost to follow -up 
d) Withdrawal of consent for any required observations or data submission. 
e) Enrollment onto another COG therapeutic (anti -cancer) study  
f) Patient did not receive protocol treatment after study enrollment  
 
 
 
 
11.0 STATISTICAL AND ETHICAL CONSIDERATIONS  
 
11.1 Sample Size and Study Duration  
 
The study will be completed in 2 parts. Part A will be a dose -escalation phase including 
patients with non -CNS solid tumors, and Part B will include a safety and imaging 
evaluation in patients with CNS tumors. 
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
51 
Version Date: 01/31/19 
 
A minimum of 2 evaluable patients will be entered at each dose level for determination of 
MTD. Once the MTD or recommended Phase 2 dose has been defined, up to 6 additional 
patients with recurrent or refractory solid tumors without restrictions on hem atologic 
evaluability may be enrolled to acquire PK data in a representative n umber of young 
patients ( e.g six  patients < 12 years old  and six patients  â‰¥12 years old).  Review of the 
enrollment rate into previous COG new agent studies indicates that 1 -2 patients per 
month are available.  The anticipated maximum number of evaluable subjects required to 
complete Part A is 24 patients. Assuming a 20% inevaluable rate, 29 patients may be 
enrolled and the study would be expected to be completed within 15- 29 months. A 
maximum of 51 patients may be required in the unlikely event that each of the three dose levels are expanded to 12 because two DLTs of different types are observed at each of the three dose levels, 6 additional patients are needed for PK analysis, and a 20% inevaluable 
rate. The maximum of 51 would be completed within 26- 51 months. 
 Part B of the study will require  up to 6 evaluable patients  enrolled at the MTD or RP2D 
as determined in Part A . Allowing for 20% inevaluability, [ADDRESS_690581] one dose of the study drug(s) and who 
experiences a dose- limiting toxicity  is considered evaluable for Adverse E vents . 
In addition, during Cycle 1, patients must have the appropriate toxicity monitoring studies performed to be considered evaluable for dose lim iting 
toxicity. Patients who do not have DLT and do not receive at least 85% of the 
prescribed dose within the first cycle for reasons other than toxicit ies (e.g. 
progressive disease) will not be considered evaluable for toxicity and will be 
replaced.  
 
11.2.2  Maximum Tolerated Dose 
â€¢ The MTD will be the maximum dose at which fewer than one-third of 
patients experience DLT (See Section 5.5 ) during Cycle 1 of therapy.  
 
â€¢ In the event that two DLTs observed out of 6 evaluable patients ar e different 
classes of Adverse Effects (e.g. hepatotoxicity and myelosuppression), expansion of the cohort to 12 patients will be considered if all of the 
following conditions are met:  
 
â€¢  One of the DLTs does not appear to be dose- related  
â€¢  The Adverse Effects are readily reversible  
â€¢  The study chair, DVL statistician, DVL committee chair or vice chair, 
and IND sponsor all agree that expansion of the cohort is acceptable 
 
If fewer than 1/3 of patients in the expanded cohort experience dose- limiting 
toxicities, the dose escalation can proceed.  
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
52 
Version Date: 01/31/19 
 
â€¢ The DLTs  observed in the pharmacokinetic (PK) expansion cohort will be 
counted towards the total number of DLTs observed at the MTD during the 
dose escalation portion of the study. If â‰¥ 1/3 of the cohort of patients at the 
MTD (during the dose escalation plus the PK expansion) experience DLT 
then the MTD will be exceeded.  
 
11.2.3  Recommended Phase 2 Dose (RP2D) :  
After accrual to dose l evel [ADDRESS_690582] tolerable dose at which C
min of â‰¥ 50 ug/mL has been achieved in at least 5 out of 6 
evaluable patients  to acquire PK data in a representative number of young 
patients (i.e. patients < 12 years old). If at least [ADDRESS_690583] a steady state concentration of ramucirumab greater than 50 Âµg/mL, 
then the RP2D has been defined. If C
min,ss of â‰¥ 50 Âµg/mL has not been achieved in 
at least [ADDRESS_690584] of this study. 
82 Two to 
six patients can be concurrently enrolled onto a dose level, dependent upon (1) the 
number of patients enrolled at the current dose level, (2) the number of patients who have 
experienced DLT at the current dose level, and (3) the number of patients  entered but 
with tolerability data pending at the current dose level.  Accrual is suspended when a 
cohort of six has enrolled or when the study endpoints have been met.  
  
Dose level assignment is based on the number of participants currently enrolled in the 
cohort, the number of DLTs observed, and the number of participants at risk for developi[INVESTIGATOR_007] a DLT (i.e., participants enrolled but who are not yet assessable for toxicity). 
For example, when three participants are enrolled onto a dose cohort, if toxicit y data is 
available for all three when the fourth participant entered and there are no DLTs, the dose is escalated and the fourth participant is enrolled to the subsequent dose level. If data is 
not yet available for one or more of the first three particip ants and no DLT has been 
observed , or if one DLT has been observed, the new participant is entered at the same 
dose level.  Lastly, if two or more DLTs have been observed, the dose level is de -
escalated. This process is repeated for participants five and si x. In place of suspending 
accrual after every three participants, accrual is only suspended when a cohort of six is filled. When participants are inevaluable for toxicity, they are replaced with the next available participant if escalation or de -escalation  rules have not been fulfilled at the time 
the next available participant is enrolled onto the study. 
 
 
The following table provides the decision rules for enrolling a patient at (i) the current dose level (ii) at an escalated dose level, (iii) at a de- escalated dose level, or whether the 
study is suspended to accrual:  
 
 # Pts 
Enrolled  # Pts with 
DLT  # Pts without 
DLT  # Pts with 
Data Pending  Decision  
 2 0 or 1  0, 1 or 2  0, 1 or 2  Same dose level  
 2 2 0 0 De-escalate* 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
53 
Version Date: 01/31/19 
 
      
 3 0 0, 1 or 2  1, 2 or 3  Same dose level  
 3 1 0, 1 or 2  0, 1 or 2  Same dose level  
 3 0 3 0 Escalate** 
 3 â‰¥ 2 0 or 1  0 or 1  De-escalate* 
      
 4 0 0, 1, 2 or 3  1, 2, 3 or 4  Same dose level  
 4 1 0, 1, 2 or 3  0, 1, 2 or 3  Same dose level  
 4 0 4 0 Escalate** 
 4 â‰¥ 2 0, 1 or 2  0, 1 or 2 De-escalate* 
      
 5 0 0, 1, 2, 3 or 4  1, 2, 3, 4 or 5  Same dose level  
 5 1 0, 1, 2, 3 or 4  0, 1, 2, 3 or 4  Same dose level  
 5 0 5 0 Escalate** 
 5 â‰¥ 2 0, 1, 2 or 3  0, 1, 2 or 3  De-escalate* 
      
 6 0 0, 1, 2, 3, or 4  2, 3, 4, 5 or 6  Suspend  
 6 1 0, 1, 2, 3 or 4  0, 1, 2, 3 or 4  Suspend  
 6 0 or 1  5 or 6  0 or 1  Escalate** 
 6 â‰¥ 2 0, 1, 2, 3 or 4  0, 1, 2, 3 or 4  De-escalate* 
* If six patients already entered at next lower dose level, the MTD has been defined.  
**If final dose level has been reached, the recommended dose has been reached.  
 
If two or more of a cohort of up to six patients experience DLT at a given dose level, then 
the MTD has been exceeded and dose escalation will be stopped (see Section 11.2.2  for 
exception to rule). If there are no further dose escalations based on toxicity assessment , 
then the Recommended Phase 2 Dose (RP2D ) will be confirmed  as per  Section 11.2.[ADDRESS_690585] be struck between patient safety considerations and limitations on the number of individuals exposed to potentially toxic or ineffective treatments on the 
one hand and the need to explore gender, racial, and ethnic aspects of clinical research on 
the other. If differences in outcome that correlate to gender, racial, or ethnic identity are 
noted, accrual may be expanded or additional studies may be performed to investigate 
those differences more fully.  
  
11.5 Pharmacokinetic and Correlative Studies and Response Analysis  
 
A descriptive analysis of pharmacokinetic (PK) parameters of ramucirumab  will be 
performed to define systemic exposure, drug clearance, and other pharmacokinetic parameters. The PK parameters will be summarized with simple summary statistics . 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
54 
Version Date: 01/31/[ADDRESS_690586] criteria for patients with solid tumors, and will be 
reported descriptively. 
 All these analyses will be descriptive in nature. 
 
11.6 Statistical methods  
 
11.6.1  Analysis Sets  
Safety Analysis Set (SAS) will consist of subjects who receive any amount  of 
study drug.  
 
11.6.2  Dose Evaluable Set (DES)  will con sist of: 1) subjects who receive any amount 
of study drug and then experience DLT during Cycle 1; and 2) subjects who 
receive at least 85% of the prescribed dose in Cycle [ADDRESS_690587] cycle. DES will be used for evalu ation of each dose level 
for dose- escalation.  
 
11.6.3  Pharmacokinetic Analysis Set  (PAS) will include subjects who have sufficient 
PK data to derive at least one PK parameter .  
 
11.6.4  Efficacy Analyses:  
Preliminary efficacy analyses will also be performed by [CONTACT_531912]. Data cut -off for primary study analysis will occur when all 
enrolled subjects have completed 6 cycles of treatment or discontinued study 
drug administration. After the final analysis, additional analyses may be performed as appropriate.  
 
11.6.5  Pharmacokinetic Analyses  
Serum  concentrations of Ramucirumab  will be tabulated and summarized by 
[CONTACT_354566]. Ramucirumab  PK parameters will be derived from serum  
concentrations by [CONTACT_105]- compartmental analyses using actual times. Minimally, the 
following PK parameters will be calculated: C max, tmax, and AUC (t Â½, CL, and 
Vd ss will be calculated only if the data permit ). Additional analysis utilizing the 
population pharmacokinetic approach may also be conducted if deemed 
appropriate. 
 
11.6.[ADDRESS_690588] one dose of study therapy. 
  Listing of patients including those treated at the MTD  will be generated.  
 
Treatment -emergent CTCAEs will be summarized by [CONTACT_531913]1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
55 
Version Date: 01/31/[ADDRESS_690589] -discontinuation will be provided. 
Listing of SAEs will also be produced. Listing of AEs leading to treatment 
discontinuation will be provided. 
 
CTCAEs possibly study drug related or regardless  of causality will be presented 
separately.  
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
56 
Version Date: 01/31/19 
 
12.0 EVALUATION CRITERIA 
 
12.1 Common Terminology C riteria for Adverse Events (CTCAE) 
The descriptions and grading scales found in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.[ADDRESS_690590] access to a c opy of the CTCAE version 5.0. A 
copy of the CTCAE version 5.0 can be downloaded from the CTEP web site http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.   
12.1.1  Adverse Event (AE or Adverse Experience): Any untoward medical 
occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be ANY unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal  (investigational) product, 
whether or not considered related to the medicinal (investigational) product 
(attribution of Unrelated [â€œunrelatedâ€, â€œunlikelyâ€] or Related [â€œpossibleâ€, 
â€œprobableâ€, or â€œdefiniteâ€]). (International Conference on Harmonisation [IC H] 
E2A, E6). 
 
12.1.[ADDRESS_690591] be reported routinely as 
outlined in the protocol (see Section 13.5 ). All Serious AEs (as defined in  Table 
A in Section 13.1 ) must be reported expeditiously. For detailed AE reporting 
guidelines refer to the â€œNCI Guidelines for Investigators: Adverse Event 
Reporting Requirements for DCTD (CTEP and CIP) and DCP INDs and IDEsâ€:    
http://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm . 
 
12.1.[ADDRESS_690592] of monitoring and recording all AEs, including all CTCAE v  4.0 grades (for both increasing and decreasing severity) and SAEs; 
regular laboratory evaluation for  hematology, blood chemistry, and urine values; 
periodic measurement of vital signs;  and the performance of physical 
examinations. 
 
12.2 Response Criteria for Patients with Solid Tumors  
See the table in section 8.0
 for the schedule of tumor evaluations. In addition to the 
scheduled scans, a confirmatory scan should be obtained the next consecutive cycle 
following initial documentation of objective response.  
Response and progression will be evaluated in this study using the revised Response 
Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) [ Eur J Ca  45:228-
247, 2009].  Key points are that [ADDRESS_690593]  diameter (unidimensional measurement) of the tumor lesions but the shortest  
diameter of malignant lymph nodes are used in the RECIST v 1.1 criteria. 
 
12.2.1  Definitions  
 
[IP_ADDRESS] Evaluable for objective response : Patients who exhibit objective 
disease progression prior to the end of cycle [ADDRESS_690594] had their disease re- evaluated will be 
considered evaluable for response.  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
57 
Version Date: 01/31/19 
 
 
[IP_ADDRESS] Evaluable Non- Target Disease Response: Patients who have lesions 
present at baseline that are evaluable but do not meet the definitions of 
measurable disease, have received at least one cycle of therapy, and  
have had their disease re- evaluated will be considered evaluable for 
non-target disease.  The response assessment is based on the presence, 
absence, or unequivocal progression of the lesions.  
 
12.2.2  Disease Parameters  
 
[IP_ADDRESS] Measurable disease: Measurable l esions are defined as those that can 
be accurately measured in at least one dimension (longest diameter to 
be recorded) as â‰¥[ADDRESS_690595] x -ray, as â‰¥[ADDRESS_690596] scan, or 
â‰¥[ADDRESS_690597] be recorded in millimeters (or decimal fractions of centimeters).  
 
Note :  Tumor lesions that are situated in a previously irradiated area 
might or might not be considered measurable.  If the 
investigator thinks it appropriate to include them, the conditions 
under which such lesions should be considered must be defined 
in the protocol. 
 
[IP_ADDRESS] Malignant lymph nodes : To be considered pathologically enlarged and 
measurable, a lymph node must be â‰¥[ADDRESS_690598] scan (CT scan slice thickness no greater than 5 mm).  
At baseline and in follow -up, only the short axis will be measured and 
followed. 
 
[IP_ADDRESS] Non-measurable disease:  All other lesions (or sites of disease), 
including small lesions (longest diameter < 10 mm or pathological 
lymph nodes with â‰¥ 10 to <15 mm short axis), are considered non-
measurable disease.  Bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by 
[CONTACT_462]), are considered as non -measurable.  
 
Note:   Cystic lesions that meet the criteria for radiographically defined 
simple cysts should not be considered as malignant lesions 
(neither measurable nor non- measurable) since they are, by 
[CONTACT_108], simple cysts. â€˜Cystic lesionsâ€™ thought to represent cystic metastases can be considered as measurable lesions, if 
they meet the definition of measurability described above. 
However, if non- cystic lesions are present in the same patien t, 
these are preferred for selection as target lesions.  
 
[IP_ADDRESS] Target lesions:  All measurable lesions up to a maximum of [ADDRESS_690599] ed and measured at 
baseline.  Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
58 
Version Date: 01/31/[ADDRESS_690600] lesion that can be 
measured reproducibly should be selected.  A sum of the diameters 
(longest for non -nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated and reported as the baseline sum 
diameters.  If lymph nodes are to be included in the sum, then only the 
short axis is added into the sum.  The baseline sum diameters will  be 
used as reference to further characterize any objective tumor regression in the measurable dimension of the disease.  
 
[IP_ADDRESS] Non-target lesions: All other lesions (or sites of disease) including any 
measurable lesions over and above the 5 target lesi ons should be 
identified as non -target lesions and should also be recorded at baseline.  
Measurements of these lesions are not required, but the presence, 
absence, or in rare cases unequivocal progression of each should be 
noted throughout follow -up.  
 
12.2.3  Methods for Evaluation of Measurable Disease  
 
All measurements should be taken and recorded in metric notation using a ruler 
or calipers.  
 The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion  at baseline and during follow -up. 
Imaging -based evaluation is preferred to evaluation by [CONTACT_147877](s) being followed cannot be imaged but are assessable by 
[CONTACT_461].  
 
[IP_ADDRESS] Clinical lesions:   Clinical lesions will only  be considered measurable 
when they are superficial (e.g., skin nodules and palpable lymph 
nodes) and â‰¥10 mm diameter as assessed using calipers (e.g., skin 
nodules).  In the case of skin lesions, documentation by [CONTACT_3977], including a ruler to es timate the size of the lesion, is 
recommended.  
 
[IP_ADDRESS] Chest x -ray:  Lesions on chest x -ray are acceptable as measurable 
lesions when they are clearly defined and surrounded by [CONTACT_6776].  However, CT is preferable.  
 
[IP_ADDRESS] Conventional CT and MRI:   This guideline has defined measurability 
of lesions on CT scan based on the assumption that CT slice thickness is [ADDRESS_690601] slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice 
thickness.  MRI is also acceptable in certain situations (e.g. for body 
scans). Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior 
scans.  
 
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
59 
Version Date: 01/31/19 
 
[IP_ADDRESS] PET-CT:  At present, the low dose or attenuation correction CT portion 
of a combined PET -CT is not always of optimal diagnostic CT quality 
for use with RECIST measurements.  However, if the site can 
document that the CT performed as part of a PET -CT is of identical 
diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET -CT can be used for RECIST measurements 
and can be used interchangeably with conventional CT in accurately 
measuring cancer lesions over time.  Note, however, that the PET 
portion of the CT introduces additional data which may bias an 
investigator if it is not routinely or serially performed.   
 
[IP_ADDRESS] Tumor markers : Tumor markers alone cannot be used to assess 
response.  If markers are initially above the upper normal limi t, they 
must normalize for a patient to be considered in complete clinical response.  
 
[IP_ADDRESS] Cytology, Histology:  These techniques can be used to differentiate 
between partial responses (PR) and complete responses (CR) in rare 
cases (e.g., residual lesi ons in tumor types, such as germ cell tumors, 
where known residual benign tumors can remain). 
 
   Cytology should be obtained if an effusion appears or worsens during 
treatment when the measurable tumor has met criteria for response or stable disease.  
 
[IP_ADDRESS] FDG -PET:  While FDG -PET response assessments need additional study, 
it is sometimes reasonable to incorporate the use of FDG -PET 
scanning to complement CT scanning in assessment of progression (particularly possible 'new' disease).  New lesions on the  basis of FDG-
PET imaging can be identified according to the following algorithm:  
 
a. Negative FDG -PET at baseline, with a positive FDG -PET at follow -
up is a sign of PD based on a new lesion. 
b. No FDG- PET at baseline and a positive FDG -PET at follow -up:  If 
the positive FDG -PET at follow- up corresponds to a new site of 
disease confirmed by [CONTACT_4654], this is PD.  If the positive FDG- PET at 
follow- up is not confirmed as a new site of disease on CT, 
additional follow -up CT scans are needed to determine if there is 
truly  progression occurring at that site (if so, the date of PD will be 
the date of the initial abnormal FDG -PET scan).  If the positive 
FDG -PET at follow -up corresponds to a pre -existing site of disease 
on CT that is not progressing on the basis of the anatomi c images, 
this is not PD. 
 
 Note :  A â€˜positiveâ€™ FDG -PET scan lesion means one that is FDG avid 
with an uptake greater than twice that of the surrounding tissue on the attenuation corrected image.  
  
 
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
60 
Version Date: 01/31/19 
 
12.2.4  Response Criteria for Patients with Solid Tumor and Measurable Disease  
 
[IP_ADDRESS] Evaluation of Target Lesions  
 
Complete Response (CR) : Disappearance of all target and non -target 
lesions.  Any pathological lymph nodes (whether 
target or non- target) must have reduction in 
short axis to <[ADDRESS_690602] be detected by [CONTACT_531914].  Normalization of urinary 
catecholamines or other tumor markers if elevated at study enrollment (for patients with 
neuroblastoma).  
 
Partial Response (PR) : At least a 30% decrease in the sum  of the 
diameters of target lesions, taking as reference the baseline sum diameters  
 
Progressive Disease (PD) : At least a 20% increase in the sum of the 
diameters of target lesions, taking as reference 
the smallest sum on study (this includes the 
baseline sum if that is the smallest on study).  In 
addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at 
least 5 mm.  (Note:  the appearance of one or 
more new lesions is also considered 
progressions). Note:  in presence  of SD or PR in 
target disease but unequivocal progression in 
non-target or non- measurable disease, the 
patient has PD  if there is an overall level of 
substantial worsening in non- target disease such 
that the overall tumor burden has increased sufficiently  to merit discontinuation of therapy 
 
Stable Disease (SD) : Neither sufficient shrinkage to qualify for PR 
nor sufficient increase to qualify for PD, taking 
as reference the smallest sum diameters while on 
study 
 
[IP_ADDRESS] Evaluation of Non- Target Lesions  
 
Complete Response (CR) : Disappearance of all non -target lesions and 
normalization of tumor marker level.  All lymph 
nodes must be non- pathological in size (<10 mm 
short axis) 
 
Note:  If tumor markers are initially above the 
upper normal limit, they must normalize for a 
patient to be considered in complete clinical 
response.  
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
61 
Version Date: 01/31/19 
 
Non-CR/Non -PD: Persistence of one or more non- target lesion(s) 
and/or maintenance of tumor marker level above 
the normal limits  
 
Progressive Disease (PD) : Appearance of one or more new lesions and/or 
unequivocal progression  of existing non -target 
lesions.  Unequivocal progression  should not 
normally trump target lesion status.  It must be 
representative of overall disease status change, 
not a single lesion increase.     
 
12.2.[ADDRESS_690603] Response Assessment  
Each patient will be classified according to his â€œbest responseâ€ for the purposes 
of analysis of treatment effect.  Best response is determined as outlined in 
Section 12.[ADDRESS_690604] one dimension.  Such lesions may be evaluable by [CONTACT_531915], immunocytochemistry techniques, tumor markers or other reliable measures.
  
 
12.3.2  Complete Response  
Disappearance of all evaluable disease.  
 
12.3.3  Partial response  
Partial responses cannot be determined in patients with evaluable disease  
 
12.3.4  Stable Disease (SD)  
That which does not qualify as Complete Response (CR), Partial Response (PR), 
or Progressive Disease.  
 
12.3.[ADDRESS_690605] Response Assessment  
Each patient will be classified according to his â€œbest responseâ€ for the purposes of analysis of treatment effect.  Best response is determined as outlined in 
Section 12.[ADDRESS_690606] show viable neuroblastoma. 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
62 
Version Date: 01/31/19 
 
 
12.4.2 The following criteria will be used to report MIBG response by [CONTACT_6778]:  
 
Complete response :  Complete resolution of all MIBG positive lesions  
Partial Response :  Resolution of at least one MIBG positive lesion, with 
persistence of other MIBG positive lesions  
Stable disease :  No change in MIBG scan in number of positive lesions 
Progressive disease: Development of new MIBG positive lesions 
 
12.4.3 The response of MIBG lesions will be assessed on central review using the Curie 
scale14 as outlined below. Central review respon ses will be used to assess 
efficacy for study endpoint. See Section 8.3.2  for details on transferring images 
to the Imaging Research Center.  
 NOTE: This scoring should also be done by [CONTACT_6779].  
 
The body is divided into 9 anatomic sectors for osteomedullary lesions, with a 
10
th general sector allocated for any extra- osseous lesion visible on MIBG scan . 
In each region, the lesions are scored as follows. The absolute extens ion score is 
graded as:  
0 = no site per segment,  
1 = 1 site per segment,  
2 = more than one site per segment,  
3 = massive involvement (>50% of the segment).  
 
The absolute score is obtained by [CONTACT_6780]. See 
diagram of sectors below:  
 
 
The relative score  is calculated by [CONTACT_99239] -treatment absolute score. The relative score of each 
patient is calculated at each response assessment compared to baseline and 
classified as below:  
1. Complete response : all areas of uptake on MIBG scan completely resolved.  
If morphological evidence of tumor cells in bone marrow biopsy or 

                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
63 
Version Date: 01/31/[ADDRESS_690607] 21 days apart to be considered a Complete Response. 
2. Partial response : Relative score â‰¤ 0.2 (lesions almost disappeared) to â‰¤ 0.5 
(lesions strongly reduced). 
3. Stable disease : Relative score > 0.5 (lesions weakly but significantly 
reduced) to 1.0 (lesions not reduced). 
4. Progressive disease : New lesions on MIBG scan.  
 
12.4.[ADDRESS_690608] Response Assessment  
Each patient will be classified according to his â€œbest responseâ€ for the purposes 
of analysis of treatment effect.  Best response is determined from the sequence of 
the overall response assessments as described in  Table 5 in Section 12.7 . 
 
12.5  Response Criteria for Neuroblastoma Patients with Bone Marrow Involvement  
 
12.5.1  Bone Marrow Involvement  
Bone marrow obtained within 14 days prior to study enrollment with tumor cells 
seen on routine morphology (not by [CONTACT_442837]) of bilateral aspi[INVESTIGATOR_99203]. 
 
Bone Marrow responses are determined by H&E Staining of bilateral bone 
marrow biopsies and aspi[INVESTIGATOR_4026].  
 
Complete Response :  No tumor cells detectable by [CONTACT_6785] [ADDRESS_690609] 21 days apart. Normalization of 
urinary catecholamines or other tumor markers if elevated at study enrollment.  
 
Progressive Disease :  In patients who enroll with neuroblastoma in bone 
marrow by [CONTACT_527323] a doubling in the amount of tumor in the marrow AND a minimum of 25% tumor in bone marrow by 
[CONTACT_5293]. (For example, a patient entering with 5% tumor in marrow by [CONTACT_6787] â‰¥ 25% 
tumor to have progressive disease; a patient entering 
with 30% tumor must increase to > 60%). 
 
In patients who enroll without evidence of neuroblastoma in bone marrow will be defined as 
progressive disease if tumor is detected in [ADDRESS_690610] 21 
days apart.  
 
Stable Disease: Persistence of tumor in bone marrow that does not me et 
the criteria for either complete response or progressive 
disease.  
 
12.5.[ADDRESS_690611] Response Assessment  
Each patient will be classified according to his â€œbest responseâ€ for the purposes 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
64 
Version Date: 01/31/[ADDRESS_690612] CNS tumors, only one lesion/mass is present and therefore is 
considered a â€œtargetâ€ for measurement/follow up to assess for tumor progression/response. If multiple measurable lesions are present, up to 5 should 
be selected as â€œtargetâ€ lesions. Target lesions should be selected on the basis of size and suitability for accurate repeated measurements. All other lesions will be 
followed as non- target lesions.  The lower size limit of the target lesion(s) should 
be at least twice the thickness of the slices showing the tumor to decrease the 
partial volume effect (e.g., 8 mm lesion for a 4 mm slice).  
 
Any change in size of non -target lesions should be noted, though does not need to 
be measured.  
 
12.6.[ADDRESS_690613] perpendicular diameter. Development of new disease or progression in 
any established lesions is considered progressive disease, regardless of response 
in other lesions â€“ e.g., when multiple lesions show opposite responses, the 
progressive disease takes precedence. Response Criteria for target lesions:  
 
â€¢ Complete Response (CR): Disappearance of all target lesions.  
 
â€¢ Partial response (PR):  â‰¥50% decrease in the sum of the products of the two 
perpendicular diameters of all target lesions (up to 5), taking as reference the initial baseline measurements.  
 
â€¢ Stable Disease (SD):  Neither sufficient decrease in the sum of the products 
of the two perpendicular diameters of all target lesions to qualify for PR, nor sufficient increase in a single target lesion to qualify for PD.  
 
â€¢ Progressive Disease (PD):  25% or more increase in the sum of the products 
of the perpendicular diameters of the target lesions, taking as reference the smallest sum of the products observed since the start of treatment, or the 
appearance of one or more new lesions.  
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
65 
Version Date: 01/31/19 
 
12.6.5  Response Criteria for Non- Target Lesions:  
 
â€¢ Complete Response (CR):  Disappearance of all non -target lesions.  
 
â€¢ Incomplete Response/Stable Disease (IR/SD):  The persistence of one or 
more non- target lesions.  
 
â€¢ Progressive Disease (PD):  The appearance of one or more new lesions 
and/or unequivocal progression of existing non- target lesions.  
 
12.6.6  Response criteria for tumor markers (if available):  
Tumor markers will be classified simply as being at normal levels or at abnormally 
high levels.  
 
12.6.7  Overall Response Assessment  
The overall response assessment takes into account response in both target and 
non-target lesions, the appearance of new lesions and normalization of markers 
(where applicable), according to the criteria described in the table below. The 
overall response assessment is shown in the last column, and depends on the 
assessments of target, non -target, marker and new lesions in the preceding 
columns.   
 
 
Target Lesions   
Non-target Lesions  
Markers   
New Lesions  
Overall 
Response  
CR CR Normal  No CR 
CR IR/SD  Normal  No PR 
CR  CR, IR/SD  Abnormal  No PR 
PR CR, IR/SD  Any No PR 
SD CR, IR/SD  Any No SD 
PD Any Any Yes or No  PD 
Any PD Any Yes or No  PD 
Any Any Any Yes PD 
 Each patient will be classified according to his â€œbest responseâ€ for the purposes 
of analysis of treatment effect.  Best response is determined as outlined in Section 12.[ADDRESS_690614] response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for 
progressive disease the smallest measurements recorded since the treatment 
started).  Th e patient's best response assignment will depend on the achievement 
of both measurement and confirmation criteria. 
 
Table 1: For Patients with Measurable Disease (i.e., Target Disease)  
 
Target Non-Target New Overall Best Overall Response 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
66 
Version Date: 01/31/19 
 
Lesions  Lesions  Lesions  Response  when Confirmation is 
Required*  
CR CR No CR >28 days Confirmation  
CR Non-
CR/Non -PD No PR  
>28 days Confirmation  
CR Not evaluated  No PR 
PR Non-
CR/Non -
PD/not 
evaluated  No PR 
SD Non-
CR/Non -
PD/not 
evaluated  No SD documented at least once 
>28 days from baseline  
PD Any Yes or No  PD  
no prior SD, PR or CR  Any PD**  Yes or No  PD 
Any Any Yes PD 
*      See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
**  In exceptional circumstances, unequivocal progression in non- target lesions may be 
accepted as disease progression.  
Note : Patients with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at tha t time should be 
reported as â€œsymptomatic deterioration.â€   Every effort should be made to document 
the objective progression even after discontinuation of treatment.  
 
Table 2: For Patients with Non -Measurable Disease (i.e., Non -Target Disease)  
 
Non-Target  Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
* â€˜Non -CR/non -PDâ€™ is preferred over â€˜stable diseaseâ€™ for non -target disease since SD is 
increasingly used as an endpoint for assessment of efficacy in some trials so to assign this 
category when no lesions can be measured is not advised  
 
Table 3.  Sequences of overall response assessments with corresponding best response.  
1st Assessment  2nd Assessment  Best Response  
Progression   Progressive disease  
Stable, PR, CR  Progression  Progressive disease  
Stable  Stable  Stable  
Stable  PR, CR  Stable  
Stable  Not done  Not RECIST classifiable  
PR PR PR 
PR CR PR 
PR, CR  Not done  Not RECIST classifiable  
CR CR CR 
 
Table 4: Overall Response for Patients with Neuroblastoma and Measurable Disease 
CT/MRI  MIBG  Bone Scan  Bone Marrow  Catechol  Overall  
PD Any Any Any Any PD 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
67 
Version Date: 01/31/19 
 
Any PD Any Any Any PD 
Any Any PD Any Any PD 
Any Any Any PD Any PD 
SD CR/PR/SD  Non-PD Non-PD Any SD 
PR CR/PR  Non-PD Non-PD Any PR 
CR/PR  PR Non-PD Non-PD Any PR 
CR CR Non-PD Non-PD Elevated  PR 
CR CR CR CR Normal  CR 
 
Table 5: Overall Response Evaluation for Neuroblastoma Patients and MIBG Positive Disease Only 
If patients are enrolled without disease measurable by [CONTACT_4654]/MRI, any new or newly identified lesion 
by [CONTACT_4654]/MRI that occurs during therapy would be considered progressive disease. 
MIBG  CT/MRI  Bone Scan  Bone Marrow  Catechol  Overall  
PD Any Any Any Any PD 
Any New Lesion  Any Any Any PD 
Any Any PD Any Any PD 
Any Any Any PD Any PD 
SD No New Lesion  Non-PD Non-PD Any SD 
PR No New Lesion  Non-PD Non-PD Any PR 
CR No New Lesion  Non-PD Non-PD Elevated  PR 
CR No New Lesion  CR CR Normal  CR 
 
 
 
 
 
12.7.2  Duration of Response  
 
Duration of overall response:  The duration of overall response is measured from 
the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented 
(taking as reference for prog ressive disease the smallest measurements recorded 
since the treatment started).  This will be described by [CONTACT_531916]. 
 
The duration of overall CR is measured from the time mea surement criteria are 
first met for CR until the first date that progressive disease is objectively documented.   
 
Duration of stable disease:  Stable disease is measured from the start of the 
treatment until the criteria for progression are met, taking as reference the 
smallest measurements recorded since the treatment started, including the 
baseline measurements. This will be described by [CONTACT_531917]. 
  
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
68 
Version Date: 01/31/19 
 
13.0 ADVERSE EVENT REPORT ING REQUIREMENTS  
 
Adverse event data collection and reporting which are required as part of every clinical trial, are 
done to ensure the safety of patients enrolled in the studies as well as those who will enroll in 
future studies using similar agents.  Adverse events are reported in a routine manner at scheduled times during a trial.  (Please follow directions for routine reporting provided in the Case Report 
Forms  for this protocol).  Additionally, certain adverse events must be reported in an expedited 
manner to allow for optimal monitoring of patient safety and care.  The following sections provide information about expedited reporting. 
 
 
Reporting requirements may include the following considerations: 1) whether the patient has received an investigational or commercial agent; 2) whether the adverse event is considered 
serious; 3 ) the grade  (severity); and 4) whether or not hospi[INVESTIGATOR_332821].  
An investigational agent  is a protocol drug administered under an Investigational New Drug 
Application (IND).  In some instances, the investigational agent may be available commercially, 
but is actually being tested for indications not included in the approved package label. 
 
Commercial agents are those agents not provided under an IND but obtained instead from a 
commercial source.  The NCI, rather than a commercial distribut or, may on some occasions 
distribute commercial agents for a trial.  
 
All CTCAE v 5.0 codable AEs are considered reportable for this study . For detailed AE 
reporting guidelines refer to the â€œNCI Guidelines for Investigators: Adverse Event Reporting 
Requirements for DCTD (CTEP and CIP) and DCP INDs and IDEsâ€:    
http://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm. 
 
13.1 Steps to Determin e If an Adverse Event Is To Be Reported In an Expedited Manner  
 
Step 1 : Identify  the type of adverse event using the NCI CTCAE  version 5.0.  All 
appropriate treatment areas should have access to a copy of the CTCAE version 5.0. A copy of the CTCAE version 5.0 can be downloaded from the CTEP web 
site http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
 
Step 2 :  Grade the adverse event using the NCI CTCAE.  
 
Step 3:  Review Table A in this section to determine if:  
â€¢ the adverse event is considered serious; 
â€¢ there are any protocol -specific requirements for expedited reporting of 
specific adverse events that require special monitoring;  
 
Note :  This includes all events that occur within [ADDRESS_690615] dose of treatment and is attributed as Related (possibly, probably, or 
definitely) to the agent(s) must al so be reported according to the 
instructions in the table  below . Attribution categories are as follows:  
Unrelated ( Unrelated, Unlikely); Related  (Possible, Probable, and 
Definite ). 
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
69 
Version Date: 01/31/19 
 
 
Table A:  Phase 1 and Early Phase 2 Studies:  Expedited Reporting Requirements for Adverse 
Events that Occur on Studies under an IND/IDE within [ADDRESS_690616] Administration of the 
Investigational Agent/Intervention 1, 2 
 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
NOTE:   Investigators MUST  immediately report to the sponsor ANY Serious Adverse Events, whether or not they 
are considered related to the investigational agent(s)/intervention (21 CFR 312.64)  
An adverse event is considered serious if it results in ANY  of the following outcomes:   
1) Death  
2) A life -threatening adverse event  
3) An adverse event that results in inpatient hospi[INVESTIGATOR_1328] â‰¥ 24 
hours  
4) A persis tent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospi[INVESTIGATOR_708], based upon medical judgment, they may jeopardize the patient or subject 
and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 
21 CFR 312.32; ICH E2A and ICH E6).  
ALL SERIOUS  adverse events that meet the above criteria MUST be immediately reported via CTEP -AERS within 
the timeframes detailed in the table below.  
Hospi[INVESTIGATOR_317] 1 and Grade 2 Timeframes  Grade 3 -5 
Timeframes  
Resulting in 
Hospi[INVESTIGATOR_059]        24-Hour, 7 Calendar Days  
 24-Hour 5 Calendar 
Days  
Not resulting in 
Hospi[INVESTIGATOR_531888]:  
o â€œ24-Hour; 5 Calendar Daysâ€ - The AE must initially be reported via CTEP -AERS within 24 hours of 
learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour report.  
o â€œ24-Hour; 7 Calendar Daysâ€ - The AE must initially be reported via CTEP -AERS within 24 hours of 
learning of the AE, followed by a complete expedited report within 7 calendar days of the initial 24 -
hour report.  
 
Important note: In the narrative of the CTEP -AERS Report, please provide an explanation of the 
investigatorâ€™s  opi[INVESTIGATOR_531889](s) is related or unrelated to any protocol procedures  aside from the investigational agent  (e.g 
required observations in Table 8.1) . 
1Serious adverse events that occur more than [ADDRESS_690617] administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:  
Expedited 24 -hour notification followed by [CONTACT_6794] 5 calendar days for:  
â€¢ All Grade 3, 4, and Grade 5 AEs  
Expedited 24-hour notification followed by [CONTACT_432] 7 calendar day s for: 
â€¢ Grade [ADDRESS_690618] whole day, after the agent/intervention was last administered.  Footnote â€œ1â€ above 
applies after this reporting period.  
Effective Date:  May 5, 2011  
 
â€¢ Any medical event that precipi[INVESTIGATOR_99204] (or prolongation of existing hospi[INVESTIGATOR_059]) 
must be rep orted regardless of attribution and design ation as expected or unexpected. 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
70 
Version Date: 01/31/19 
 
 
â€¢ Any adverse event that results in persistent or significant disabilities/incapacities, congenital 
anomalies, or birth defects or exposure to study drug through breastfeeding  must be reported via 
CTEP -AERS  if the event occurs following treatment with the study drug . 
 
â€¢ Use the NCI protocol nu mber and the protocol -specific patient ID provided during trial 
registration on all reports.   
Additional Instructions or Exceptions to CTEP -AERS  Expedited Reporting Requirements for Phase 1 
Trials Utilizing an Agent under a CTEP -IND or Non -CTEP IND:  
 
â€¢ Death  due to progressive disease should be reported as Grade 5 â€œ Disease progression â€ in the 
system organ class (SOC) â€œGeneral disorders and administration site conditionsâ€.  Evidence that 
the death was a manifestation of underlying disease (e.g., radiological changes suggesting tumor 
growth or progression: clinical deterioration associated with a disease process) should be 
submitted.  
 
â€¢ Any death occurring within [ADDRESS_690619] dose, regardless of attribution to the investigational agent/intervention requires  expedited reporting within 24 hours.  
 
â€¢ Any death that occurs more than [ADDRESS_690620] dose of treatment with an investigational 
agent which can be attributed as Related  (possibly, probably, or definitely) to the agent and is not 
clearly due to progres sive disease must be reported via CTEP -AERS  for an agent under a CTEP 
or non- CTEP IND agent  per the timelines outlined in the table above. 
 
â€¢ Myelosuppression, (Grade 1 through Grade 4 adverse events as defined in the table below), does 
not require expedited reporting , unless it is associated with hospi[INVESTIGATOR_059] . 
Category  Adverse Events  
INVESTIGATIONS  Platelet count decreased  
INVESTIGATIONS  White blood cell decreased  
INVESTIGATIONS  Neutrophil count decreased  
INVESTIGATIONS  Lymphocyte count decreased  
BLOOD/LYMPHATICS DISORDERS  Anemia   
As referenced in the CTEP Adverse Events Reporting Requirements, an AE that resolves and then recurs 
during a subsequent cycle does not require CTEP -AERS  reporting unless (1) the Grade increases; or (2) 
hospi[INVESTIGATOR_99205].  
 
13.2 When to Report an Event in an Expedited Manner  
 
â€¢ Some adverse events require notification within 24 hours  (refer to Table A) via the 
web at http://ctep. cancer.gov (email the ADVL1416 COG Study Assigned Research 
Coordinator within 24 hours of becoming aware of the event if the CTEP -AERS 24 -
Hour Notification web- based application is unavailable) and by [CONTACT_531918] . Once internet connec tivity is restored, a [ADDRESS_690621] be entered electronically into CTEP -AERS  by [CONTACT_433].  
 
â€¢ When the adverse event requires expedited reporting, submit the report within 5 or 7 
calendar days  of learning of the event (refer to Table A ). 
 
â€¢ Expedited AE reporting for this study must only use CTEP- AERS  (Adverse Event 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
71 
Version Date: 01/31/19 
 
Expedited Reporting System), accessed via the CTEP home page https://eapps-
ctep.nci.nih.gov/ctepaers.  
13.3 Expedited Reporting Methods  
 
13.3.1  CTEP -AERS  Reporting 
To report adverse events in an expedited fashion use the NCIâ€™s Adverse Event 
Expedited Reporting System ( CTEP -AERS ) that can be found at 
http://ctep.cancer.gov. 
 
A CTEP -AERS report must be submitted electronically via the CTEP -AERS 
Web -based application located at https://eapps- ctep.nci.nih.gov/ctepaers/.  If 
prompted to enter a sponsor email address, please type in: 
[EMAIL_1961]. 
 
Email supporting documentation to the ADVL1416 COG Study Assigned Research Coordinator.  ALWAYS include the ticket number on all emailed 
documents . 
 
13.3.[ADDRESS_690622] SAE  reports  via email to Eli Lilly  within 24 hours of receipt from the 
site. 
 
13.4 Definition of Onset and Resolution of Adverse Events    
Note:  These guidelines below are for reporting adverse events on the COG data 
submission forms and do not alter the guidelines for CTEP -AERS  reporting. 
 
13.4.1  If an adverse event occurs more than once in a course (cycle) of therapy only the 
most severe grade of the event should be reported . 
 13.4.[ADDRESS_690623] (most severe) 
grade of the Adverse Effects.  
 13.4.4  The resolution date of the AE is defined as the date at which the AE returns to baseline or less than or equal to Grade 1, whichever level is higher  (note that the 
resolution date may therefore be different from the date at which the grade of the AE decreased from its highest grade).  If the AE does not return to baseline the 
resolution date should be recorded as "ongoing."   
 13.4.[ADDRESS_690624] be reported 
each course it recurs.  
 
13.5 Other Recipi[INVESTIGATOR_6681]  
 
13.5.1  Events that do not meet the criteria for CTEP -AERS  reporting ( Section 13.2
) 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
72 
Version Date: 01/31/19 
 
should be reported at the end of each cycle using the forms provided in the CRF  
packet (See Section 14.1 ). 
 
13.5.[ADDRESS_690625] reports and supporting documentation to the Study Chair, to 
the FDA (when COG holds the IND) and to the pharmaceutical company (for 
industry sponsored trials). The CTEP -AERS reports will be filed with Eli Lilly 
Global Patient Safety (GPS) by [CONTACT_86951]. Eli Lilly will retain 
responsibility for global reporting and distribution of all such reports to the health 
authorities, ethics committees and investigators.  
 13.5.[ADDRESS_690626] responsible for 
oversight of the patient.  
 
13.6 Reporting Secondary AML/MDS  
All cases of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) that occur in patients following their chemotherapy for cancer must be reported via CTEP -
AERS  and included as part of the second malignant neoplasm reporting requirements for 
this protocol (see data submission packet).  Submit the completed CTEP -AERS  report 
within 14 days  of an AML/MDS diagnosis occurring after protocol treatment for cancer . 
  Secondary Malignancy :  
A secondary malignancy is a cancer caused by [CONTACT_437] a previous malignancy ( e.g., 
treatment with investigational agent/intervention, radiation or chemotherapy). A secondary malignancy is not considered a metastasis of the initial neoplasm.  
All secondary malignancies that occur following treatment must  be reported via CTEP -
AERS . Three options are available to describe the event:  
1) Leukemia secondary to oncology chemotherapy  (e.g., acute myelocytic 
leukemia [AML])   
2) Myelodysplastic syndrome (MDS)   
3) Treatment -related secondary malignancy.  
 
Any malignancy possibly related to cancer treatment (including AML/MDS) should also 
be reported via the routine reporting mechanisms outlined in each protocol. 
Second Malignancy :  
A second malignancy  is one unrelated to the treatment of a prior malignancy (and is 
NOT a metastasis from the initial malignancy).  Second malignancies require ONLY 
routine reporting via CDUS unless otherwise specified. 
 
13.7 Reporting Pregnancy, Pregnancy Loss , and Death Neonatal 
When submitting CTEP -AERS  reports for â€œPregnancyâ€, â€œPregnancy lossâ€, or â€œNeonatal 
lossâ€, the Pregnancy Information Form should be completed and emailed to the 
ADVL1416 COG Study Assigned Research Coordinator  along with any additional 
medical information  along with any additional medical information . The potential risk of 
exposure of the fetus to the investigational agent should be documented in the â€œDescription of Eventâ€ section of the CTEP -AERS  report. 
 
13.7.1  Pregnancy  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
73 
Version Date: 01/31/19 
 
â€¢ Patients who become pregnant on study risk intrauterine exposure of the 
fetus to agents which may be teratogenic. For this reason, pregnancy 
occurring on study or within [ADDRESS_690627] dose of study 
therapy should be reported in an expedited manner via CTEP- AERS  as 
Grade 3  â€œPregnancy, puerperium and perinatal conditions - Other 
(Pregnancy) â€ under the â€œPregnancy, puerperium and perinatal 
conditionsâ€ System Organ Class ( SOC ). 
 
â€¢ Pregnancy should be followed until the outcome is known. If the baby [CONTACT_170727] a birth defect or anom aly, then a second CTEP -AERS report is 
required. 
 
13.7.2  Pregnancy Loss (Fetal Death)  
â€¢ Pregnancy loss is defined in CTCAE as â€œDeath in utero.â€  
â€¢ Any pregnancy loss  should be reported expeditiously, as Grade 4  
â€œPregnancy lossâ€  under the  â€œPregnancy, puerperium and pe rinatal 
conditionsâ€ SOC . Do NOT report a pregnancy loss as a Grade 5 event 
since CTEP -AERS recognizes any Grade 5 event as a patient death.  
 
13.7.3  Death Neonatal  
â€¢ Neonatal death, defined in CTCAE as â€œNewborn deaths occurring 
during the first 28 days after birthâ€  that is felt by  [CONTACT_349662]/intervention, should be 
reported expeditiously. 
 
â€¢ A neonatal death should be reported expeditiously as Grade 4 â€Death 
neonatalâ€ under the â€œGeneral disorders and administrationâ€ SOC when 
the death is the result of a patient pregnancy or pregnancy in 
partners of men on study  
 
â€¢ Do NOT report a neonatal death resulting from a patient pregnancy or 
pregnancy in partners of men  as a Grade 5 event since CTEP -AERS 
recognizes any Grade 5 event as a patient death.  
 
Pregnancy should be followed up until the outcome of the pregnancy is known at intervals deemed appropriate by [CONTACT_6795]. The â€œPregnancy Information Formâ€ 
should be used for all necessary follow-ups. This form  is available at  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/PregnancyRepo
rtForm.pdf .  
 
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
74 
Version Date: 01/31/19 
 
14.0 RECORDS, REPORTING, AND DATA AND SAFETY MONITORING  PLAN  
 
14.1 Categories of Research Records  
Research records for this study can be divided into three categories   
1. Non-computerized Information:  Roadmaps, Pathology Reports, Surgical 
Reports. These forms are uploaded into RAVE. 
 
2. Reference Labs, Biopathology Reviews, and Imaging Center data:  These data 
accompany submissions to these centers, which forward their data electronically 
to the COG Statistics & Data Center.  
 
3. Computerized Information Electronically Submitted:  All other data will b e 
entered in RAVE with the aid of schedules and worksheets (essentially paper copi[INVESTIGATOR_6722]) provided in the case report form (CRF) packet.   
See separate CRF Packet, which includes submission schedule.  
 
14.[ADDRESS_690628] for Data Submiss ion/ Data Reporting 
Data collection for this study will be done through the Medidata Rave clinical data 
management system.  Access to the trial in Rave is granted through the iMedidata 
application to all persons with the appropriate roles assigned in Regulatory Support 
System  (RSS).  To access Rave via iMedidata, the site user must have an active CTEP -
IAM account (check at < https://eapps- ctep.nci.nih.gov/iam/index.jsp >) and the 
appropriate Rave role (Rave CRA, Read -Only, Site Investigator) on either the COG or 
COGC  roster at  the enrolling site. 
 Upon initial site registration approval for the study in RSS, all persons with Rave roles assigned on the appropriate roster will be sent a study invitation e -mail from 
iMedidata.   To accept the invitation, site users must log into the Select Login 
(https://login.imedidata.com/selectlogin ) using their CTEP -IAM user name [CONTACT_25558], and click on the â€œacceptâ€ link in the upper right -corner of the iMedidata 
page.   Pleas e note, site users will not be able to access the study in Rave until all required 
Medidata and study specific trainings are completed.   Trainings will be in the form of 
electronic learnings (eLearnings), and can be accessed by [CONTACT_261352].  
 Users that have not previously activated their iMedidata/Rave account at the time of initial site registration approval for the study in RSS will also receive a separate invitation 
from iMedidata to activate their  account.  Account activation instructions are located on 
the CTSU website, Rave tab under the Rave resource materials (Medidata Account Activation and Study Invitation Acceptance).  Additional information on iMedidata/Rave 
is available on the CTSU membersâ€™ website under the Rave tab at  www.ctsu.org/RAVE/ 
or by [CONTACT_6821] 1 -888-823- 5923 or by e -mail at 
[EMAIL_013] , or by [CONTACT_527325].  
 
14.3 CDUS  
This study will be monitored by [CONTACT_470] (CDUS) version 3.0. 
Cumulative CDUS data will be submitted quarterly to CTEP by [CONTACT_10075].  Reports 
are due January 31, April 30, July 31 and October 31.  This is not a responsibility of 
institutions participating in this trial.  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
75 
Version Date: 01/31/19 
 
 
 
14.4 Data and Safety Monitoring Plan  
Data and safety is ensured by [CONTACT_99247].  
 
14.4.1  Data and Safety Monitoring Committee  
This study will be monitored in accordance with the Childrenâ€™s Oncology Group 
policy for data and safety monitoring of Phase [ADDRESS_690629] the interests of 
patie nts and the scientific integrity for all Phase 1 and 2 studies. The DSMC 
consists of a chair; a statistician external to COG; one external member; one consumer representative; the lead statistician of the PEP- CTN scientific 
committee; and a member from the NCI. The DSMC meets at least every 6 
months to review current study results, as well as data available to the DSMC 
from other related studies. Approximately 6 weeks before each meeting of the Phase 1 and 2 DSMC, study chair  will be responsible for working with the study 
statistician to prepare study reports for review by [CONTACT_6802]. The DSMC will provide recommendations to the COG PEP- CTN  Chair and the Group Chair for 
each study reviewed to  change the study or to continue the study unchanged. 
Data and Safety Committee reports for institutional review boards can be prepared using the public data monitoring report as posted on the COG Web site. 
 
14.4.2  Monitoring by [CONTACT_166126]â€™ 
eligibility, evaluability, and dose limiting toxicities into the study database. In 
addition, study data and the study chairâ€™s evaluations will be reviewed by [CONTACT_531919] -CTN  Chair, Vice Chair and Statistician on a weekly conference call.  
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
76 
Version Date: 01/31/19 
 
REFERENCES  
1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-6, 1971 
2. Folkman J: Angiogenesis, in Braunwald A (ed): Harrison's Principles of internal Medicine (ed 
15th). [LOCATION_001], McGraw- Hill, 2001 
3. Aprile G, Bonotto M, Ongaro E, et al: Critical appraisal of ramucirumab (IMC -1121B) for cancer 
treatment: from benchside to clinical use. Drugs 73:2003-15, 2013 
4. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669 -76, 
2003 
5. Koch S, Claesson -Welsh L: Signal transduction by [CONTACT_531920]. 
Cold Spring Harb Perspect Med 2:a006502, 2012 
6. Ferrara N, Davis- Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18:4-
25, 1997 
7. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and 
leucovorin for metastatic colorectal cancer . N Engl J Med 350:2335-42, 2004 
8. Sandler A, Gray R, Perry MC, et al: Paclitaxel- carboplatin alone or with bevacizumab for non-
small -cell lung cancer. N Engl J Med 355:2542-50, 2006 
9. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single -agent bevacizumab followed by 
[CONTACT_20562]. J Clin Oncol 27:740-5, 2009 
10. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa- 2a for treatment 
of metastatic renal cell carcino ma: a randomised, double -blind phase III trial. Lancet 370:2103-
11, 2007 
11. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-76, 2007 
12. Brufsky AM, Hurvitz S, Perez E, et al: RIBBON -2: a randomized, double- blind, placebo-
controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with 
chemotherapy for second- line treatment of human epi[INVESTIGATOR_3506] 2- negative 
metastat ic breast cancer. J Clin Oncol 29:4286-93, 2011 
13. Saltz LB, Clarke S, Diaz -Rubio E, et al: Bevacizumab in combination with oxaliplatin- based 
chemotherapy as first -line therapy in metastatic colorectal cancer: a randomized phase III study. J 
Clin Oncol 26:2013-9, 2008 
14. Tabernero J, Van Cutsem E, Lakomy R, et al: Aflibercept versus placebo in combination with 
fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50:320-31, 2014 
15. Amini A, Masoumi Moghaddam S, Morris DL, et al: The critical role of vascular endothelial growth factor in tumor angiogenesis. Curr Cancer Drug Targets 12:23-43, 2012 
16. Smith MA: Lessons learned from adult  clinical experience to inform evaluations of VEGF 
pathway inhibitors in children with cancer. Pediatr Blood Cancer 61:1497-505, 2014 
17. Spratlin JL, Cohen RB, Eadens M, et al: Phase I pharmacologic and biologic study of 
ramucirumab (IMC -1121B), a fully human immunoglobulin G1 monoclonal antibody targeting 
the vascular endothelial growth factor receptor -2. J Clin Oncol 28:780-7, 2010 
18. Clarke JM, Hurwitz HI: Targeted inhibition of VEGF receptor 2: an update on ramucirumab. 
Expert Opin Biol Ther 13:1187-96, 2013 
19. Tugues S, Koch S, Gualandi L, et al: Vascular endothelial growth factors and receptors: anti -
angiogenic therapy in the treatment of cancer. Mol Aspects Med 32:88 -111, 2011 
20. Lu D, Jimenez X, Zhang H, et al: Selection of high affinity human ne utralizing antibodies to 
VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 97:393-9, 2002 
21. Lu D, Shen J, Vil MD, et al: Tailoring in vitro selection for a pi[INVESTIGATOR_531890] 2 for enhanced neutralizing activity. J Biol Chem 278:[ZIP_CODE]-507, 2003 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
77 
Version Date: 01/31/19 
 
22. Jimenez X, Lu D, Brennan L, et al: A recombinant, fully human, bispecific antibody neutralizes 
the biological activities mediated by [CONTACT_531921] 2 and 3. 
Mol Cancer Ther 4:427-34, 2005 
23. Tvorogov D, Anisimov A, Zheng W, et al: Effective suppression of vascular network formation 
by [CONTACT_531922]. Cancer 
Cell 18:630 -40, 2010 
24. Blann AD, Li JL, Li C, et al: Increased serum VEGF in 13 children with Wilms' tumour falls after 
surgery but rising levels predict poor prognosis. Cancer Lett 173:183-6, 2001 
25. Holzer G, Obermair A, Koschat M, et al: Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediatr Oncol 36:601-4, 2001 
26. Ghanem MA, van Steenbrugge GJ, Sudaryo MK, et al: Expression and prognostic relevance of 
vascular endothelial growth factor (VEGF) and its receptor (FLT -1) in nephroblastoma. J Clin 
Pathol 56:107-13, [ADDRESS_690630] SE, Rademaker AW, et al: Tumor angiogenesis correlates with metastatic 
disease, N -myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14:405-
14, 1996 
28. Eggert A, Ikegaki N, Kwiatkowski J, et al: High -level expression of angiogenic factors is 
associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6:1900-8, 2000 
29. Zhou Z, Reddy K, Guan H, et al: VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Mol Cancer Res 5:1125-32, 
2007 
30. Jia SF, Guan H, Duan X, et al: VEGF165 is necessary to the metastatic potential of Fas( -) 
osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol 7:89 -97, 2008 
31. Gee MF, Tsuchida R, Eichler -Jonsson C, et al: Vascular endothelial growth factor acts in an 
autocrine manner in rhabdomyosarcoma cell lines and can be inhibited wit h all -trans -retinoic 
acid. Oncogene 24:8025-37, 2005 
32. Abdeen A, Chou AJ, Healey JH, et al: Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 115:5243-50, 2009 
33. Kaya M, Wada T, Nagoya S, et al: Prevention of postoperative progression of pulmonary 
metastases in osteosarcoma by [CONTACT_531923]. J Orthop Sci 12:562-7, 
2007 
34. Huang J, Frischer JS, Serur A, et al: Regression of established tumors and metastases by [CONTACT_531924] r endothelial growth factor blockade. Proc Natl Acad Sci U S A 100:7785-90, 2003 
35. Glade Bender J, Yamashiro DJ, Fox E: Clinical development of VEGF signaling pathway 
inhibitors in childhood solid tumors. Oncologist 16:1614-25, 2011 
36. Glade Bender JL, Adamson PC, Reid JM, et al: Phase I trial and pharmacokinetic study of 
bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group 
Study. J Clin Oncol 26:399-405, 2008 
37. Glade Bender J, Blaney SM, Borinstein S, et al: A phase I trial and pharmacokinetic study of 
aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group 
phase I consortium report. Clin Cancer Res 18:5081-9, 2012 
38. Fox E, Aplenc R, Bagatell R, et al: A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan -vascular endothelial growth factor receptor inhibitor, in children and 
adolescents with refractory solid tumors. J Clin Oncol 28:5174-81, 2010 
39. Glade Bender JL, Lee A, Reid JM, et al: Phase I pharmacokinetic and pharmacodynamic study of 
pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's 
oncology group phase I consortium report. J Clin Oncol 31:3034-43, 2013 
40. Kieran MW, Supko JG, Wallace D, et al: Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous 
system tumors. Pediatr Blood Cancer 52:169-76, 2009 
41. Widemann BC, Kim A, Fox E, et al: A phase I trial and pharmacokinetic study of sorafenib in 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
78 
Version Date: 01/31/19 
 
children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I 
Consortium report. Clin Cancer Res 18:6011-22, 2012 
42. Dubois SG, Shusterman S, Ingle AM, et al: Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer 
Res 17:5113-22, 2011 
43. Broniscer A, Baker JN, Tagen M, et al: Phase I study of vandetanib during and after radiotherapy 
in children with  diffuse intrinsic pontine glioma. J Clin Oncol 28:4762-8, 2010 
44. Jain RK: Lessons from multidisciplinary translational trials on anti- angiogenic therapy of cancer. 
Nat Rev Cancer 8:309 -16, 2008 
45. Gururangan S, Fangusaro J, Poussaint TY, et al: Efficacy of bevacizumab plus irinotecan in children with recurrent low -grade gliomas-- a Pediatric Brain Tumor Consortium study. Neuro 
Oncol 16:310-7, [ADDRESS_690631] O, Boissier E, Blanchet B, et al: Drug safety evaluation of sorafenib for treatment of solid tu mors: consequences for the risk assessment and management of cancer patients. Expert 
Opin Drug Saf 13:663-73, 2014 
47. Sennino B, McDonald DM: Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 
12:699-709, 2012 
48. LLC I: Ramucirumab IMC -1121B (LY3009806) Investigatorâ€™s Brochure Version 11.0, 2013 
49. Prewett M, Huber J, Li Y, et al: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human 
tumors. Cancer Res 59:5209-18, 1999 
50. Bruns CJ, Liu W, Davis DW, et al: Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89:488-99, 2000 
51. Zhu Z, Hattori  K, Zhang H, et al: Inhibition of human leukemia in an animal model with human 
antibodies directed against vascular endothelial growth factor receptor 2. Correlation between 
antibody affinity and biological activity. Leukemia 17:604 -11, 2003 
52. Surguladze D: Efficacy of VEGFR2 targeted monoclonal antibody therapy in preclinical models 
of hepatocellular carcinoma, Proc ILCA , 2013 
53. Chiorean EG: Phase I dose -escalation study of the anti -VEGFR -2 recombinant human IgG1 
monoclonal antobody (MoAb) IMC -1121B, a dministered every other week (q2w) or every 3 
weeks (q3w) in patients (pts) with advanced cancers. Presented at the 19th Annual EORTC -NCI-
AACR Symposium on Molecular Targets and Cancer Therapeutics, San Francisco, [LOCATION_004], 
[ADDRESS_690632], Wong MK, Thompson JA, et al: A phase 2 randomised study of ramucirumab 
(IMC -1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer 
50:2099-107, 2014 
55. Garcia JA, Hudes GR, Choueiri TK, et al: A phase 2, single-arm study of ramucirumab in patients 
with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase 
inhibitor therapy. Cancer, 2014 
56. Zhu AX, Finn RS, Mulcahy M, et al: A phase II and biomarker study of ramucirumab, a human monoclonal anti body targeting the VEGF receptor -2, as first -line monotherapy in patients with 
advanced hepatocellular cancer. Clin Cancer Res 19:6614-23, 2013 
57. Fuchs CS, Tomasek J, Yong CJ, et al: Ramucirumab monotherapy for previously treated 
advanced gastric or gast ro-oesophageal junction adenocarcinoma (REGARD): an international, 
randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31-9, 2014 
58. Mackey JR, Ramos- Vazquez M, Lipatov O, et al: Primary results of ROSE/TRIO -12, a 
randomized placebo- controlled phase III trial evaluating the addition of ramucirumab to first- line 
docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol 33:141 -8, 2015 
59. Perol M, Ciuleanu T -E, Arrieta O, et al: REVEL: A randomized, double -blind, phase II I study of 
docetaxel (DOC) and ramucirumab (RAM; IMC -1121B) versus DOC and placebo (PL) in the 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
79 
Version Date: 01/31/19 
 
second -line treatment of stage IV non- small cell lung cancer (NSCLC) following disease 
progression after one prior platinum -based therapy. ASCO Meeting Abstracts 32:LBA8006, 2014 
60. Release LP: Lilly Announces Top -Line Results Of Phase III Hepatocellular Carcinoma Trial. 
PRNewswire, June 11, 2014 
61. Wilke H, Van Cutsem E, Oh SC, et al: RAINBOW: A global, phase III, randomized, double -
blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of 
metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease 
progression on first -line platinum - and fluoropyrimidine -containing combination therapy rainbow 
IMCL C P12-0922 (I4T- IE-JVBE). ASCO Meeting Abstracts 32:LBA7, 2014 
62. Tabernero J, Cohn AL, Obermannova R, et al: RAISE: A randomized, double -blind, multicenter 
phase III study of irinotecan, folinic acid, and 5- fluorouracil (FOLFIRI) plus ramucirumab 
(RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) 
progressive during or following first -line combination therapy with bevacizumab (bev), 
oxaliplatin (ox), and a fluoropyrimidine (fp). ASCO Meeting Abstracts 33:512, 2015 
63. Keizer RJ, Huitema AD, Schellens JH, et al: Clinical pharmacokinetics of therapeutic monoclonal 
antibodies. Clin Pharmacokinet 49:493-507, 2010 
64. Willett CG, Duda DG, di Tomaso E, et al: Efficacy, safety, and biomarkers of neoadjuvant 
bevacizumab, radiation the rapy, and fluorouracil in rectal cancer: a multidisciplinary phase II 
study. J Clin Oncol 27:3020-6, 2009 
65. Batchelor TT, Duda DG, di Tomaso E, et al: Phase II study of cediranib, an oral pan- vascular 
endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent 
glioblastoma. J Clin Oncol 28:2817-23, 2010 
66. Norden- Zfoni A, Desai J, Manola J, et al: Blood -based biomarkers of SU11248 activity and 
clinical outcome in patients with metastatic imatinib -resistant gastrointestinal st romal tumor. Clin 
Cancer Res 13:2643 -50, 2007 
67. Jain RK, Duda DG, Clark JW, et al: Lessons from phase III clinical trials on anti -VEGF therapy 
for cancer. Nat Clin Pract Oncol 3:24-40, 2006 
68. Estes ML, Mund JA, Ingram DA, et al: Identification of endot helial cells and progenitor cell 
subsets in human peripheral blood. Curr Protoc Cytom Chapter 9:Unit 9 33 1-11, 2010 
69. Ingram DA, Mead LE, Tanaka H, et al: Identification of a novel hierarchy of endothelial 
progenitor cells using human peripheral and umbilical cord blood. Blood 104:2752-60, 2004 
70. Prater DN, Case J, Ingram DA, et al: Working hypothesis to redefine endothelial progenitor cells. Leukemia 21:1141-9, 2007 
71. Yoder MC: Defining human endothelial progenitor cells. J Thromb Haemost [ADDRESS_690633] 1: 49-52, 
2009 
72. Yoder MC: Human endothelial progenitor cells. Cold Spring Harb Perspect Med 2:a006692, 2012 
73. Estes ML, Mund JA, Mead LE, et al: Application of polychromatic flow cytometry to identify 
novel subsets of circulating cells with angiogenic po tential. Cytometry A 77:831-9, 2010 
74. Mund JA, Shannon H, Sinn AL, et al: Human proangiogenic circulating hematopoietic stem and 
progenitor cells promote tumor growth in an orthotopic melanoma xenograft model. 
Angiogenesis 16:953-62, 2013 
75. Pradhan KR, Mund JA, Johnson C, et al: Polychromatic flow cytometry identifies novel subsets 
of circulating cells with angiogenic potential in pediatric solid tumors. Cytometry B Clin Cytom, 
2011 
76. Miller K, Estes, M, Perkins, S, Schneider, B, Storniolo, A, Matei, D, Ingram, D, Yoder, M, Kern, 
K, Sledge, G: An exploratory study of the biological activity of sunitinib as a component of neoadjuvant therapy for breast cancer., San Antonio Breast Cancer Conference. San Antonio, TX, 
2009 
77. Padhani AR, Neeman M: Challen ges for imaging angiogenesis. Br J Radiol 74:886 -90, 2001 
78. Jain R: Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications. NMR Biomed 26:1042-9, 2013 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
80 
Version Date: 01/31/19 
 
79. Bhujwalla ZM, Artemov D, Natarajan K, et al: Reduction of vascular and permeable regions in 
solid tumors detected by [CONTACT_531925]-470. Clin Cancer Res 9:355-62, 2003 
80. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan- VEGF  receptor tyrosine kinase 
inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer 
Cell 11:83 -95, 2007 
81. Sorensen AG, Batchelor TT, Zhang WT, et al: A "vascular normalization index" as potential 
mechanistic biomarker to predict survival after a single dose of cediranib in recurrent 
glioblastoma patients. Cancer Res 69:5296-300, 2009 
82. Skolnik JM BJ, Jayaraman B, Patel D, Adamson PC. : Shortening the timeline of pediatric phase I 
trials: the rolling six design. J Clin  Oncol. 2008 Jan 10;26(2):190-5., 2008 
83. Xin G, Wang M, Jiao LL, et al: Protein -to-creatinine ratio in spot urine samples as a predictor of 
quantitation of proteinuria. Clin Chim Acta 350(1-2):35-9, 2004  
  
 $'9/ 

7+,6[ZIP_CODE]&2/,6)255(6($5&+385326(621/< 6((3$*( )2586$*(32/,&< 

9HUVLRQ'DWH

CCI
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
82 
Version Date: 01/31/19 
 
APPENDIX II: CORRELATIVE STUDIES GUIDE     
Correlative Study  Appx.  Tube Type  Blood 
Volume per 
Sample  Total 
Volume  
Cycle 1  Total Volume  
 
Pharmacokinetics  III Refer to manual  2 mL  24 mL  34 mL  
Immunogenicity IV Refer to manual  2.5 mL  7.5 mL  15 mL  
Circulating Plasma 
Molecular Marker 
Studies  V-A Refer to manual  4 mL  4 mL  12 mL  
Pharmacogenomics V-B Refer to manual  0.5 mL 0.5 mL 0.5 mL 
Peripheral Blood  
Flow -Cytometry  
Studies  (Part A 
Only)  VI K2EDT A tube 8 mL  8 mL  16 mL  
Total Volume for 
All Studies   44 mL  77.5 mL  
Tumor Tissue  VII  
 
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
83 
Version Date: 01/31/19 
 
APPENDIX III: PHARMACOKINETIC STUDY FORM   
COG Pt ID # _______________ ACC # _______________ 
Please do not write patient names on this form or on samples.   
Weight: _______kg  Dose Level: _______mg/ kg   Total Dose: _______mg 
  
Blood samples (2 mL) will be collected for pharmacokinetic studies at the time points listed in the table below. 
Record the exact date and time each sample is drawn and the time of the ramucirumab administration. If this form 
will be used as a source document, the site personnel who collected the samples or research staff responsible for the 
research specimen must initial in the table below, next to the respective sample . 
Blood 
Sample 
No. Time Point  Scheduled Sample Collection Time  Scheduled  
Ramucirumab  
Time Point  Actual Date 
Sample Collected 
or Dose Given  Actual Time 
Sample 
Collected or 
Dose Given 
(24-hr clock)  Staff 
Initials  
1 Cycle 1, Day 1  Prior to Infusion   ___/___/___  |__|__| : |__|__|   
 Cycle 1, Day 1  ___/___/___  |__|__| :  |__|__|   
2 Cycle 1, Day 1  End of Infusion (EOI) on Cycle 1, Day 1   ___/___/___  |__|__| : |__|__|   
3 Cycle 1, Day 1  1 hour  after EOI on Cycle 1, Day 1   ___/___/___  |__|__| : |__|__|   
4 Cycle 1, Day 3 Â± 1 48 (Â± 24) hours  after Cycle 1, Day 1 dose  ___/___/___  |__|__| : |__|__|   
5 Cycle 1, Day 8 Â± 1 7 (Â± 1) days after Cycle 1, Day 1 dose  ___/___/___  |__|__| : |__|__|   
6 Cycle 1, Day 1 5 Prior to Infusion   ___/___/___  |__|__| : |__|__|   
 Cycle 1, Day 1 5 ___/___/___  |__|__| : |__|__|   
7 Cycle 1, Day 1 5 1 hour  after EOI on Day 15   ___/___/___  |__|__| : |__|__|   
8 Cycle 1, Day 29 Prior to Infusion   ___/___/___  |__|__| : |__|__|   
 Cycle 1, Day 29 ___/___/___  |__|__| : |__|__|   
9 Cycle 1, Day 29 End of Infusion (EOI) on Day 29   ___/___/___  |__|__| : |__|__|   
10 Cycle 1, Day 29 1 hour  after EOI on Day 29   ___/___/___  |__|__| : |__|__|   
11 Cycle 1, Day 31 Â± 
1 48 (Â± 24) hours after Day 29 dose  ___/___/___  |__|__| : |__|__|   
12 Cycle 1, Day 36 Â± 
1 7 (Â± 1) days after Day 29 dose  ___/___/___  |__|__| : |__|__|   
13* Cycle 2, Day 1* 14 (Â± 1) days after Day 29 dose  
(Prior to dose on Cycle 2, Day 1)   ___/___/___  |__|__| : |__|__|   
 Cycle 2, Day 1 ___/___/___  |__|__| : |__|__|   
14 Cycle 2, Day 1 1 hour  after EOI on Cycle 2, Day 1   ___/___/___  |__|__| : |__|__|   
15 Cycle 3, Day 1 Prior to Infusion   ___/___/___  |__|__| : |__|__|   
16 Cycle 5, Day 1 Prior to Infusion   ___/___/___  |__|__| : |__|__|   
FOLLOW -UP:   Date of last dose of Ramucirumab:     ___/___/___ Cycle #______   
Sample 
No. Scheduled Sample Collection Time  Date Sample 
Collected  Time Sample 
Collected (24 -
hr clock)   
17 ~ [ADDRESS_690634] dose of ramucirumab  ___/___/___  |__|__| : |__|__|   
 
* Patients who are removed from therapy during Cycle [ADDRESS_690635] this sample collected on Day 42 
Â± 1 of Cycle 1.  
 
In the event an infusion -related reactio n is experienced, an additional blood sample for each PK and Immunogenicity 
will be collected if possible as close to the onset of the infusion -related reaction, at the time of its resolution, and 
approximately 30 days after resolution of the event.  
Sample 
No. Time Point  Scheduled Sample 
Collection Time  Date of IRR 
Onset/Resolution  Date Sample 
Collected  Time Sample 
Collected or Dose 
Given (24 -hr clock)  Staff Initials  
IRR-1 Onset of IRR  unscheduled  ___/___/___  ___/___/___    |__|__| : |__|__|   
IRR-2 Resolution of IRR  unscheduled  ___/___/___  ___/___/___    |__|__| : |__|__|   
IRR-3 ~[ADDRESS_690636] -Resolution  unscheduled   ___/___/___    |__|__| : |__|__|    
Sample Collection and Processing: Refer to manual for sample processing and shippi[INVESTIGATOR_21382].  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
84 
Version Date: 01/31/[ADDRESS_690637]. See manual for detailed guidelines for packaging 
and shippi[INVESTIGATOR_531891].    
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
85 
Version Date: 01/31/19 
 
 
APPENDIX IV: IMMUNOGENICITY FO RM:  ANTI - RAMUCIRUMAB ANTIBODY  STUDIES   
COG Pt ID # _______________  ACC # _______________  
Please do not write patient names on this form or on samples.   
Cycle 1, Day 1 Date: |__/__|__/__|__/__|     
Weight: _______kg  Dose Level: _______  mg/kg    Total Dose: _______mg  
Sample Collection:  Blood samples ( 2.5 ml) will be obtained at the time points listed in the table below. Record the 
exact date and time each sample is drawn and the time of the ramucirumab administration.  If this form will be used 
as a source document, the site personnel who collected the samples  or research staff responsible for the research 
specimen  must initial in the table below, next to the respective sample.   
Blood 
Sample 
No. Time Point  Scheduled 
Sample 
Collection Time  Scheduled  
Ramucirumab  
Time Point  Date Sample 
Collected or 
Dose Given  Time Sample Collected or 
Dose Given (24- hr clock)  Staff 
Initials  
1 Cycle 1, Day 1  Prior to infusion   ___/___/___    |__|__| : |__|__|   
 Cycle 1, Day 1  ___/___/___  Start time |__|__| : |__|__|   
2 Cycle 1, Day 15 Prior to infusion  ___/___/___    |__|__| : |__|__|   
 Cycle 1, Day 15 ___/___/___  Start time |__|__| : |__|__|   
3 Cycle 1, Day 29 Prior to infusion  ___/___/___    |__|__| : |__|__|   
 Cycle 1, Day 29 ___/___/___  Start time |__|__| : |__|__|   
4 Cycle 3, Day 1  Prior to infusion  ___/___/___    |__|__| : |__|__|   
 Cycle 3, Day 1  ___/___/___  Start time |__|__| : |__|__|   
5 Cycle 5, Day 1  Prior to infusion  ___/___/___    |__|__| : |__|__|   
 Cycle 5, Day 1  ___/___/___  Start time |__|__| : |__|__|   
FOLLOW -UP:   Date of last dose of Ramucirumab:     ___/___/___ Cycle #______   
Blood 
Sample 
No. Scheduled Sample Collection Time  Date Sample 
Collected  Time Sample 
Collected (24 -hr 
clock)   
6 ~ [ADDRESS_690638] dose of ramucirumab  ___/___/___     |__|__| : |__|__|   
 
In the event an infusion -related reaction is experienced, an additional blood  sample for PK and Immunogenicity will 
be collected as close to the onset of the infusion -related reaction, at the time of its resolution, and approximately 30 
days after resolution of the event.  
Blood 
Sample 
No. Time Point  Scheduled Sample 
Collection Time  Date of IRR 
Onset/Resolution  Date Sample 
Collected  Time Sample 
Collected or Dose 
Given (24 -hr clock)  Staff Initials  
IRR-1 Onset of IRR  unscheduled  ___/___/___  ___/___/___    |__|__| : |__|__|   
IRR-2 Resolution of IRR  unscheduled  ___/___/___  ___/___/___    |__|__| : |__|__|   
IRR-3 ~[ADDRESS_690639] -Resolution  unscheduled   ___/___/___    |__|__| : |__|__|   
 
Sample Processing  Procedures : Refer to manual for sample processing and shippi[INVESTIGATOR_21382].  
 
One copy of this Immunogenicity Study F orm should be uploaded into RAVE. See manual for detailed 
guidelines for packaging and shippi[INVESTIGATOR_531892].   
 
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
86 
Version Date: 01/31/19 
 
APPENDIX V-A : CIRCULATING PLASMA MOLECULAR MARKER STUDIES  FORM   
COG Pt ID # _______________  ACC # _______________  
Please do not write patient names on this form or on samples.   
Cycle 1, Day 1 Date: |__/__|__/__|__/__|     
Weight: _______kg  Dose Level: _______  mg/kg    Total Dose: _______mg  
 
Blood samples ( 4 mL) will be obtained at the time points listed in the table below. Record the exact date 
and time each sample is drawn and the time of the ramucirumab administration.  If this form will be used 
as a source document, the site personnel who collected the samples or research staff responsible for the 
research specimen  must initial in the table below, next to the respective sample.  
 
Sample Collection:  
Blood 
Sample 
No. Time Point  Scheduled Sample 
Collection Time  Scheduled  
Ramucirumab  
Time Point  Date Sample 
Collected or 
Dose Given  Time Sample Collected 
or Dose Given (24- hr 
clock)  Staff 
Initials  
1 Cycle 1, Day 1  Prior to infusion   ___/___/___  |__|__| : |__|__|   
 Cycle 1, Day 1  ___/___/___  Start time |__|__| : |__|__|   
2* Cycle 2, Day 1  Prior to infusion   ___/___/___  |__|__| : |__|__|   
 Cycle 1, Day 1  ___/___/___  Start time |__|__| : |__|__|   
FOLLOW -UP:   Date of last dose of Ramucirumab:     ___/___/___ Cycle #______   
Blood 
Sample 
No. Scheduled Sample Collection Time  Date Sample 
Collected  Time Sample Collected 
(24-hr clock)   
3 ~ [ADDRESS_690640] dose of ramucirumab  ___/___/___  |__|__| : |__|__|   
* Patients who are removed from therapy during Cycle [ADDRESS_690641] this sample collected 
on Day 42 of Cycle 1.    
Sample Processing Procedures: Refer to manual for sample processing and shippi[INVESTIGATOR_21382].  
 
 
One copy of this Circulating Plasma Molecular  Marker Studies  Form should be uploaded into RAVE. See 
manual for detailed guidelines for packaging and shippi[INVESTIGATOR_531893].   
 
 
Notification of sample shippi[INVESTIGATOR_007]:  
Notification of sample shipment is necessary.  
 
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
87 
Version Date: 01/31/19 
 
APPENDIX V-B : PHARMACOGENOMICS  STUDY FORM   
COG Pt ID # _______________  ACC # _______________  
Please do not write patient names on this form or on samples.   
Cycle 1, Day 1 Date: |__/__|__/__|__/__|     
Weight: _______kg  Dose Level: _______  mg/kg    Total Dose: _______mg  
 
A single blood sample (0.5 mL) will be obtained in consenting patients . Effort should be made to collect 
the sample prior to infusion on Cycle [ADDRESS_690642] initial in the table below, next to the res pective 
sample.  
 
Sample Collection:  
Blood 
Sample 
No. Time Point  Scheduled Sample 
Collection Time  Date Sample 
Collected or 
Dose Given  Time Sample Collected or 
Dose Given (24- hr clock)  Staff Initials  
1 Cycle 1, Day 1  Prior to infusion * ___/___/___                |__|__| : |__|__|   
 
*If sample is not collected at Cycle [ADDRESS_690643]. See manual for detailed 
guidelines for packaging and shippi[INVESTIGATOR_531894].   
 
Notification of sample shippi[INVESTIGATOR_007]:  
Notification of sample shipment is necessary.  
 
  
 $'9/ 

7+,6[ZIP_CODE]&2/,6)255(6($5&+385326(621/< 6((3$*( )2586$*(32/,&< 

9HUVLRQ'DWH

$33(1',;9,3(5,3+(5$/%/22')/2:&<720(75<6(78',(6)2503$5 7$
21/<


&2*3W,'BBBBBBBBBBBBBBB  $&&BBBBBBBBBBBBBBB
3OHDVHGRQRWZULWHSDWLHQWQDPHVRQWKLVIRUPRURQVDPSOHV
&\FOH'D\'DWH_BBBB_BBBB_BBBB_  
:HLJKWBBBBBBBNJ 'RVH/HYHOBBBBBBB PJNJ  7RWDO'RVHBBBBBBBPJ
6DPSOH&ROOHFWLRQ 6DPSOHVZLOOEHFROOHFWHGLQFRQVHQWLQJSDWLHQWVDWEDVHOLQH RQ'D\RI&\FOHSULRU
WRWKHVWLQIXVLRQDQGRQ'D\&\FOH'D\ZHHNVIRO ORZLQJWKHUGLQIXVLRQ6HH 6HFWLRQ
IRUVDPSOHFROOHFWLRQDQGSURFHVVLQJGHWDLOV,IWKLVIRUPZLOO EHXVHGDVDVRXUFHGRFXPHQWWKHVLWH
SHUVRQQHOZKRFROOHFWHGWKHVDPSOHVRUUHVHDUFKVWDIIUHVSRQVLE OHIRUWKHUHVHDUFKVSHFLPHQPXVWLQLWLDOLQ
WKHWDEOHEHORZQH[WWRWKHUHVSHFWLYHVDPSOH

%ORRG
6DPSOH
1R7LPH3RLQW6FKHGXOHG6DPSOH
&ROOHFWLRQ7LPH6FKHGXOHG
5DPXFLUXPDE
7LPH3RLQW'DWH6DPSOH
&ROOHFWHGRU
'RVH*LYHQ7LPH6DPSOH&ROOHFWHG
RU'RVH*LYHQKU
FORFN6WDII
,QLWLDOV
 &\FOH'D\ 3ULRUWRLQIXVLRQ  BBBBBBBBB _BB_BB__BB_BB_ 
 &\FOH'D\ BBBBBBBBB 6WDUWWLPH_BB_BB__BB_BB_ 
&\FOH'D\ 3ULRUWRLQIXVLRQ
  BBBBBBBBB _BB_BB__BB_BB_ 

3DWLHQWVZKRDUHUHPRYHGIURPWKHUDS\GXULQJ&\FOHDIWHUUH FHLYLQJWKHGRVHVKRXOGKDYHWKLVVDPSOHFROOHFWHG
RQ'D\RI&\FOH


2QHFRS\RIWKLV3HULSKHUDO%ORRG)ORZ&\WRPHWU\6WXGLHV)RUPV KRXOGEHXSORDGHGLQWR5$9($
VHFRQGFRS\VKRXOGEHVHQWZLWKWKHVDPSOHVWR RU&KLOGUHQDWW KHDGGUHVVOLVWHGLQ
6HFWLRQ 


 [COMPANY_003]
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
89 
Version Date: 01/31/19 
 
APPENDIX VII: TISSUE STUDIES FORM  
 
COG Pt ID #  _______________  ACC #  _______________     Date:__________  
(Please do not write patient names on this form or on samples )  
Sample Labeling:  
Samples should be labeled with the following information:  
Protocol number:    ADVL141 6 
Institution:        _________________ 
Patient ID #:     _________________ 
Accession #:     _________________ Sample Date:    _________________ 
Site of Acquired Tissue:  __________________ 
 
Tissue obtained at (check one option below):  
ï‚¨Diagnosis            ï‚¨ Relapse         ï‚¨Subsequent Resection/Biopsy  
 
Tissue sample is from a:  
   ï‚¨ Resection     or      ï‚¨  Biopsy
 
  
Archived paraffin -embedded tissue must be available for any previous resections for that patient 
(approximately 10 unstained slides or tumor block). The blocks or slides of tumor material should be sent 
at room temperature  via courier . During the warmer months (June â€“ August), it is advisable to ship the 
block(s) with a frozen gel ice- pack in order to prevent the melting of paraffin- embedded tissue blocks 
during transit. Ensure cold pack is not in direct contact [CONTACT_531926].   
All blocks or slides must be labeled with the patientâ€™s study registration number (COG Patient ID #), the 
study I.D. (ADVL1416), and the sample collection date. Data should be recorded on this Tissue Studies 
Form, which must accompany the sample(s).  
 
One copy of this Tissue Studies Form should be uploaded into RAVE . See lab manual for detailed 
guidelines for packaging and shippi[INVESTIGATOR_531895].   
 
One copy of this form should be uploaded into RAVE. If this form will be used as a source document, the site personnel responsible for samples  must sign and date this form below:  
 Signature: _______________________________               Date:__________________________________  
(site personnel responsible for samples ) 
   
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
90 
Version Date: 01/31/19 
 
APPENDIX VIII: BLOOD PRESSURE LEVELS FOR  CHILDREN BY [CONTACT_531927] (BP) levels for BOYS   
 
  Systolic Blood Pressure, mm Hg  Diastolic Blood Pressure, mm Hg  
Age BP Percentile of Height  Percentile of Height  
(years)  Percentile  5th 10th 25th 50th 75th 90th 95th 5th 10th 25th 50th 75th 90th 95th 
1 95th 98 99 101 103 104 106 106 54 54 55 56 57 58 58 
2 95th 101 102 104 106 108 109 110 59 59 60 61 62 63 63 
3 95th 104 105 107 109 110 112 113 63 63 64 65 66 67 67 
4 95th 106 107 109 111 112 114 115 66 67 68 69 70 71 71 
5 95th 108 109 110 112 114 115 116 69 70 71 72 73 74 74 
6 95th 109 110 112 114 115 117 117 72 72 73 74 75 76 76 
7 95th 110 111 113 115 117 118 119 74 74 75 76 77 78 78 
8 95th 111 112 114 116 118 119 120 75 76 77 78 79 79 80 
9 95th 113 114 116 118 119 121 121 76 77 78 79 80 81 81 
10 95th 115 116 117 119 121 122 123 77 78 79 80 81 81 82 
11 95th 117 118 119 121 123 124 125 78 78 79 80 81 82 82 
12 95th 119 120 122 123 125 127 127 78 79 80 81 82 82 83 
13 95th 121 122 124 126 128 129 130 79 79 80 81 82 83 83 
14 95th 124 125 127 128 130 132 132 80 80 81 82 83 84 84 
15 95th 126 127 129 131 133 134 135 81 81 82 83 84 85 85 
16 95th 129 130 132 134 135 137 137 82 83 83 84 85 86 87 
â‰¥17 95th 131 132 134 136 138 139 140 84 85 86 87 87 88 89 
Instructions for using this BP Chart:  
1. Measure the patientâ€™s blood pressure using an appropriate size cuff.  
2. Select appropriate chart for a female or male patient.  
3. Using the â€œageâ€ row and â€œheightâ€ column determine if the BP is within the ULN.  
4. See Section 5.5.1 for definition of dose limiting hypertension,  Section 6.4  for man agement and grading of hypertension, and Section 7.7  for medical 
treatment of ramucirumab  related hypertension.  
 
This table was taken from â€œThe Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescentsâ€ PEDIATRICS 
Vol. [ADDRESS_690644] 2004, pp. 555 -576. 
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
91 
Version Date: 01/31/19 
 
 
Blood pressure  (BP)  levels for GIRLS   
 
  Systolic Blood Pressure, mm Hg  Diastolic Blood Pressure, mm Hg  
Age BP Percentile of Height  Percentile of Height  
(years)  Percentile  5th 10th 25th 50th 75th 90th 95th 5th 10th 25th 50th 75th 90th 95th 
1 95th 100 101 102 104 105 106 107 56 57 57 58 59 59 60 
2 95th 102 103 104 105 107 108 109 61 62 62 63 64 65 65 
3 95th 104 104 105 107 108 109 110 65 66 66 67 68 68 69 
4 95th 105 106 107 108 110 111 112 68 68 69 70 71 71 72 
5 95th 107 107 108 110 111 112 113 70 71 71 72 73 73 74 
6 95th 108 109 110 111 113 114 115 72 72 73 74 74 75 76 
7 95th 110 111 112 113 115 116 116 73 74 74 75 76 76 77 
8 95th 112 112 114 115 116 118 118 75 75 75 76 77 78 78 
9 95th 114 114 115 117 118 119 120 76 76 76 77 78 79 79 
10 95th 116 116 117 119 120 121 122 77 77 77 78 79 80 80 
11 95th 118 118 119 121 122 123 124 78 78 78 79 80 81 81 
12 95th 119 120 121 123 124 125 126 79 79 79 80 81 82 82 
13 95th 121 122 123 124 126 127 128 80 80 80 81 82 83 83 
14 95th 123 123 125 126 127 129 129 81 81 81 82 83 84 84 
15 95th 124 125 126 127 129 130 131 82 82 82 83 84 85 85 
16 95th 125 126 127 128 130 131 132 82 82 83 84 85 85 86 
â‰¥17 95th 125 126 127 129 130 131 132 82 83 83 84 85 85 86 
Instructions for using this BP Chart:  
1. Measure the patientâ€™s blood pressure using an appropriate size cuff.  
2. Select appropriate chart for a female or male patient.  
3. Using the â€œageâ€ row and â€œheightâ€ column determine if the BP is within the ULN . 
4. See Section 5.5.1 for definition of dose limiting hypertension,  Section 6.4  for management and grading of hypertension, and Section 7. 7 for medical 
treatment of ramucirumab  related hypertension.  
 
This table was taken from â€œThe Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children a nd Adolescentsâ€ PEDIATRICS 
Vol. [ADDRESS_690645] 2004, pp. 555 -576.
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
92 
Version Date: 01/31/19 
 
APPENDIX IX :  URINE PROTEIN TO CREATININE (UPC) RATIO  
 
 
Clinical Meaning of UPC  
There is a good correlation between the ratio of urine protein to creatinine concentrations (UPC) in a 
random urine sample and the amount  of protein excreted in a 24- hour urine collection period.83 Thus, the 
UPC allows for an estimation of the 24- hour urine protein excretion from a random sample.  The 
creatinine excretion is fairly constant throughout the day regardless of changes in urine flow  rate:  
â€¢ Men excrete 20 mg to 25 mg of creatinine/kg of body weight/day 
â€¢ Women excrete 15 mg to 20 mg of creatinine/kg of body weight/day 
â€¢ Normal protein excretion is <100 mg to 150 mg per 24 hours. 
â€¢ The UPC ratio is roughly equal to the 24 hour urine protein excretion in g/day 
 
 
Calculating UPC Ratio 
UPC ratio = (Urine protein [mg/dL]) / (urine creatinine [mg/dL]) = numerically equivalent to grams (g) protein excreted in urine over 24 hours.  
 
Example :  If a s ubject has a urine protein of  90 mg/dL and urine cre atinine of 30 mg/dL ,   
then UPC ratio =  90 ( mg/dL)   = 3 
30 (mg/dL)  
Result UPC is 3 correlat ing to roughly 3g of protein excretion in a 24-hour period. 
  
Units for UPC ratio  
UPC is a calculated ratio. The guidelines in the protocol are based on having urine protein and urine 
creatinine measured in the same units (e.g., mg/dL). The SI units for urine protein and urine creatinine are 
not the same, so these must be converted to mg/dL before calculating the ratio.  For reference, the 
conversion factors for commonly used units for protein and creatinine are provided below. 
 
Starting units  Conversion to mg/dL  
Protein (g/L)  Multiply by 100  
Creatinine ( Âµmol/L)  Divide by 88.4  
Creatinine (mmol/L)  Multiply by 11.3  
 
  
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
93 
Version Date: 01/31/19 
 
APPENDIX X: TOXICITY -SPECIFIC GRADING  
 
Bilirubin  
 
Grade 1:  > ULN â‰¤ 1.[ADDRESS_690646]  
Grade 2:  > 1.[ADDRESS_690647]  
Grade 3:  > 3.[ADDRESS_690648]  
Grade 4:  > 10.[ADDRESS_690649]  
 
ALT: For the purpose of this study, the ULN for SGPT is 45 U/L regardless of baseline.  
  
Grade 1:  > 45 U/L â‰¤ 135  U/L 
Grade 2: 136 U/L - 225 U/L 
Grade 3:  226 U/L - 900 U/L 
Grade 4:  > 900 U/L 
 
AST:  For the purpose of this study, the ULN for SG OT is 50 U/L regardless of baseline.  
 
Grade 1:  > 50 U/L â‰¤ 150  U/L 
Grade 2:  151 U/L -250 U/L 
Grade 3:  251 U/L -1000  U/L 
Grade 4:  > 1000  U/L 
 
GGT:  
 
Grade 1:  > ULN - 2.[ADDRESS_690650]  
Grade 2:  > 2.[ADDRESS_690651]  
Grade 3:  > 5.[ADDRESS_690652]  
Grade 4:  > 20.[ADDRESS_690653]  
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
94 
Version Date: 01/31/19 
 
APPENDIX XI: CTEP AND CTSU REGISTRATION PROCEDURES  
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy require all 
individuals contributing to NCI -sponsored trials to register and to renew their registration annually.  To 
register, all individuals must obtain a Cancer Therapy Evaluation Program (CTEP) Identity and Access 
Management (IAM) account (https:// ctepcore.nci.nih.gov/iam ).  In addition, persons with a registration 
type of Investigator (IVR), Non- Physician Invest igator (NPI[INVESTIGATOR_6731]), or Associate Plus (AP) (i.e., clinical site 
staff requiring write access to OPEN, RAVE, or TRIAD or acting as a primary site contact) must complete 
their annual registration using CTEPâ€™s web- based Registration and Credential Repository (RCR ) 
(https://ctepcore.nci.nih.gov/rcr).  Documentation requirements per registration type are outlined in the table below.  
 
Documentation Required  IVR NPI[INVESTIGATOR_6732] A 
FDA Form 1572 ï¡ ï¡ 
  
Financial Disclosure Form  ï¡ ï¡ ï¡ 
 
NCI Biosketch (education, training, 
employment, license, and certification) ï¡ ï¡ ï¡ 
 
HSP/GCP training  ï¡ ï¡ ï¡ 
 
Agent Shipment Form (if applicable) ï¡ 
   
CV (optional) ï¡ ï¡ ï¡ 
   
An active CTEP -IAM user account and appropriate RCR registration is required to access all CTEP and 
CTSU (Cancer Trials Support Unit) websites and applications.  In addition, IVRs and NPI[INVESTIGATOR_360376] 1572 in RCR to allow the following:  
â€¢ Added to a site roster 
â€¢ Assigned the treating, credit, consenting, or drug shipment (IVR only) tasks in OPEN 
â€¢ Act as the site-protocol PI [INVESTIGATOR_6734] 
â€¢ Assigned the Clinical Investigator (CI) role on the Delegation of Tasks Log (DTL).     
 Additional information can be found on the CTEP website at < https://ctep.cancer.gov/investigatorResources/default.htm
 >.  For questions, please contact [CONTACT_531928] < [EMAIL_088]  >. 
 
 
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
95 
Version Date: 01/31/19 
 
CTSU Registration Procedures 
 
This study is supported by [CONTACT_6818] (CTSU). 
 
IRB Approval:   
Each investigator or group of investigators at a clinical site must obtain IRB approval for this protocol and submit IRB approval and supporting documentation to the CTSU Regulatory Office before they can 
be approved to enroll patients.  Assignment of site registration status in the CTSU Regulatory Support System (RSS) uses extensive data to make a determination o f whether a site has fulfilled all regulatory 
criteria including but not limited to the following: 
â€¢ An active Federal Wide Assurance (FWA) number  
â€¢ An active roster affiliation with the Lead Network or a participating organization 
â€¢ A valid IRB approval 
â€¢ Complia nce with all protocol specific requirements. 
 
In addition, the site- protocol Principal Investigator (PI) must meet the following criteria:  
â€¢ Active registration status  
â€¢ The IRB number of the site IRB of record listed on their Form FDA 1572 
â€¢ An active status on  a participating roster at the registering site.  
 ites participating on the NCI CIRB initiative that are approved by [CONTACT_360432]. For sites using the CIRB, IRB 
approval information is received from the CIRB and applied to the RSS in an automated process. Signatory Institutions  must submit a Study Specific Worksheet for Local Context (SSW) to the CIRB via 
IRBManager to indicate their intent to open the study local ly.  The CIRBâ€™s approval of the SSW is then 
communicated to the CTSU Regulatory Office.  In order for the SSW approval to be processed, the Signatory Institution must inform the CTSU which CIRB -approved institutions aligned with the 
Signatory Institution a re participating in the study. 
 
Requirements F or ADVL1416  Site Registration:  
 
â€¢ IRB approval (For sites not participating via the NCI CIRB; local IRB documentation, an IRB-signed 
CTSU IRB Certification Form, Protocol of Human Subjects Assurance Identification/IRB 
Certification/Declaration of Exemption Form, or combination is accepted ) 
â€¢ For applicable studies with a radiation and/or imaging (RTI) component, the enrolling site must be aligned to a RTI provider.  To manage provider associations access the Provider Association tab on the CTSU website at  https://www.ctsu.org/RSS/RTFProviderAssociation
, to add or remove 
associated providers.  Sites must be linked to at least one IROC credentialed provid er to participate on 
trials with an RT component. Enrolling sites are responsible for ensuring that the appropriate agreements are in place with their RTI provider, and that appropriate IRB approvals are in place.   
 
                         ADVL1 416 
 
THIS PROTOCOL IS FOR RESEARCH PURPOSES ON LY, SEE PAGE 1 FOR [LOCATION_003]GE POLICY   
96 
Version Date: 01/31/19 
 
Submitting Regulatory Documents:  
Submit required forms and documents  to the CTSU Regulatory Office, where they will be entered and 
tracked in the CTSU RSS.  
 
Regulatory Submission Portal: www.ctsu.org   (membersâ€™ area) ïƒ  Regulatory Tab ïƒ Regulatory 
Submission  
When applicable, original documents should be mailed to: 
CTSU Regulatory Office  
      [ADDRESS_690654] 
      Philadelphia, PA [ZIP_CODE] 
 
Institutions with patients waiting that are unable to use the Portal should alert the CTSU Regulatory 
Office immediately at 1 -[PHONE_102] in order to receive further instruction and support. 